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Abstract 
The equine sarcoid is the most commonly detected skin tumour in equidae worldwide and 
has been reported in horses, donkeys, mules and zebra. Sarcoids can be defined as locally 
aggressive,  fibroblastic,  benign  tumours  of  the  equine  skin  and  although  they  do  not 
metastasise, they exhibit variable clinical presentations ranging from small alopecic areas 
to  rapidly  growing,  ulcerated  fleshy  masses.  Clinical  behaviour  may  also  vary,  from 
aggressive infiltrative growth to spontaneous regression. Diverse treatment modalities have 
been reported, and these have been used separately, or have been combined, with variable 
efficacy.  No  single  therapeutic  approach  has  been  found  to  be  universally  successful. 
Although rarely life-threatening, equine sarcoids can have important welfare and economic 
implications. There is a large body of evidence now supporting the hypothesis that bovine 
papilloma virus (BPV) is the aetiological agent of equine sarcoids and our understanding 
of  the  general  pathophysiology  of  the  disease  continues  to  progress;  however,  several 
fundamental aspects of the disease remain unclear.  
In the first chapter, the clinical aspects of the disease are discussed and evidence to support 
a  viral  aetiology  is  presented,  along  with  background  information  regarding  papilloma 
virus  infections  in  the  natural  host.  An  epidemiological  overview  of  the  disease  that 
considers the most current theories and understanding of equine sarcoids is also given. 
Chapter  II describes the materials and methods used in the course of carrying out the 
investigations detailed in Chapters III, IV and V. 
The  aim  of  Chapter  III  was  to  investigate  the  potential  role  of  flies  as  vectors  in 
transmission of equine sarcoids between infected and susceptible animals. We found that 
BPV-1  DNA  can  be  detected  in  flies  trapped  from  areas  where  animals  with  BPV-1 
infected sarcoids are housed. This study provides evidence to support the hypothesis that 
flies may therefore be significant in disease transmission. Such evidence will be of benefit 
in formulating management control strategies for fly control measures that will reduce the 
incidence and spread of equine sarcoids. 
The work described in Chapter IV was carried out to investigate the hypothesis that the 
development  of  the  sarcoid  tumour  arises  primarily  through  inhibition  of  apoptotic 
pathways by viral gene products. Assessment of DNA-damage-induced apoptosis in BPV 
transformed equine fibroblasts revealed that sarcoid derived cells and BPV-1 transfected 
fibroblasts  are  less  resistant  to  apoptosis  than  normal,  BPV-negative  control  equine iii 
fibroblasts, but are more likely to recover from DNA damage and continue to grow and 
divide. Further research was directed towards identifying the viral genes responsible for 
conferring resistance to apoptosis through siRNA knock-down and monitoring expression 
of endogenous cellular proteins known to be involved in apoptotic pathways. Using an 
siRNA targeted to a particular viral protein, we were able to reduce the ability of the BPV 
transformed cells to survive after DNA damage. Potentially, this information can now be 
used to develop novel therapeutic strategies. 
The final chapter describes the results of a study in to the expression of the p53 protein in 
sarcoids in vivo and in BPV transformed cells in vitro in tissue culture. In vivo, analysis of 
51 equine sarcoid lesions showed that 48% of tumours are associated with nuclear p53 
protein expression and that high levels of p53 were associated with clinically aggressive 
tumour types (fibroblastic).  Interestingly, we observed high levels of cytoplasmic p53 
staining with no nuclear staining in one tumour in vivo.  In vitro, p53 mRNA levels were 
assessed  in  BPV  transformed  and  BPV  negative  fibroblasts.  The  half-life  of  the  p53 
protein, the cellular location and functionality were also investigated in vitro. The results 
showed that BPV transformed equine fibroblast cells also exhibit increased nuclear p53 
protein  expression  and  one  cell  line  (EqS04b)  showed  a  cytoplasmic  staining  pattern 
similar to that observed in vitro. However, the abnormal level and location of the p53 does 
not appear to affect the transactivational functionality of p53 since p21 expression was 
induced by exposing the cells to UVB irradiation. iv 
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1.1  GENERAL INTRODUCTION 
Over  70  years  after  their  first  description,  equine  sarcoids  remain  a  frustrating  and 
challenging entity for veterinary practitioners and research scientists alike. These common 
tumours of the skin in equidae are varied in their clinical presentation and unpredictable in 
their response to treatment. The widely embraced hypothesis that bovine papilloma virus 
(BPV) is the aetiological agent of equine sarcoids makes this disease entity a fascinating 
addition to the arena of papilloma virus research. Papilloma virus research began in earnest 
in the 1930’s with the discovery that filtered extracts from cutaneous papillomas of wild 
cottontail rabbits could induce lesions with malignant potential in cottontail and domestic 
rabbits.  In  the  1970s  a  ‘technical  revolution’  began,  and  the  advances  in  molecular 
understanding that followed eventually led to the identification of Human Papilloma Virus 
(HPV) as a major public health problem. So significant were these developments that the 
2008 Nobel Prize in Physiology or Medicine went to Harald zur Hausen, who discovered 
the role that HPV plays in the pathogenesis of cervical cancer. He demonstrated novel 
properties of HPV that have led to an understanding of mechanisms for papilloma virus-
induced  carcinogenesis  and  the  predisposing  factors  for  viral  persistence  and  cellular 
transformation. His discovery that specific ‘high-risk’ HPVs are most commonly involved 
in cervical cancer development led to the development of a now widely used vaccine that 
will potentially save thousands of lives worldwide, every year. 
The pathogenesis of equine sarcoids does not conform precicesly to many of the currently 
understood models of papilloma virus infection. This makes the study of equine sarcoids 
particularly intriguing and challenging.  20 
1.2  CLINICAL PRESENTATION 
Equine  sarcoids  are  locally  invasive,  fibroblastic  skin  tumours  and  represent  the  most 
common skin tumour in equidae worldwide (Jackson 1936; Ragland et al., 1970; Pascoe 
and Summers 1981). They can occur as single lesions or, more commonly, multiple lesions 
in different forms, ranging from small wart-like protuberances to large ulcerated fibrous 
growths.  There  is  an  established  system  of  clinical  classification  which  was  originally 
proposed by Professor D.C. Knottenbelt (2005) and is based on the physical appearance 
and behaviour of the tumour; 
1.2.1  Occult 
These tumours are persistent, grey and hairless; often circular or roughly circular (Fig 
1.1a), and probably represent the earliest form of the disease.  Although they are early 
forms it does not necessarily mean that they have been a recent occurrence.  Some of these 
lesions remain static for years without any clinical implication. Careful palpation of the 
lesion will usually reveal one, several or occasionally many tiny nodules in the skin of the 
affected  area.   The  skin  may  also  feel  slightly  thickened  and  lacking  in  its  normal 
elasticity. They are most commonly found on the face, axilla, inguinal and groin areas but 
can occur at any body site, although they are rarely identified on the distal limb region. 
Interference with occult lesions (either accidentally or intentionally during biopsy or ill 
advised treatments) usually results in a dramatic deterioration and transformation to one of 
the more serious forms.  In many such cases, the lesion will develop into a fibroblastic 
lesion within weeks. 
In addition to being mistaken for common and benign abrasions such as rub marks from 
tack, fence-posts or other solid objects, occult sarcoids may be confused with several other 
skin  conditions  such  as  ringworm  (dermatophytosis),  alopecia  areata  and  pemphigus 
foliaeceus. 
1.2.2  Verrucose 
Verrucose tumours are grey, scabby or warty in appearance (hence the term verrucous or 
verrucose or wart-like sarcoid). The lesions can be small and ‘papilloma-like’ extensions 
from the skin, but often they coalesce to cover large, ill-defined areas (Fig. 1.1b). Usually 
there is alopecia and the skin lacks normal flexibility, cracking easily when manipulated, 
particularly if the skin is folded over on itself. The surface of most verrucous lesions is 
hyperkeratinised and flakes and scale are easily rubbed from the surface. There may be 
some  ulceration  of  the  surface  exposing  red,  fleshy  tissue  underneath.  They  are  most 21 
commonly  identified  in  the  face,  groin,  sheath,  and  axilla  areas.  Interference  with 
verrucose  lesions  (either  accidentally  or  intentionally  during  biopsy  or  inadequate 
treatments) usually results in a dramatic deterioration and transformation to one of the 
more serious forms. In many cases the lesion will develop into a fibroblastic lesion within 
weeks and some cases will deteriorate dramatically into a malignant form. 
1.2.3  Nodular 
These can be single (Fig. 1.1c) or multiple and are often present in large numbers. Some 
have interlocking nodules giving a ‘bunch of grapes’- like appearance.  Some have no skin 
involvement (the skin can be moved freely over the surface) but some are firmly attached 
to the overlying skin (the skin cannot be moved over the surface of the nodule). Some 
ulcerate and form bleeding exudative masses. Two types are recognised based upon the 
extent of skin involvement: 
(i) Type A nodules 
Type A nodules are characterised as nodular tumours that have no skin involvement (Fig. 
1.1d). They lie entirely under the skin so that the skin can be moved freely over the lesion 
and the lesion can be moved freely over the deeper structures. Some type A nodules can be 
very deep beneath the skin (especially common in the girth and brisket regions and in the 
sides of the sheath).  These sites have quite thick skin overlying the sarcoid and this may 
be both an explanation for their depth and for their common failure to erupt through the 
skin or to influence the skin in any secondary fashion. The overlying skin may become 
hairless  and  thinned  and  eventually  the  skin  may  break  open  (often  spontaneously  or 
during minor handling) and the lesion then either presents as an ulcerated nodule, or the 
nodule may fall away spontaneously leaving a haemorrhagic cavity. Extensive groups of 
nodules that may or may not be linked together may develop in one or more locations. 
Apart from the eyelid, a type A nodule can be highly dangerous in some other locations 
such as the sheath and groin.  Some can be very extensive despite having no outward skin 
involvement. Histopathologically, the Type A nodule has an encapsulated nature with a 
loose fibrocellular surrounding that is responsible for its mobility.  
(ii) Type B nodules 
These sarcoids are those with visible or palpable skin involvement so that the skin cannot 
be moved independently.  Sometimes the overlying skin is alopecic and of a verrucous 
nature (Fig1.1e). This type of sarcoid can develop from a type A nodule (especially if these 22 
are interfered with or those that are neglected for long periods). The affected overlying 
skin is usually hairless, thickened and verrucous in appearance until the skin becomes 
ulcerated  when  a  fleshy  bleeding  surface  will  be  exposed.  Once  these  lesions  become 
ulcerated (for example, after interference / trauma) they develop rapidly into fibroblastic 
lesions. Eyelid nodules of this type are particularly dangerous – it has been shown that they 
have major propensity to deep and extensive “roots” that permeate the muscles of the 
eyelids  (Knottenbelt,  2005).  Histopathologically,  Type  B  nodules  have  poorly  defined 
margins both in the skin and the deeper tissues – this is consistent with their “fixed” nature 
and lack of independent mobility. 
1.2.4  Fibroblastic 
These tumours comprise fleshy masses, either with thin pedicle or a wide flat base that 
commonly bleed easily (Fig. 1.1f(i) and (ii)). They may have a wet, haemorrhagic surface. 
They  are  common  at  almost  every  site  and  may  develop  quickly  from  a  milder  form 
following even slight damage. They also commonly develop at the site of skin injuries on 
the limbs. 
1.2.5  Mixed 
The term ‘mixed tumour’ is used to describe lesions which contain variable mixtures of 
two or more of the other types (Fig. 1.1g). They can develop at any site but are commonest 
on the head, axilla and groin. It has been observed clinically, that many lesions are actually 
mixtures of the other types and so mixed sarcoid is a common diagnosis. 
1.2.6  Malevolent 
This  is  the  most  recently  classified  form  (Knottenbelt  2005)  and  is  applied  to  any 
aggressive lesion in which there is extensive local or wider spread through the skin and the 
subcutaneous  tissues  (Fig.  1.1h).  These  tumours  can  infiltrate  local  lymphatic  vessels 
resulting in the development of multiple nodular or fibroblastic type growths along these 
vessels. Local lymph nodes may also be involved. The skin need not be broken and there 
may be no superficial ulceration. There are often some overlying verrucous and occult 
changes in the skin; there are some cases that develop large areas of verrucous sarcoid with 
underlying smaller cords of nodular or fibroblastic sarcoids. Usually affected horses have 
multiple  sarcoids  at  other  sites  but  isolated  malignant  lesions  can  develop;  this  is 
commonest at the point of the elbow, the medial thigh and the side of the face. This form is 
a possible consequence of repeated and unsuccessful treatment attempts but some cases 
develop spontaneously. These are also classified as malignant. There is no recorded case in 23 
which the sarcoid has spread to internal organs and so the term malevolent is used to try to 
differentiate it from the metastatic, disseminating tumours of other neoplastic diseases that 
are also commonly referred to as ‘malignant’.  24 
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Figure 1.1 Equine sarcoids exhibit variable clinical presentation (Knottenbelt, 2005) 
There is an established system of clinical classification which was originally proposed by 
Professor D.C. Knottenbelt (2005) and is based on the physical appearance and behaviour 
of the tumour. Occult sarcoids appear as circular, hairless lesions (Fig. 1.1a). Verrucose 
(‘wart-like’) sarcoids can range from small well defined warts, to large areas of thickened, 
rough and warty skin (Fig 1.1b). Nodular sarcoids (Fig 1.1c) are further divided into two 
sub-groups. Nodular Type A sarcoids (Fig 1.1d) are classified as those nodular sarcoids 
with  no  skin  involvement,  so  that  the  skin  covering  the  sarcoid  shows  no  gross 
pathological change, and can be freely moved independently of the tumour mass. Nodular 
Type  B  sarcoids  (Fig  1.1e)  are  those  nodular  sarcoids  in  which  there  is  an  obvious 
involvement of the overlying skin, such as hair-loss and ulceration, and the skin cannot be 
moved independently of the tumour mass. 25 
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Figure 1.1 (cont.) Equine sarcoids exhibit variable clinical presentation  
Fibroblastic sarcoids often have a wet, ulcerated, haemorrhagic surface and tend to be 
large,  aggressive  type  tumours.  They  can  have  a  wide  tumour  base  (Fig  1.1f(i))  often 
referred to as sessile type fibroblastic sarcoids, or, they may have a distinct 'stalk' (Fig 
1.1f(ii)) and are referred to as pedunculated fibroblastic sarcoids. Mixed sarcoids are a 
combination of two or more of the previously mentioned types. Figure 1.1g shows a mixed 
tumour mass consisting of nodular and fibroblastic sarcoid types. Malevolent sarcoids (Fig 
1.1h)  are  comparatively  rare  and  are  the  only  tumour  type  shown  to  infiltrate  local 
lymphatic vessels and lymph nodes. 
(Pictures from Knottenbelt, 2005) 26 
1.3  HISTOLOGY 
On  histological  examination,  in  common  with  observations  of  gross  pathology,  equine 
sarcoids  continue  to  lack  predictable  and  consistent  characteristics.    Jackson  (1936) 
originally described the equine sarcoid as a biphasic tumour composed of epidermal and 
dermal components (Fig. 1.2a). However, occasionally the epidermal component can be 
normal, atrophic or even absent (Marti et al., 1993; Lepage et al., 1998; Martens et al., 
2000). Sections obtained from whole tumours allow for the most accurate histopathological 
assessment, however, surgical excision for the purpose of diagnosis may lead to a high rate 
of recurrence (50 - 64%) (Tarwid et al., 1985; Knottenbelt et al., 1995; Martens et al., 
2001b). Even taking a small biopsy of small and flat lesions may trigger rapid growth and 
ulceration.  Typical  changes  include  dermal  proliferation  of  fusiform  or  spindle-shaped 
fibroblasts, forming whorls, interlacing bundles and haphazard arrays with one another 
(Goodrich et al., 1998). Indeed, put simply, histological diagnosis is made on the presence 
of a capillary poor, fibroblastic proliferation of moderate to high cell density. Fibroblast 
morphology varies from slender with elongated, pointed nuclei, to plump cells with large, 
irregular  nuclei.  The  cytoplasmic  boundaries  are  often  ill-defined.  When  present,  the 
epidermis is reported to show hyperplasia and hyperkeratosis as well as rete peg formation 
in  the  majority  of  cases  (Fig  1.2b).  At  the  dermo-epidermal  junction,  a  perpendicular 
orientation  of  fibroblasts  towards  the  basement  membrane,  commonly  referred  to  as  a 
‘picket fence’ pattern, is considered characteristic (Ragland et al., 1970; Tarwid et al., 
1985; Scott 1988; Pulley and Stannard 1990; Marti et al., 1993). The mitotic rate is usually 
low, there is variable amounts of collagen and rarely infiltration of inflammatory cells 
(Goodrich et al., 1998; Martens et al., 2000; Tarwid et al., 1985). As alluded to above, 
there are few consistent histological changes that will lead to a confident diagnosis of 
sarcoid tumour. This is particularly relevant in the occult and nodular sarcoids as these 
types most commonly exhibit minimal histological changes (Martens et al., 2000) and 
helps explain why occult sarcoids are often overlooked histologically and why nodular 
sarcoids are sometimes identified as fibromas, neurofibromas or fibrosarcomas. Epithelial 
changes seen in sarcoids are likely the result of growth-promoting factors expressed by the 
neoplastic fibroblasts that stimulate proliferation of surrounding epithelial cells (Carr et al., 
2001b). 27 
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Figure 1.2 Histological findings in equine sarcoids 
Histopathological  section  of  an  equine  sarcoid  tumour  illustrating  some  of  the  more 
commonly observed morphological changes in the skin.  
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1.4  DIFFERENTIAL DIAGNOSES 
There are several alternative diagnoses to consider when investigating a sarcoid-like lesion 
(Tarwid  et  al.,  1985;  McConaghy  et  al.,  1994;  Knottenbelt  et  al.,  1995).  In  order  of 
prevalence, the most likely differentials are; 
Exuberant  granulation  tissue  (‘proud  flesh’)  with  epidermal  hyperplasia  is  grossly 
indistinguishable from fibroblastic sarcoids (Fig 1.3a) and may also present a problem on 
histological  examination.  However,  exuberant  granulation  tissue  sections  are  generally 
more vascular than sarcoids, and lack any ‘picket fence’ pattern. 
Equine Papillomas usually develop as multiple, cauliflower-like nodules on the nose and 
lips of young horses (Fig. 1.3b; Sullins et al., 1986). On histological examination, there is 
no dermal component. Equine papillomas often spontaneously regress, but this is rarely 
seen in sarcoids (Brostrom et al., 1979). 
Squamous  Cell  Carcinoma  occur  most  commonly  at  muco-cutaneous  junctions, 
particularly  of  the  ocular  tissue  and  external  genitalia  (Fig  1.3c).  They  can  readily  be 
differentiated from sarcoids on the basis of histological features. 
Neurofibromas  may  resemble  peri-ocular  sarcoids  but  are  found  to  be  associated  with 
nerve fibres. 
Fibromas may have ulcerated surfaces which can make differentiation between sarcoids 
particularly challenging. They may be recognised by their different growth pattern as they 
expand by compressing the surrounding tissue, rather than infiltration. 
Fibrosarcomas can be more challenging again, as they are more locally invasive, vary in 
size, and are usually irregular and poorly demarcated. Histological examination is the only 
way to confirm the diagnosis (Fig. 1.3d). The fibrosarcoma is a structure usually formed by 
fibroblasts, collagen and reticulin fibres. Tumor cells are fusiform, but they can also be 
stellate, separated by scarce collagen bundles. Mitoses are usually numerous, nuclei show 
prominent nucleoli, sometimes with the presence of multinucleated giant cells. The cell 
cytoplasm  is  poorly  coloured,  varying  in  shape  and  size,  cell  margins  are  difficult  to 
distinguish (van Roggen, 1999). 29 
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Figure 1.3 Common differential diagnoses for sarcoid like lesions. 
There are several alternative diagnoses to consider when investigating a sarcoid-like lesion. 
Proud  flesh  (Fig  1.3a;  www.hideawayhillfarm.com)  often  forms  at  wound  sites  on  the 
distal  limbs  –  a  not  uncommon  site  of  equine  sarcoid  development.  Squamous  cell 
carcinomas  (Fig  1.3b;  www.aht.org.uk)  are  occur  most  commonly  at  muco-cutaneous 
junctions, particularly of the ocular tissue and external genitalia – anatomical predilections 
for sarcoids. Figure 1.3c (www.homepage.usask.ca) shows the result of equine papilloma 
virus infection – the common wart. Fibrosarcomas can only be differentiated from sarcoids 
on the basis of histological examination (Fig 1.3d; www.pathologyatlas.ro). 30 
1.5  TREATEMENT OPTIONS 
Currently, there is no universally effective therapy for the treatment of sarcoids. Factors 
that owners and veterinary practitioners must consider in the treatment of equine sarcoids 
include  availability  of  treatment,  location  of  tumour,  cosmetic  considerations,  cost  of 
treatment,  potential  complications  and  the  risks  to  both  the  patient  and  the  owner. 
Commonly  employed  treatments  include  cryotherapy,  excision  and  local  immune 
modulation (Goodrich et al., 1998). A number of unconventional treatments have also 
enjoyed  some  popularity  as  owners  seek  cheaper  and,  possibly  anecdotally,  more 
successful  alternatives.  These  include  homeopathy,  acupuncture  and  various  topical 
ointments and feed supplements. Despite the lack of any scientific evidence, anecdotal 
evidence suggests tumour regression can occasionally be seen after application of these 
alternative therapies. Efficacy of different treatments is difficult to assess because most 
studies have not been designed to include controls and are frequently based on referral 
populations of horses treated at veterinary hospitals due to the hazardous nature of some of 
the treatment options (Goodrich et al., 1998; Martens et al., 2001a; McCauley et al., 2002) 
These  populations  are  more  likely  to  represent  a  subset  of  fast-growing,  recurrent  or 
multiple  tumours  that  first  opinion  veterinary  practitioners  have  been  unable  to  treat 
successfully. There are also reports of practitioners having treated sarcoids successfully 
with a policy of non-intervention, but again, these may represent a specific population of 
sarcoids that remain quiescent or those that spontaneously regress (up to 32%; Bromstrom, 
1995; Martens et al., 2001a). It is generally accepted that the prognosis for treatment is 
significantly  worse  if  one  or  more  unsuccessful  attempts  have  been  made  previously 
(Knottenbelt and Walker, 1994). The number of sarcoid treatments available continues to 
increase  on  a  regular  basis  and  many  therapeutic  approaches  have  been  investigated 
including surgical, intra-lesional, topical and immunomodulatory. Rather than merely list 
the many treatment options here, a selection of the more frequently employed modalities 
and their relative success rates, will be discussed below.  
1.5.1  Surgical Excision 
Ragland  et  al.  (1970)  reported  that  approximately  50%  of  surgically  excised  tumours 
recurred within 3 years, with most re-growths occurring within 6 months of the surgery. 
Other studies have reported recurrence rates from 40 to 72% when surgical excision has 
been employed as the sole therapeutic approach (McConaghy et al., 1994; Knottenbelt and 
Kelly, 2000; Martens et al., 2001b). Small, well-defined tumours carry the best prognosis 
for surgical removal, while extensive areas of poorly defined verrucose and mixed sarcoid 31 
may result in rapid re-growth of a more aggressive sarcoid type (Knottenbelt et al., 1995). 
Other major factors influencing the outcome of surgical intervention have recently been 
identified. If the surgery is performed on a horse under general anaesthesia (as opposed to 
a  standing,  sedated  animal),  wide  surgical  margins  are  taken  (which  may  negatively 
influence wound healing), and a ‘non-touch’ surgical approach is used to ensure auto-
inoculation with tumour cells and viral material is avoided, the success rates of 80% can be 
achieved (Howart, 1990; Brostrom, 1995; Martens et al., 2001b). 
Because  sarcoid  tumours  frequently  recur  if  treated  by  surgical  excision,  it  was 
hypothesised that this could be due to activation of latent BPV in apparently normal tissue 
surrounding  the  lesion.  Martens  et  al.,  (2001c)  used  PCR  to  test  for  BPV  in  sarcoids 
removed by surgery  and also tested apparently normal skin around the sarcoids. They 
found BPV in all of the sarcoids and also in the surrounding normal skin. The frequency of 
detection of BPV in the normal skin decreased as the resection margin was increased. They 
also found that in animals with a surgical margin containing BPV, there was a greater 
probability that these animals would show local recurrence. The role of BPV in equine 
sarcoid pathogenesis is discussed more fully in Section 1.4 Aetiology. 
1.5.2  Cryosurgery 
Cryosurgery alone, or in combination with debulking of larger sarcoids has been employed 
with some success (Laursen, 1987). Approximately 70% of horses treated appeared to be 
free from recurrences in most studies, although rates as high as 100% and as low as 60% 
have been reported (Lane, 1977; Goodrich et al., 1998; Fretz and Barber, 1980). Cell death 
(cryonecrosis)  is  achieved  by  repeated  freeze-thaw  cycles  and  complications  of  the 
technique arise due to damage of adjacent or underlying structures. These include scarring, 
leucotrichia, facial paralysis, haemorrhage and decreased strength of cortical bone (Fretz 
and  Barber,  1980;  Genetzky  et  al.,  1983,  McConaghy  et  al.,  1994).  Such  potential 
complications make cryosurgery less suitable for periocular sarcoids and those tumours 
located on larger vessels, nerves, ligaments or joints. 
1.5.3  Laser Surgery 
The carbon dioxide (CO2) laser is the preferred instrument for excision of sarcoids due to 
its minimal degree of collateral thermal injury and it is used to cut and evaporate tumour 
tissue (Vingerhoets et al., 1988; Palmer, 1989; Carstanjen et al., 1997). Vingerhoets et al. 
(1988) reported that 81% of 59 horses treated by CO2 laser were free from recurrence after 
12 months. Laser ablation minimises contamination of the surgical site with tumour cells 32 
and viral material compared to sharp surgical excision (Carr, 2006). Post-resection, there is 
minimal swelling and discomfort for the animal, and although there is considered to be 
superior cosmetic results, there is a risk of scar tissue formation and alopecia/leucotrichia. 
1.5.4  Hyperthermia 
Hyperthermia  is  a  radiofrequency  (orthovoltage)  current-induced  method  of  heating 
sarcoids to 50 
oC for 30 seconds, at intervals of 1 – 3 weeks. There are limited reports in 
the literature, so the true efficacy of this treatment option is unclear. One study reported 
induced regression with no recurrence at 7 to 12 months after the last treatment, in just 3 
cases  of  equine  sarcoid  (Hoffman  et  al.,  1983).  Hyperthermia  is  often  combined  with 
radiotherapy, immunotherapy and chemotherapy (Scott and Miller, 2003). 
1.5.5  Immunotherapy 
Bacillus of Calmette and Guerin (BCG), an attenuated strain of Mycobacterium bovis is 
the immunomodulator most commonly employed for immunotherapy of equine sarcoids. 
BCG activates mononuclear cells resulting in the release of interleukin-1. Interleukin-1 
non-specifically amplifies the immune response to antigens and malignant cells and has an 
immunoregulatory function (Vaneslow et al., 1988; Martens et al., 2001a). Optimal results 
are obtained if BCG is used in an immunocompetent host with a limited tumour burden, or 
post-debulking in the periocular region. An 83.5% rate of remission has been achieved 
with periocular sarcoids, while use in other body  regions,  resulted in  a 48.4% rate of 
remission (Webster and Webster, 1985; Owen and Jagger, 1987; Marti et al., 1993). There 
are several potential complications using this method of treatment, ranging in severity from 
general  inflammation  and  malaise  to  severe  anaphylactic  reactions  and  death  after 
inoculation. Advantages include tumour specificity whereby only sarcoid cell necrosis is 
noted on histopathologic post-BCG evaluation (Owen and Jagger, 1987).   
1.5.6  Radiotherapy 
The gold standard for treatment of the equine sarcoid is radiation but the availably of 
teletherapy and interstitial brachytherapy is very limited. Expense and practicality are the 
main limiting factors of this treatment as the absolute requirements for protective measures 
to ensure the safety of the operators and the need for patient isolation in a specialised 
facility post-treatment, all add to the considerable costs. Isotopes of various origin (e.g. 
permanently implanted seeds of radon-222 or gold-198; removable needles of radium-226, 
cobalt-60 or iridium-192) are placed in the tissue to deliver a continuous, high, local dose 
of ionising radiation (Wyn-Jones, 1983; Turrel et al., 1985; Theon and Pascoe, 1995). 33 
Responses range from 50 – 100% sarcoid-free for 1 year, where radiotherapy is used alone 
or  in  combination  with  hyperthermia  and/or  surgical  debulking  (Walker  et  al.,  1991; 
Knottenbelt and Kelly, 2000; Byam-Cook et al., 2006). 
1.5.7  Chemotherapy 
Chemotherapy  can  be  applied  topically  or  intralesionally.  Injection  of  cytotoxic  drugs 
directly  into  the  tumour  has  the  benefit  of  achieving  high  drug  concentration  for  a 
sustained period of time in the tumour, while sparing surrounding normal tissue (Mair and 
Couto, 2006). The drugs can be mixed with viscous fluids such as sesame oil prior to 
injection – this prolongs the persistence of the drug within the tumour tissue (Theon et al., 
1993). Chemotherapy drugs can be administered as a sole treatment to small sarcoids, but 
it  is  recommended  that  larger  lesions  are  surgically  debulked  prior  to  drug  treatment 
(Theon  et  al.,  1993;  Theon,  1997).  Cisplatin  is  currently  the  most  commonly  used 
intratumoural chemotherapeutic, although there are reports of intratumoural 5-fluorouracil 
(5FU) being used in a similar manner, but reports suggest it is less effective than cisplatin 
(Theon,  1997;  Stewart  et  al.,  2006).  Both  cisplatin  and  5-FU  require  strict  safety 
precautions to be employed by those treating and handling treated animals, due to the 
potential carcinogenicity and teratogenicity of the drugs. Disadvantages of intratumoral 
injection of these drugs include potential for secondary peri-injectional infections, some 
degree of tissue sloughing and peri-lesional swelling. 
Fluorouracil (5FU) 
As  a  pyrimidine  analogue,  5-fluorouracil  is  transformed  inside  the  cell  into  different 
cytotoxic metabolites which are then incorporated into DNA and RNA, finally inducing 
cell cycle arrest and apoptosis by inhibiting the cell's ability to synthesize DNA. It has 
been shown that the use of intratumoural 5-fluorouracil compares favourably with other 
treatment modalities for sarcoids, with a long term successful resolution rate of 61.5%. 
Resistant sarcoids and sarcoids larger than 13.5 cm3 have a poorer prognosis for resolution 
and more aggressive therapeutic options should be considered (Stewart et al., 2006). 5FU 
is commonly used as a topical treatment, but due to poor diffusion from the skin surface, 
its use is limited to flat lesions (Theon, 1998). 
Cisplatin 
The current understanding regarding the mechanism of action of cisplatin, is that the drug 
induces  its  cytotoxic  properties  through  binding  to  nuclear  DNA  and  subsequent 34 
interference with normal transcription, and/or DNA replication mechanisms (Alderden et 
al., 2006).  However, there is now much evidence suggesting that the cytotoxic effects 
induced by binding of cisplatin to non-DNA targets (especially proteins) may contribute to 
its biochemical mechanism of action (Fuertesa et al., 2003). Several studies have shown 
cisplatin to be a useful chemotherapeutic option in the treatment of equine sarcoids with 
one particular study observing complete regression in 78% of the tumours. It was also 
stated that no systemic side-effects were encountered (Spoormakers et al., 2002). Most 
recently, cisplatin containing biodegradable beads have been developed for use in solid 
tumours. A retrospective study by Hewes and Sullins (2006) reported an 85% success rate 
in  equine  sarcoids  treated  with  these  beads,  after  a  2  year  follow-up.  Additional 
developments in the application of intralesional cisplatin include combining cisplatin with 
adjuvant therapies to try and improve responses. The addition of a single high-dose of 
interleukin-2 has not improved efficacy over cisplatin injections alone (Spoormakers et al., 
2003). However, cisplatin intralesional injections followed by electropulsation of sarcoids 
(a  technique  that  improves  the  diffusion  of  chemotherapeutic  through  the  tumours), 
resulted  in  regression  after  only  2  or  3  electrochemotherapies  in  100%  of  the  treated 
lesions. No adverse effect from the electric pulses was observed and no regrowth was 
observed in the 18 months follow-up period (Rols et al., 2002). 35 
1.6  EPIDEMIOLOGY 
Sarcoids account for 35-90% of dermatological neoplasms of equidae (Goodrich et al., 
1998; Pascoe and Knottenbelt, 1999; Foy et al., 2002; Scott and Miller, 2003). A variable 
prevalence ranging from 1% to 12% is reported across the world (Mohammed et al., 1992; 
Goodrich et al., 1998; Studer et al., 2007) but studies on the epidemiology of the sarcoid 
have been hampered by a lack of population data and the low prevalence of the disease in 
individual, or small groups of animals. In addition, prevalence calculations are most likely 
to be based on populations of animals referred for sarcoid treatment, and do not include 
those animals that are successfully treated by first-opinion practitioners, or indeed, those 
cases  which  required  no  intervention.  Most  reports  suggest  that  there  is  no  apparent 
gender,  coat-colour,  seasonal,  geographic  or  breed  predilection  for  the  occurrence  of 
sarcoids in horses (Genetzky et al., 1983; Scott and Miller, 2003). Horses of all ages may 
be affected but reports show the majority of affected horses are younger than 6 years, with 
a peak incidence between 3 and 6 years (Sullins et al., 1986; Torrontegui and Reid, 1994; 
Foy et al., 2002; Scott and Miller, 2003). 
1.6.1  Anatomical predilection 
Lesions  can  occur  all  over  the  body  but  show  sites  of  predilection  particularly  in  the 
paragenital/inguinal region, the thorax–abdomen and head, and the lower limbs (Sullins et 
al., 1986; Teifke et al., 1994; Goodrich et al., 1998). Lesions frequently occur at sites of 
previous injury and scarring, or at sites that are predisposed to trauma (Torrontegui & 
Reid, 1994; Goodrich et al., 1998; Foy et al., 2002). They can occur as single or, more 
commonly, multiple lesions in different forms, ranging from small wart-like lesions to 
large ulcerated fibrous growths. Horses with multiple lesions tend to have larger sized 
tumours compared to horses with a single sarcoid lesion (Brostrom, 1995). 
1.6.2  Breed associations and genetic factors 
Evidence for a genetic basis for sarcoid susceptibility comes from family and population 
studies. The accumulation of cases of sarcoids in equine families has been reported, and 
more  recently,  an  association  between  sarcoid  susceptibility  and  the  major 
histocompatibility complex (MHC)-encoded class-11 allele ELA W13 was reported at the 
population level in several breeds (James, 1968; Lazary et al., 1985; Meredith et al., 1986; 
Angelos et al., 1988; Brostrom et al., 1988). A long-term epidemiological study into the 
association of sarcoid development with breed, carried out in the USA, showed that quarter 
horses were nearly twice as likely to develop sarcoids compared to thoroughbreds. The 36 
standardbred breed were found to be least likely to develop sarcoids, with the frequency of 
sarcoids in standardbred horses being less than half that of thoroughbreds (Angelos et al., 
1988). A higher incidence of sarcoid has also been reported in Arabians and Appaloosas 
(Miller and Campbell, 1982; Mohammed et al., 1992). In Arabian horses, a statistically 
significant link has been identified between sarcoid development and heterozygosity for 
the  defective  DNA  protein  kinase  catalytic  subunit  (DNA-PKcs)  allele  responsible  for 
severe combined immunodeficiency (SCIDS) (Ding et al., 2002). 
Research has shown a strong association between risk of sarcoid development and certain 
alleles of the equine major histocompatibility complex (MHC). In horses, these proteins 
are called the equine leucocyte antigens (ELA). The MHC is comprised of three different 
classes of genes with different locations and functions – all code for proteins involved in 
the immune response and for protein components of the compliment system (Piscopo, 
1999). The Class I genes code for proteins expressed in most nucleated cells; they have a 
role in the recognition and killing of virus infected cells. Class II genes code for proteins 
found on the surface of lymphocytes and macrophages which act as receptors for foreign 
antigens (Cresswell, 1994).  There are 17 internationally recognised Class I alleles (A1-10, 
A14-15, W12, W16-18, W20) and 3 Class II alleles (W13, W22-23), in addition, several 
regional/local variants are recognised in both classes (Lazary, 1988; Hesford et al., 1989).  
When  the  frequency  of  equine  MHC  haplotypes  was  examined  in  Thoroughbred  and 
Standardbred horses in  the USA, it was found  that the equine leukocyte antigen W12 
occurred more frequently  in sarcoid affected horses than unaffected horses. The MHC 
antigen ELA W12 was found to be rare in the standardbred breed (Meredith et al., 1986). It 
was subsequently found that the W13 haplotype is associated strongly with sarcoids in 
Swedish halfbreds (Brostrom et al., 1988) and Swiss Warmbloods (Gerber et al., 1988). A 
further Swedish study showed that there is an association between increased recurrence of 
sarcoids following surgery with the W13 haplotype and association between early onset of 
sarcoids and the A5 haplotype (Brostrom, 1995). However, the ELA specificities described 
so far are probably not directly involved in the pathogenesis of the equine sarcoid. The 
strong, breed-dependent association between certain ELA specificities and the prevalence 
of the disease might be explained by as yet undefined histocompatibility antigens that map 
within the MHC and/or by other genes (Brostrom et al., 1988). Further work is needed in 
this area to elucidate the exact role of genetics in the sarcoid pathogenesis. This would 
potentially  allow  development  of  novel  immunotherapeutic  approaches  and  informed 
breeding policies to help control the disease. 37 
1.6.3  Transmission 
Details  of  how  equine  sarcoids  may  be  transmitted  between  susceptible  animals,  is 
discussed at the end of the aetiology section (Section 1.6.6). 38 
1.7  AETIOLOGY 
The results of many studies have suggested the involvement of an infectious agent in the 
development  of  equine  sarcoid  tumours.  The  first  report  describing  the  equine  sarcoid 
suggested a virus origin for the tumours based on their appearance and pattern of spread 
(Jackson,  1936).  Outbreaks  have  been  described  in  closed  herds  of  horses  and  zebra, 
suggestive of an infectious agent (Ragland et al., 1966; Nel et al., 2006).  In 1951, Olson 
and Cook demonstrated that intra-dermal inoculation of cell-free extracts from bovine skin 
tumours  containing  bovine  papillomavirus  into  horses,  resulted  in  the  development  of 
lesions resembling the equine sarcoid (Olson and Cook, 1951). Subsequently, Voss (1969) 
provided more substantial evidence when he observed that inoculation with either sarcoid 
tissue or cell-free extracts from equine sarcoid tumours onto the scarified skin of sarcoid-
free horses, resulted in the appearance of sarcoid-like tumours at the inoculation site (Voss, 
1969).  However,  these  experimentally  induced  sarcoid  tumours  showed  spontaneous 
regression, which is only rarely encountered in naturally occurring sarcoids. Nevertheless, 
there  is  now  a  large  body  of  evidence  supporting  the  hypothesis  that  Bovine 
Papillomavirus (BPV) is the aetiological agent of equine sarcoids. DNA of BPV 1 or BPV 
2 has been detected in  most of the equine sarcoids examined (Amtmann et al., 1980; 
Müller, 1991; Goodrich et al., 1998; Campo, 2002; Chambers et al., 2003; Yuan et al., 
2007). Viral genes and proteins have also been detected in sarcoids, indicative of an active 
infection (Nasir and Reid, 1999; Carr et al., 2001; Chambers et al., 2003). Most work 
looking at BPV gene expression in equine sarcoid tissue has focussed on the early genes, 
namely E2, E5, E6 and E7 (Nasir and Reid, 1999; Carr et al., 2001; Chambers et al., 
2003).  Nasir  and  Reid  (1999)  also  detected  expression  of  the  L1  gene  in  50%  of  the 
tumours they studied. Little other work has been done looking specifically at the L1 and l2 
capsid genes. Whilst viral particles have not been detected, Brandt et al., (2008) have 
demonstrated BPV-1 virus-like structures in a subset of sarcoids using immunocapture 
PCR. This is the first evidence for the presence of potential intralesional BPV virions in the 
disease.  
1.7.1  Papillomaviruses 
Papillomaviruses (PVs) were first identified in the early 20th century, when it was shown 
that skin warts, or papillomas, could be transmitted between individuals by a filterable 
infectious  agent.  In  1935  Francis  Peyton  Rous,  who  had  previously  demonstrated  the 
existence  of  a  cancer-causing  sarcoma  virus  in  chickens,  went  on  to  show  that  a 
papillomavirus could cause skin cancer in infected rabbits. This was the first demonstration 39 
that a virus could cause cancer in mammals. PVs comprise a heterogeneous group of viral 
agents with a double stranded DNA genome of approximately 8 kb (Lowy & Howley, 
2002). Several hundred types of papillomaviruses have been identified, including the more 
than 100 PV types found in humans. PVs are normally strictly species-specific and have 
been  found  to  infect  all  birds  and  mammals  but  also  a  small  number  of  reptiles,  in 
particular turtles and tortoises (de Villiers et al., 2004). Infection by most papillomavirus 
types, depending on the type, is either asymptomatic or causes benign hyperproliferations 
of the skin or of mucosal tissues (Lowy & Howley, 2002). Papillomas caused by some 
types, however, such as human papillomaviruses (HPV) 16 and 18, carry a risk of the 
development of malignant disease, in particular cancer of the cervix uteri (Munoza et al., 
2006). PV infection of animals can also induce mucosal or skin warts, some of which can 
subsequently progress into malignant disease (Breitburd et al., 1996; Goodrich et al., 1998; 
Campo, 1997a; Chambers et al., 2003).  
1.7.2  Bovine Papillomavirus (BPV) 
Like other papillomaviruses, BPVs are small non-enveloped viruses with an icosahedral 
capsid around 50–60 nm in diameter. Figure 1.4a shows the BPV virion. The capsid is 
formed of the L1 and L2 structural proteins (discussed later in this chapter), with the L1 C-
terminus exposed. Ten BPV types (BPV 1-10) have been characterised and have recently 
been re-classified (de Villiers et al., 2004) following the Greek letter nomenclature used 
for other virus families. According to the new nomenclature, the epitheliotropic BPV-3, 
BPV-4  and  BPV-6  are  defined  as  Xipapillomaviruses  and  BPV-1  and  BPV-2  as 
Deltapapillomaviruses. BPV-5 has been designated an Epsilonpapillomavirus. In addition, 
16 novel putative BPV have been characterised by sequence determination of the highly 
conserved L1 region and by phylogenetic analysis (Antonsson and Hansson, 2002). 
Some types of papillomavirus, including BPV types 1 and 2, can infect fibroblasts and 
induce  fibro-epithelial  tumours,  which  cause  benign  fibropapillomas  in  cattle.  BPV  is 
highly prevalent, with around 50% of cattle being estimated to bear lesions in the UK 
(Campo,  1995). Cutaneous  warts  are  most  common  in  younger  animals  and  usually 
spontaneously  regress  as  they  age,  due  to  the  animal's immune  response.  Chronically 
immunosuppressed  animals  may  develop  extensive  papillomatosis  in  the  upper 
gastrointestinal  tract,  which  can  cause  difficulties  with  eating  and  breathing  (Campo, 
2006).  
BPVs  have  a  genome  of  up  t0  7945 bp  of  double-stranded  DNA,  with  at  least  nine 
potential reading frames. Like other papillomaviruses, the genome can be split into two 40 
principal regions as shown in Figure 1.4b. The early (E) region, encodes the transforming 
proteins E5, E6 and E7, and the replication and transcription regulatory proteins E1 and 
E2. The late (L) region encodes the structural proteins of the virus L1 and L2. The early 
and late regions are separated by a stretch of non-transcribed DNA, called the long control 
region (LCR), which contains the transcriptional promoters and enhancer, the origin of 
DNA replication and binding sites for numerous cellular transcription factors (Chen et al., 
1982). Seven promoters and alternative splicing produces more than 20 mRNA transcripts 
(Zheng and Baker, 2006; Jia and Zheng, 2009).  
The expression of BPV-1 and -2 early and late genes is highly regulated in the natural host, 
at both transcription and post-transcriptional levels and strictly tied to the differentiation of 
keratinocytes. For example, in papilloma formation, the virus initially infects the basal 
keratinocytes.  Papillomaviruses  gain  access  to  keratinocyte  stem  cells  through  small 
wounds in the skin or mucosal surface. Interactions between L1 and sulphated sugars on 
the cell surface promote initial attachment of the virus (Joyce et al., 1999; Giroglou et al., 
2001). The virus is then able to enter from the cell surface via interaction with a specific 
receptor, likely to be the alpha-6 beta-4 integrin, and is transported to endosomes (Evander 
et al. 1997; McMillan et al., 1999). The capsid protein L2 disrupts the membrane of the 
endosome, allowing the viral genome to escape and transit, along with L2, to the cell 
nucleus  (Kamper  et  al.,  2006).  The  early  region  genes  are  then  expressed  in  the 
undifferentiated basal and suprabasal layers. Viral DNA is replicated in the differentiating 
spinous and granular layers and, in the upper, terminally differentiated layers of the host 
epithelium,  the  late  genes  L1  and  L2  are  transcribed/translated  and  serve  as  structural 
proteins  which  encapsidate  the  amplified  viral  genomes.  The  new  viral  particles  are 
released into the environment as the cells die (Figs. 1.4c and 1.4d).  
Malignant transformation is linked to a disruption in the regulated expression of the early 
virus  genes,  the  consequences  of  which  are  an  uncontrolled  proliferation  and  loss  of 
differentiation  of  the  infected  cells.  Persistent  viral  infection  is  required  for  neoplastic 
progression and failure of virus clearance is attributed to a poor immunological response 
(Campo, 1997a). 41 
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1.7.3 
Figure  1.4  The  classification,  genome  organisation  and  life 
cycle of the bovine papilloma virus (BPV). BPVs are small non-
enveloped DNA viruses (Fig 1.4a; www.bristol.ac.uk). BPV has a 
genome of 7945 bp of double stranded DNA containing 6 early 
(E1, E2, E4, E5, E6 and E7) and 2 late (L1 and L2) genes (Fig 
1.4b).  Figure  1.4c  (www.ncbi.nlm.nih.gov)  illustrates  the  life 
cycle of BPV in the natural host, where the virus life cycle is 
strictly linked to the differentiation of the infected cell. Figure 
1.4d  (www.lab.anhb.uwa.edu.au)  shows  the  corresponding  skin 
section in an H and E stained slide.  42 
BPV -1 and -2 and neoplastic transformation 
Cancer, including PV-associated cancer, is a multi-factorial disease and several steps are 
required  before  full  neoplastic  transformation  is  achieved.  Bracken  fern  (Pteridium 
aquilinum)  has  been  identified  as  a  major  environmental  co-factor  in  BPV-induced 
carcinogenesis  in  cattle.  Bracken  fern  contains  immunosuppressants  and  a  number  of 
mutagens.  Bracken-induced  immunosuppression  is  associated  with  two  marked 
haematological  changes.  The  first  of  these  is  a  dramatic  fall  in  polymorph  nuclear 
leucocytes. If unchecked, this leads to severe acute immunosuppression with invasion of 
the  bloodstream  by  alimentary  bacteria  and  death  from  septicaemia.  This  is  the  well 
described veterinary syndrome of Acute Bracken Poisoning (ABP). The second effect of 
bracken  feeding  is  a  chronic  drop  in  circulating  lymphocytes.  Even  during  periods  of 
bracken withdrawal the  lymphocyte count remains very low. Field cases of upper and 
lower  GI  tract  cancer  are  found  to  occur  at  a  high  frequency  in  areas  such  as  the 
Nasampolai Valley of Kenya and the Western Highlands of Scotland where cattle graze on 
bracken-infested land (Plowright et al., 1971; Jarrett, 1980). In addition, bracken-eating 
cattle  develop  chronic  enzootic  haematuria,  urinary  bladder  cancers  and  chromosomal 
abnormalities (Jarrett et al., 1978; Moura et al., 1988; Stocco dos Santos et al., 1998; 
Borzacchiello et al., 2001; Borzacchiello et al., 2003; Lioi et al., 2004). The involvement 
of bracken and BPV-1 or BPV-2 in bladder carcinogenesis has been recognised for a long 
time  (Olson  et  al.,  1959),  and  the  virus-bracken  interaction  has  been  reproduced 
experimentally (Campo et al., 1992). BPV-1/2 infects the epithelium of the urinary bladder 
and establishes an abortive infection, with no production of virions. The viral DNA in the 
bladder  lesions  is  still  infectious  and  capable  of  initiating  a  replicative  cycle  in  the 
permissive environment of the skin, as extracts from urinary bladder cancers could induce 
skin warts (Olson et al., 1965). The immunosuppression induced by bracken fern prevents 
tumour rejection and the fern mutagens contribute to genome destabilisation. 
Viruses and their hosts are in a delicately balanced relationship. Viruses must be able to 
overcome  the  host  immune  response  to  replicate  and  produce  infectious  progeny.  The 
immune response of cattle to BPV is surprisingly poor (Campo, 1998). Animals may carry 
massive tumours, actively producing virus in large quantities, but cattle do not respond 
easily to BPV antigens during the course of infection and anti-BPV antibodies are seldom 
detected.  The  poor  immune  response  to  BPV  is  likely  to  be  the  main  reasons  for  the 
persistence of infection: even in immunocompetent hosts, the papillomas persist for many 
months  before  regression  takes  place.  In  addition  to  a  passive  evasion  of  the  immune 
system (by localisation inside epithelial cells), papillomaviruses have evolved active ways 43 
of hiding from the host immune system (O'Brien and Campo, 2002). Among these there is 
down-regulation of the Major Histocompatibility Complex class I (MHC I) by expression 
of BPV E5 protein. MHC I plays a critical role in immune surveillance as it is responsible 
for the presentation of antigenic peptides to effector T-cells. Once the heavy chain of MHC 
I  associates  with  β2-microglobulin  and  peptides,  the  complex  is  transported  from  the 
endoplasmic  reticulum  through  the  Golgi  apparatus  to  the  plasma  membrane  for 
recognition by T-cells (Cresswell, 2000). E5 is one of the main transforming proteins of 
BPV (the other being E6), and is a short hydrophobic membrane protein localizing to the 
Golgi apparatus and other intracellular membranes. Down-regulation of MHC I by BPV 
E5 takes place at multiple levels: transcription of the MHC I HC gene is reduced, the MHC 
I HC peptide is degraded (Ashrafi et al., 2002) and the MHC I complex is sequestered in 
the Golgi cisternae and is prevented from reaching the cell surface (Marchetti et al., 2002). 
The absence of MHC class I from the cell surface would help the infected cells evade host 
immunosurveillance. In addition, recent research has shown that the E5-induced reduction 
of MHC I has a functional impact by reducing recognition of E5 expressing cells by HPV 
specific CD8+ T cells (Campo et al., 2010). Furthermore, E5 has been shown to induce 
activation  of  the  platelet-derived  growth  factor  β  (PDGF-  β)  receptor  by  binding  to  it 
(Borzacchiello et al., 2008). Activation of PDGF- β receptors of the dermal fibroblasts 
results in mitogenesis in nearby  epithelial cells (Carr et al., 2001), contributing to the 
pseudoepitheliomatous hyperplasia that is typically observed in BPV infected lesions. E5 
also activates numerous kinases, possibly by signalling cascades triggered by PDGF- β 
receptor activation, including cyclin A-cdk2, MAP, JNK, PI3 and c-Src, thus interfering 
with proper cell-cycle control and further signal transduction cascades (Venuti & Campo, 
2002).  
The E6 protein is found localized in membrane and nuclear fractions and contains two 
highly  conserved  zinc  finger  domains  typical  of  DNA-binding  transcription  activator 
proteins. However, cell transformation by E6 appears to be independent of its transcription 
transactivation  function  (Ned  et  al.,  1997).  While  HPV  E6  binds  and  stimulates 
degradation of p53, BPV E6 does not (Scheffner et al., 1990; Rapp et al., 1999).  BPV-1 
E6 (BE6) has been described as interacting with three cellular proteins: E6AP (Ned et al., 
1997), E6BP (also known as ERC-55) (Chen et al., 1995), and paxillin (Tong and Howley, 
1997; Vande Pol et al., 1998). BE6 binds to similar peptide sequences found on each of 
these three proteins (Vande Pol et al., 1998). Unlike 16E6, where the binding to E6AP 
induces the degradation of p53, BE6 binding to E6AP has not been shown to induce the 44 
degradation of p53, and the in vivo interactions of BE6 with paxillin or E6BP have as yet 
unknown consequences. 
E7 protein cooperates with E5 and E6 in inducing cell transformation and once E7 is co-
expressed with E5 and E6, it’s transformation capacity increases many-fold (Bohl et al., 
2001). The transformation activity is partially mediated by its ability to bind p600. In a 
recent study, the ability of E7 to complex with p600 correlated with its ability to enhance 
anchorage independence of BPV-1 E6-expressing cells (DeMasi et al., 2005). 
The L1 protein is thought to be exposed on the viral surface, thus suggesting it has a role in 
infection and immunogenicity (Modis et al., 2002). L1 also mediates virus binding to the 
cell  surface,  although  it  is  thought  that  the  other  late  protein,  L2,  is  also  involved  in 
infection (Day and Schiller, 2006). L2 is also responsible for virion assembly by binding to 
DNA.  It is most abundant in the differentiated layers of the epidermis, particularly in 
mature papillomas (Anderson et al., 1997) 
The E1 protein functions in viral DNA replication (Lambert, 1991) and has been shown to 
be  involved  in  a  number  of  activities;   (i)  DNA  helicase  activity,  (ii)  BPV  origin-
containing DNA-specific binding activity, (iii) DNA-dependent ATPase activity, and (iv) 
BPV origin-specific unwinding of superhelical DNA (Seo et al., 1993). 
E2  binding  to  LCR  activates  or  represses  transcription  of  the  viral  genes  and  is  also 
required to segregate episomal BPV genomes to daughter cells by tethering them to mitotic 
chromosomes, thus ensuring equal division and retention of the viral DNA (Baxter et al., 
2005). 
The E4 ORF encodes for small proteins which are very abundant only in the cytoplasm of 
keratinocytes supporting the productive phase of viral DNA replication (Anderson et al., 
1997). 
In situ hybridization for BPV DNA of tissue sections from sarcoids reveals viral DNA in 
the dermal layer within the fibroblasts but not within the epithelial cells (Lory et al., 1993; 
Teifke et al., 1994; von Tscharner et al., 1996). 
1.7.4  BPV latency 
Like many viruses, BPVs can establish a latent infection. The viral genome can be often 
found in normal epithelia with no clinical sign of disease (Ogawa et al., 2004) both in 
tumour-bearing and in clinically normal hosts. Normal epithelia are the accepted site of 45 
latent infection, and indeed the reactivation of BPV at sites of trauma suggests that viral 
DNA is present in these sites in latent form, and that damage of the epithelium, possibly 
through production of inflammatory cytokines and stimulation of cell proliferation, induces 
expression of viral genes leading to papilloma formation (Campo et al., 1994).  
In one recent study, the presence and activity of BPV in normal skin and peripheral blood 
of 4 groups of horses was evaluated; (i) sarcoid-affected horses, (ii) horses living in contact 
with sarcoid-affected horses, (iii) horses living in contact with papilloma-affected cattle 
and (iv) control horses.  BPV DNA was found in the normal skin of 24 of 42 horses (57%). 
Mainly sarcoid-affected horses and horses living in contact with cattle were carriers (73%), 
but BPV DNA was also detected in 50% of the horses living in contact with sarcoid-
affected horses and in 30% of the control population. BPV mRNA was detected in 58% of 
the  samples  positive  for  BPV  DNA,  although  in  a  much  lower  quantity  compared  to 
sarcoids (Bogaert et al., 2007). Although the results of this study could not demonstrate the 
presence  of  BPV  DNA  in  any  of  the  blood  samples  taken,  a  more  recent  report 
demonstrates that peripheral blood mononuclear cells (PBMCs) can represent a reservoir 
of  BPV  DNA  in  sarcoid-affected  animals  (Brandt  et  al.,  2008).   Researchers  in  South 
Africa  recently  demonstrated  the  presence  of  BPV-1  and  -2  DNAs  in  zebra  sarcoid 
tumours. and demonstrated that BPV-1 and -2 DNA (either single or mixed infections) are 
present in sarcoid tumour, healthy skin and blood of sarcoid-affected and healthy zebras 
from sarcoid-affected parks as well as in the blood of zebras from parks where no sarcoid 
has been observed before (van Dyk et al., 2009). These results support the hypothesis that 
PBMCs may serve as host cells for BPV-1/-2 DNA and both contaminated blood and skin 
of infected and uninfected animals could contribute to virus latency. 
1.7.5  Equine Specific Variants 
Recently, it has emerged that sequence variation occurs within papillomavirus types, which 
can influence the cellular location and function of the oncoproteins and consequently affect 
the pathogenesis and transforming ability of the virus (Giannoudis & Herrington, 2001). 
Using sequence analysis of BPV DNA isolates extracted from sarcoids, the presence of 
distinct equine sarcoid-specific variants of BPV has been detected (Otten et al., 1993; Reid 
et al., 1994; Chambers et al., 2003; Nasir et al., 2007). The sequence changes in the E5 
protein reported by Reid et al. (1994) and Chambers et al. (2003) suggest the possibility 
that these changes are contributing factors to the pathogenesis of the disease. Variants 
particular to sarcoid BPV-1 were also identified in both the long control region (LCR) and 
E2  sequence.  The  LCR  of  papilloma  viruses  (PVs)  plays  an  important  part  in  the 46 
pathogenesis of PV infections as the LCR functions as the transcriptional control unit of 
the virus. Transcriptional control from the LCR is regulated by a range of cellular factors 
and also by the virally encoded early gene product E2, which is also required for viral 
DNA replication (McBride et al., 1991). Previous studies on PVs have shown that intra-
type  sequence  variation  within  the  LCR  and  some  LCR  variants  exhibit  altered 
transcriptional control, which may in turn alter the pathogenesis and transforming affects 
of the virus (Kammer et al., 2000; Kurvinen et al., 2000; Veress et al., 2001). Using BPV 
DNA extracted from sarcoid tumours, the functionality of the most common LCR variant 
was examined in equine and bovine cells by Nasir et al., (2007). These studies showed that 
the activity of the variant LCR was higher in equine cells than bovine cells; the activity of 
the variant LCR in the presence of the E2 variant was similar to the reference/wild-type 
sequences in equine cells, whereas in bovine cells the variant function was reduced by 
50%. These data suggest the viral BPV variants commonly detected in sarcoids have an 
enhanced function in equine cells compared to their function in bovine cells. As found for 
HPV, these sequence changes could affect the expression and function of the early virus 
proteins and may explain the different pathogenesis of the equine sarcoid compared to 
papillomas  induced  by  BPV  in  cattle.  However,  this  remains  to  be  established. 
Furthermore,  if,  as  mentioned  earlier,  horses  are  commonly  asymptomatically  infected 
with ‘equine-adapted’ BPVs (Bogaert et al., 2008), entry of the virus into the dermis, due 
to, for example, trauma, may be more important in sarcoid development than exposure to 
the PV. 
1.7.6  Transmission 
Although there is convincing evidence that BPV types 1 and 2 are the principal causative 
agent  of  sarcoids,  there  is  currently  no  definitive  evidence  to  support  any  particular 
hypothesis  of  how  the  disease  may  be  transmitted.  As  mentioned  earlier,  there  is  a 
predilection for sarcoid development at wound sites and it has been proposed this may be 
due to flies acting as a vector as they move between wound sites on different horses. BPV 
DNA  sequences  have  been  detected  in  face  flies,  which  are  commonly  seen  around 
wounds. The same viral DNA sequences were detected in the sarcoid tissue samples taken 
from  the  horses  from  which  the  flies  were  removed  (Kemp-Symonds,  2000).  BPV 
infection may also be transmitted via stable management practices, such as the sharing of 
contaminated tack, or passed into existing wounds from contaminated pasture. A recent 
study by Boegart et al., (2005) demonstrated the presence of BPV DNA on the normal skin 
of  horses  affected  by  equine  sarcoids  and,  to  a  lesser  degree,  on  the  normal  skin  of 
unaffected horses living in contact with affected animals. It seems plausible that virus 47 
present on the normal skin may gain access to the dermis through any abrasion that may 
breach the epidermal layers, and so result in the development of a sarcoid lesion in a 
susceptible animal. 48 
1.8  AIMS AND OBJECTIVES 
The aims of this PhD thesis were to: 
1.  Evaluate  the  potential  role  of  flies  as  vectors  in  transmission  of  equine 
sarcoids between infected and susceptible animals.  
2.  Investigate  the  consequences  of  BPV  transformation  in  cultured  equine 
fibroblasts with regard to cellular response to DNA damage; apoptosis and 
long term cell survival. 
3.  Identify the viral gene(s) responsible for conferring resistance to apoptosis 
and/or enhanced cell survival and evaluate the use of viral-gene targeted 
siRNA as a potential therapeutic strategy 
4.  Investigate the activity, functionality and cellular location of the tumour 
suppressor p53 gene in equine sarcoids. 49 
2  Chapter II: 
 
Materials and Methods 50 
2.1  MATERIALS 
Materials in regular use, such as equipment, general reagents and solutions are detailed in 
this section. 
2.1.1  Plasticware 
Tissue culture flasks and Falcon conical centrifuge tubes (15 and 50ml) were supplied by 
Greiner (Gloucestershire, UK). 6-well plates and pipettes (5, 10, 25, 50ml) were supplied 
by Corning (Fisher, UK). 
2.1.2  Solutions, media and supplements 
All solutions and media for cell culture were supplied by Invitrogen, UK, unless otherwise 
stated. 
2.1.2.1 Media 
All media were supplied as sterile solutions and stored at 4 
oC. 
·  Dulbecco’s  Modified  Eagle’s  Medium  (DMEM)  with  Glutamax-1  with 
sodium pyruvate, glucose and pyridoxine. 
·  Minimal Essential Media (MEM-a). 
·  Opti-MEM 
2.1.2.2 Supplements 
·  Foetal Bovine Serum (FBS): virus and mycoplasma screened. FBS was heat 
inactivated at 56 
oC for 30 minutes, then stored in 50ml aliquots at -20 
o C. 
·  Penicillin/streptomycin (P/S): supplied as a 100x stock solution of 10,000 
units penicillin and 10,000 units streptomycin per ml and stored in 5 ml 
aliquots at -20 
oC. 
·  Fungizone; Ampotericin B (Sigma, UK): supplied as a 100x stock solution 
and stored in 5 ml aliquots at -20 
oC. 
·  Trypsin-EDTA:  supplied  as  a  100x  stock  solution  and  stored  in  5  ml 
aliquots at -20 
oC. 51 
·  Sodium pyruvate: supplied as a 100mM stock solution and stored at 4 
oC. 
·  Non Essential Amino Acids (NEAA): supplied as a 100x stock solution and 
stored at 4 
oC. 
·  Essential Amino Acids (MEM EAA): supplied as a 50x stock solution and 
stored at 4 
oC. 
All cell lines were cultured in DMEM (Invitrogen, UK) supplemented with 10% foetal calf 
serum,  1% Non Essential Amino Acids (NEAA), 1% Essential Amino Acids MEM EAA), 
100 U/ml Penicillin/Streptomycin and 1.25 ug/ml Fungizone; Ampotericin B (Sigma, UK). 
2.1.2.3 Freeze Medium 
Medium  for  cryopreservation  of  cells  was  prepared  by  mixing  9  ml  growth  medium 
(appropriate to the cell line being stored) with 9 ml foetal calf serum and 2 ml DMSO 
(45% medium/45% foetal calf serum/10% DMSO). 
2.1.3  Cell lines 
Previous work done at the University of Glasgow has successfully generated equine cell 
lines harbouring BPV-1 genomes and expressing viral genes (Yuan et al., 2007).  
·  EqS cell lines (EqS01, EqS02, EqS03 and EqSO4b): These cell lines were 
derived from explants of sarcoid tumour biopsies. 
·  S6 cell lines (S6-1, S6-2 and S6-3): These cell lines were generated in vitro 
by transfection of primary fibroblasts with BPV-1 DNA (S6 cell lines).  
·  EqPalF cell line: BPV-1-negative foetal fibroblast cells cultured from tissue 
from the foetal palate. 
The EqS and S6 equine cell lines are morphologically transformed, proliferate faster than 
parental cells, have an extended life span and can grow independently of substrate.  
2.1.4  Complete kits 
·  Qiagen DNeasy Blood and Tissue Kit (QIAGEN, UK)  
·  Qiagen RNeasy Mini Kit (QIAGEN, UK) 
·  QIAquickÒ PCR Purification Kit (QIAGEN, UK) 52 
·  QIAquickÒ Gel Extraction Kit (QIAGEN, UK) 
·  ECL-PLUS  Western  Botting  Detection  Reagents  (GE  Healthcare, 
Amersham, UK) 
·  DNA Sequencing Kit Big Dye Terminator Version 3.0 Cycle Sequencing 
Ready Reaction (ABI Applied Biosystems, UK) 
·  Annexin V-FITC Apoptosis Detection Kit (Calbiochem, UK) 
·  SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, UK) 
·  Templi Phi 100 Amplification Kit (GE Healthcare, Amersham, UK) 
·  MycoAlert™ Mycoplasma Detection Kit (Cambrex Bio Science, UK) 
2.1.5  DNA 
Plasmid, molecular weight markers and oligonucleotide DNAs were stored at -20 
oC. 
2.1.5.1 Molecular Size Standards 
All markers were supplied by Invitrogen, UK and include 1 kb DNA Ladder (size range: 
75- 12,216 bp), 1 Kb Plus DNA Ladder (size range: 100- 12,000 bp), and 100 bp DNA 
Ladder (size range: 100-2072 bp). 
2.1.5.2 Oligonucleotide primers 
Oligonucleotides for use in polymerase chain reactions (PCR) and cycle sequencing were 
synthesised by IDT, UK. Primers were either reverse phase, desalted or Poly Acrylamide 
Gel  electrophoresis  (PAGE)  purified  and  supplied  as  lyophilised  DNA.  Primers  were 
reconstituted in dH2O and stored at –20 
oC in 500 ml aliquots at 10mM. 
2.1.6  Enzymes 
All enzymes were stored at –20 
oC, being removed immediately before use. 
2.1.6.1 Platinum Taq DNA Polymerase 
Platinum Taq DNA Polymerase is a recombinant Taq DNA polymerase complexed with a 
proprietary antibody that inhibits polymerase activity at ambient temperatures. Activity is 
restored  after  the  denaturation  step  in  PCR  cycling  at  94 
oC,  thereby  providing  an 53 
automatic  “hot  start”  for  Taq  DNA  polymerase  in  PCR,  which  provides  increased 
sensitivity, specificity and yield while allowing assembly of reactions at room temperature. 
2.1.6.2 Platinum Taq DNA Polymerase High Fidelity 
Platinum  Taq  DNA  polymerase  High  Fidelity,  provided  by  Invitrogen,  is  an  enzyme 
mixture  composed  of  recombinant  Taq  DNA  polymerase,  Pyrococcus  species  GB-D 
polymerase, and Platinum Taq antibody.  Pyrococcus species GB-D polymerase possesses 
a  proofreading  ability  by  virtue  of  its  3’  to  5’  exonuclease  activity.    Mixture  of  the 
proofreading enzyme with Taq DNA polymerase increases fidelity approximately six times 
over that of Taq DNA polymerase alone and allows amplification of simple and complex 
DNA templates over a large range of target sizes.  The enzyme mixture is provided with an 
optimised buffer that improves enzyme fidelity and amplification of templates. 
2.1.6.3 Superscript III Reverse Transcriptase 
Superscript  III-RT,  provided  by  invitrogen,  is  a  version  of  MMLV-RT  that  has  been 
engineered to reduce RNase H activity and provide increased thermal stability. 
2.1.6.4 RNaseOUT Recombinant Ribonuclease Inhibitor 
RNaseOUT  Recombinant  Ribonuclease  Inhibitor,  provided  by  Invitrogen,  is  an  acidic 
protein with a very high binding affinity for ribonucleases such as RNase A, B, C and is a 
non-competitive inhibitor. 
2.1.6.5 Alkaline Phosphatase 
Calf Intestinal alkaline phosphatase provided by Promega catalyses the hydrolysis of 5¢- 
phosphate groups from DNA.  
2.1.6.6 DNase I: DNA-free 
DNase I, provided by Invitrogen, is a deoxyribonuclease I enzyme that cleaves double-
stranded or single stranded DNA. Cleavage preferentially occurs adjacent to pyrimidine (C 
or  T)  residues,  and  the  enzyme  is  therefore  an  endonuclease.  Major  products  are  5'-
phosphorylated di, tri and tetranucleotides. In the presence of magnesium ions, DNase I 
hydrolyzes each strand of duplex DNA independently, generating random cleavages. In the 
presence of manganese ions, the enzyme cleaves both strands of DNA at approximately the 54 
same site, producing blunt ends or fragments with 1-2 base overhangs. DNase I does not 
cleave RNA. 
2.1.7  Equipment 
2.1.7.1 Major Equipment 
·  Benchtop centrifuge: CPR Centrifuge (Beckman) 
·  Microcentrifuges: Centrifuge 5402, 5415R and Minispin (eppendorf) 
·  Water baths: Sub 36, and W6 (Grant) 
·  Spectrophotometer: GeneQuant pro RNA/DNA calculator 
·  Automatic Sequencing Apparatus: ABI 3010 
·  Pipettes: Finnipipette Techpette (0.5-10, 5-40, 40-200, 200-1000 ml) 
·  Ultraviolet trans-illuminator: T2201 (Sigma Chemical Company) 
·  Gel documentation system: Uvi tec (Thistle Scientific) 
·  Luminometer: Dynex MLX 
·  Horizontal orbital shaker: 4628-1CE Labline Instruments inc (IL) 
·  Incubator: B5042 (Heraeus) 
·  Gel systems: Hoefer HE 33 Mini Horizontal Submarine Unit 
·  Power packs: PAB 35-0.2 (Kikusui electronics corp, Biorad, UK) 
·  Balance: Precisa 100A-300M (Precisa Balances Ltd, Bucks, UK) 
·  Stirrer: Magnetic Stirrer Hotplate (Stuart Scientific, UK) 
·  PCR  Machines:  GeneAmp  PCR  System  2400,  2700  and  DNA  Thermal 
Cycler 480 (Perkin Elmer) 
·  Flow Cytometer:  Epics XL Flow Sorter (Beckman-Coulter Inc., Miami, 
FL) 55 
2.1.7.2 Consumables 
·  Syringe top filters (0.2 mm pore size) were supplied by Nalgene, (NY, 
USA) for sterilisation of ampicillin and tissue culture reagents. 
·  Ependorf tubes: screw top 1.5ml tubes were from Camlab, and 0.5 ml and 
1.5 ml flip top tubes were supplied by Anachem. 
·  Pipette tips, universal fit yellow and blue tips, were supplied by Greiner. 
·  Filter  tip  pipette  tips;  10  ml  from  Greiner,  100,  200  and  1000  ml  were 
supplied by Starlab, UK. 
·  Petri dishes were supplied by Sterilin (Staffs, UK) 
·  Bijoux were supplied by Greiner 
·  Universals were supplied by Greiner 
·  Scalpel blades were supplied by Swan-Morton (Sheffield) 
·  Parafilm was supplied by Sigma 
2.1.7.3 Buffers, solutions and growth media 
2.1.7.3.1  Chemotherapeutic Agents 
·  Cisplatin: Supplied by Hospira, UK as a ready to use sterile solution (10 
mg/ml). 
·  5-Fluorouracil: Supplied by Hospira, UK as a ready to use sterile solution 
(50 mg/ml). 
2.1.7.3.2  Buffers and solutions 
·  50 x TAE Buffer Solution: Tris base 484.5g, NaOAc 272.15 g, NaCl 116.8 
g, Na2EDTA 74.45 g. pH adjusted to 8.15 with glacial acetic acid and made 
up to 2 L volume. 
·  TBE Buffer Solution: 0.09M Tris Borate, and 0.002M EDTA 56 
·  Lysis Buffer: 25mM Tris HCL pH 8.0 with glacial acetic acid and made up 
to 2 L volume 
·  Lysis  Buffer  for  Western  Blotting:    0.5%  NP40,  150mM  NaCl,  50mM 
TrisHCL adjusted to pH 8.0, protease inhibitor tablet (1 per 10 ml of lysis 
buffer) 
·  1M Tris HCL: 121g Tris base, 800ml dH2O. Adjusted to the desired pH 
with concentrated HCL and made up to 1L. 
·  TE Buffer: 10mM Tris-HCL (pH 8.0), 1mM EDTA 
·  1 x PBS: 140mM NaCl, 2.7mM KCL, 10mM Na2HPO4, 1.8 mM KH2PO4 
(pH 7.3) 
·  0.2M  (2x)  Phosphate  Buffered  Saline  (PBS):  0.2M  Na2HPO4,  0.2M 
NaH2PO4, 1.8% w/v NaCl, pH 7.4 
·  10x DNA Gel Loading Buffer: 30% w/v glycerol, 0.25% bromophenol blue, 
70% TE buffer. Stored at room temperature and used at a 1:10 dilution. 
·  Ethidium bromide: made to a working dilution of 10mg/ml with dH2O in a 
fume cupboard. Stored away from light. 
·  DEPC water: 0.5ml of Diethylpyrocarbonate in 500ml water, overnight at 
room temperature in the fume cupboard and autoclaved. 
·  Lysis mix: 0.32M sucrose, 10mM Tris, 5mM MgCl, 1% Triton X 
·  Nuclei lysis mix: 10mM Tris, 0.4 NaCl, 2mM EDTA 
·  TRIS-EDTA: (10/1 pH 7.4) 
·  TRIS-EDTA: (10/0.1 pH7.5) 
·  NU-PAGE Transfer Buffer: supplied by Invitrogen and diluted 1:20 
·  NU-PAGE Running Buffer: supplied by Invitrogen and diluted 1:20 
·  10x Ponceau’s Red Stain: 2 g Ponceau S, 30 g Trichloroacetic acid (TCA), 
30 g Sulphopalicylic acid. Made up to 100 ml by addition of dH2O 57 
·  TBS-Tween:  150  mM  NaCl  (8.77  g),  50  mM  Tris  (6.06  g)  and  0.05% 
Tween (0.5 ml). Made up to 1L by addition of dH2O 
·  Blocking Buffer: 1 g non-fat skimmed milk powder in 20 ml TBS-Tween 
·  Antibody  diluent:  0.2  g  non-fat  skimmed  milk  powder  in  20  ml  TBS-
Tween. 
·  Bio-Rad Reagent: supplied Bio-Rad Laboratories (Hemel Hempstead, UK)   
·  Bovine Serum Albumin (BSA): supplied by Sigma Fraction V, UK. 58 
2.2  METHODS 
Common  methods  used  throughout  the  thesis  are  described  in  this  chapter,  whilst 
techniques  specific  to  one  area  are  described  in  later  chapters.  Many  of  the  methods 
described are based on standard techniques, which are detailed in Current Protocols in 
Molecular Biology Volumes 1 & 2 (1994). 
2.2.1  Growth and manipulation of mammalian cells 
2.2.1.1 Basic techniques 
Techniques  used  in  the  culture  and  manipulation  of  mammalian  cells  were  performed 
under aseptic conditions. Where possible, all procedures were performed in a laminar flow 
hood.  
2.2.1.1.1  Cell lines 
All cell lines were grown as an adherent monolayer in culture, in either 25 or 75 cm
2 tissue 
culture flasks stored in an incubator at 37
oC with 5% CO2 
Primary foetal palate cells, EqPalF cells, and sarcoid derived cell lines from tumour were 
generated and established as described by Yuan ZQ (2008). Generation and establishment 
of  EqPalF-BPV-1  transformed  cells  are  also  described  (S6  cell  lines).  Briefly,  tissue 
samples from foetal palate and sarcoid tumours were finely dissected and washed with 
Hanks  Buffered  Salt  Solution  (HBSS)  (Invitrogen  Ltd,  Paisley,  UK)  and  incubated 
overnight at 4 °C in 0.25% trypsin/HBSS. After removal of the trypsin solution, samples 
were incubated at 37 °C for 30 min followed by the addition of warm Dulbeccos Modified 
Eagles medium (DMEM) supplemented with 10% FCS, 100 U/ml penicillin/streptomycin, 
1.25  g/ml fungizone, Ampotericin B and Ciproxin (Sigma, UK), 1% non-essential amino 
acids and 1% essential amino acids (complete DMEM). The cell suspensions were passed 
through a 100  m nylon cell strainer (BD Falcon™) and centrifuged. Resuspended cells 
were then seeded into 25 cm
2 tissue culture flasks at 1 × 10
6 cells per flask in 10 ml of 
complete DMEM and incubated in a 37 °C humidified atmosphere of 5% CO2 in air until 
cells  reached  confluence.  Cells  were  passaged  by  trypsinization  and  this  stage  was 
regarded as the first passage. Equine sarcoid tumor-derived fibroblasts were termed EqS 
cells and the fetal palate fibroblasts termed EqPalFs. All cells were maintained in culture in 
complete DMEM in a 37 °C humidified atmosphere of 5% CO2 in air.  59 
Cells were routinely tested for mycoplasma using the MycoAlert kit from Cambrex Bio 
Science. Briefly, 5 ml of cell culture supernatant was removed and spun down to remove 
floating cells. 100 µl of this supernatant was placed in a 96 well white plate.  100 µl of 
Mycoalert reagent was added and the mixture left for 5 minutes at room temperature. The 
luminescence was measured to determine Reading A.  100 µl of Mycoalert substrate was 
then added and after 10 minutes a second luminescence measurement was made (Reading 
B).  Calculate ratio = Reading B/Reading A. A positive control was included as a sample 
in the 96 well plate and negative control of fresh media was also included. 
If the Reading B/Reading A ratio was less than 1, the sample was considered negative. A 
result of 1-1.3 was considered a borderline result and a retest was conducted. A result of 
more than 1.3 means the sample is positive for mycoplasma. All tests carried out on all the 
cell lines used were consistently negative. 
2.2.1.1.2  Cell cryopreservation and storage 
For long term storage of cell line stocks, cells were stored in liquid nitrogen. Prior to 
storage, cells were grown to between 70 and 90% confluency and trypsinised with trypsin-
EDTA  before  being  transferred  to  a  sterile  15  ml  centrifuge  tube.  The  cells  were 
centrifuged at 1000 g for 5 minutes, the supernatant discarded and cells re-suspended in 
freezing medium (appropriate culture medium supplemented with foetal calf serum at 45% 
and DMSO at 10%) to a concentration of 2-4 x 106 cells/ml. The cell suspension was 
transferred in 1 ml aliquots to labelled cryovials (NALGENE) and brought to -70 
oC at a 
controlled rate (-1 
oC/min) using a NALGENE Cryo 1 
oC Freezing Container (NALGENE, 
USA) transferred to a –70 
oC freezer overnight. Finally, vials were transferred to a liquid 
nitrogen freezer for long term storage. Cell stocks were revived by rapid thawing in a 37 
oC water bath and subsequently used following standard techniques as described below. 
2.2.1.1.3  Cell Counting 
Cells  were  counted  using  a  haemocytometer.  Following  trypsinisation  or  revival  from 
frozen stocks, cells were transferred to a 15 ml centrifuge tube and centrifuged at 1200g for 
5 minutes.  Supernatant was discarded and cells were resuspended in 5 ml of complete 
medium.  A 25 ml sample was withdrawn and added to 25 ml trypan blue (Sigma) resulting 
in  a  two-fold  dilution.    A  sample  of  this  mixture  was  then  introduced  to  the 
haemocytometer chamber and counted using an inverted microscope at 40x magnification. 
Cells lying on the top and right hand perimeter of each large (1 ml) square were included 
whilst those on the bottom and left hand perimeter were excluded. Cell concentrations 60 
(cells/ml) were calculated by multiplying the mean number of cells per large square by 
10^4 and 2 to correct for the dilution factor.  
2.2.2  DNA techniques 
2.2.2.1 Extraction of DNA 
DNA was extracted from a range of source materials. These included whole flies, whole 
blood, cell cultures, buccal swabs and tumour tissue. 
2.2.2.1.1  Preparation of equine genomic DNA from peripheral blood mononuclear cells  
Equine whole blood samples (5 ml) were mixed with lysis mix (45 ml) and incubated on 
ice for 10 mins. The mixture was then centrifuged at 2800g for 10 mins at 4 
oC and the 
pellet re-suspended in nuclei lysis mix (3 ml). After the addition of 10% SDS (200ml) and 
75ml of proteinase K (10mg/ml) the mixture was incubated at 55
o C for 2 hours or at 37 
oC 
overnight. Two extractions with 3 ml phenol/chloroform (50:50) were then performed, 
each centrifuged for 10 mins at 2800g at room temperature. The upper aqueous phase was 
then transferred to a fresh tube and the DNA precipitated by addition of 10% sodium 
acetate (pH 5.2) and then 3 volumes of 96% ethanol. The DNA was re-suspended in 250ml 
of TE Buffer and the quantity and quality of genomic DNA was assessed using the Thermo 
Scientific NanoDrop 2000. The NanoDrop 2000 is a micro-volume spectrophotometer that 
can assess the concentration and quality of DNA in a particular sample. 
2.2.2.1.2  Extraction of DNA from whole flies, cell cultures, buccal swabs and tumour 
tissue. 
DNA was extracted from all other sources using the Qiagen DNeasy kit. Although initial 
preparation of the source material varied slightly between cell culture, buccal swabs, flies 
and tumour tissue, the overall process was basically the same. Firstly, cellular components 
were lysed and histones and other proteins associated with the DNA are digested with the 
enzyme  proteinase  K.  The  DNA  is  then  bound  to  a  mini-column  holding  a  silica-gel 
membrane that selectively binds DNA. The cellular debris is washed off using a series of 
buffers containing salt and ethanol and the centrifuge. The resulting extract was assessed 
for DNA yield and quality using nanodrop .   
2.2.2.2 Determination of DNA and RNA concentration and quality 
2.2.2.2.1  Determination by spectrophotometry 61 
The optical density was measured at 260 nm and 280 nm, in comparison to a reference of 
TE  buffer.  An  optical  density  (OD)  reading  of  1.0  at  260  nm  corresponds  to  an 
approximate concentration of 50 mg/ml for double stranded DNA, 40 mg/ml for RNA, or 
33 mg/ml for single stranded oligonucleotides. The ratio of the OD readings at 260 nm and 
280 nm (OD260/OD280) was used to estimate sample purity, with pure preparations of 
DNA and RNA producing an OD260/OD280 of 1.8 and 2.0, respectively. A lower value 
suggests possible protein or phenol contamination of the sample. 
2.2.2.2.2  Estimation of double stranded DNA concentration via gel electrophoresis 
In some instances, insufficient concentration of (ribo)nucleic acid or verification of the 
purity  of  DNA  fragments  of  a  particular  size  did  not  allow  quantification  via 
spectrophotometry.    In  these  cases,  the  concentration  of  double  stranded  DNA  was 
determined by running the sample on a 1% agarose gel along with a marker of known 
quantity and size. The intensity of the sample fluorescence was compared to that of a mass 
marker  (Low  DNA  Mass  Ladder)  following  staining  with  ethidium  bromide  and 
visualisation by UV transillumination. 
2.2.2.3 Electrophoresis of DNA 
DNA fragments of 0.1-10 kb were separated and identified by agarose gel electrophoresis 
using  a  Hoefer  HE  33  Mini  Submarine  Electrophoresis  Unit  (Amersham  Pharmacia 
Biotech, San Francisco, CA). Typically, 0.5 – 0.1 g of agarose was added to 50 ml of 1x 
TBE buffer, melted in the microwave (medium for 1.5 minutes), and mixed to produce a 1 
to 2% gel. Once the gel mix had cooled to 55
o C, 1.5 ml of ethidium bromide (100mg/ml) 
was added and the gel poured into a gel support (100 x 65 mm) in its casting tray and an 
appropriate gel comb (twelve or twenty well) inserted. The gel was allowed to solidify 
before transferring to an electrophoresis tank; the gel was immersed in 1x TBE buffer and 
the  comb  carefully  removed.  DNA  samples  were  prepared  by  the  addition  of  an 
appropriate volume of 10x gel loading buffer. Molecular size standard DNA was prepared 
similarly and the samples loaded into the wells using a micropipette. Gels were run at 100 
volts for 20 to 30 minutes depending on the agarose percentage, then removed from the gel 
apparatus  and  visualised  on  a  UV  transilluminator  (UVi  tec,  Thistle  Scientific)  and 
photographed using a Mitsubishi P91 photographic unit. 62 
2.2.3  RNA techniques 
Clean, full-length RNA is essential as the starting material for molecular techniques, hence 
when isolating the RNA it was necessary to ensure that all the preparation material is free 
from ribonuclease (RNAse) activity. This is a very stable, active and ubiquitous enzyme 
that  degrades  RNA  requiring  no  cofactors  for  function.  Inhibition  of  this  enzyme  was 
instigated by wiping all equipment with RNaseZAP (Invitrogen) followed by a thorough 
rinse with DEPC treated water. All plastic-ware was treated by soaking overnight in DEPC 
treated water followed by autoclaving and drying. All solutions were prepared using DEPC 
treated water. Gloves were worn and changed frequently. 
2.2.3.1 Extraction and Purification of RNA 
2.2.3.1.1  RNA extraction using Qiagen RNeasy Mini Kit 
Various methods have been used for the isolation of undegraded RNA (Chirgwin et al., 
1979). Several procedures have now been elucidated which allow RNA isolation by  a 
single-step procedure (Chomczynski and Sacchi 1987).  
In this project, RNA was extracted from a variety of sources: from tissues snap-frozen in 
liquid nitrogen and stored at –80
o C, from cells grown as a monolayer in tissue culture 
flasks, and from cell pellets stored at –80
oC.  In order to extract RNA from frozen tissue, 
tissue was firstly ground in liquid nitrogen using a mortar and pestle.  
2.2.3.1.2   DNase Treatment of RNA 
Contaminating  DNA  was  removed  from  RNA  samples  using  DNA-free  (Ambion) 
methods. Briefly, 0.1 volume of 10x DNase I buffer (final concentration: 10 mM Tris-HCl 
pH7.5, 2.5 mM MgCl2, 0.1 mM CaCl2) and 2 units of DNase I were added directly to the 
RNA samples, mixed and incubated at 37 
oC for approximately 60 minutes. The enzyme 
reaction was stopped by the addition of DNase Inactivation Reagent (5ml) for two minutes 
at room temperature. Because of the nature of the DNase Inactivation Reagent, tubes were 
periodically  agitated  to  ensure  resuspension  in  the  RNA  sample.  Samples  were  then 
centrifuged at 10,000g for one and a half minutes to pellet the Inactivation Reagent and the 
supernatant containing the pure RNA was then transferred to a clean ependorf tube. 
2.2.3.1.3  Assessment of RNA quality using agarose gel electrophoresis 63 
RNA samples were assessed by agarose gel electrophoresis on a 1% agarose TBE gel. The 
quality of the RNA samples was assessed by examining the integrity of the 18S and 28S 
ribosomal RNA bands and comparing the bands to a 100 bp molecular weight standard 
(Invitrogen, UK). The 18S ribosomal unit runs at approximately 4.5 Kb and the 28S at 
approximately 1.2 Kb.  The 18S subunit should appear at twice the intensity of the 28S 
subunit and mRNA appears as a smear from 0.5 through to 12 Kb. 
2.2.3.1.4  First strand cDNA synthesis 
The  synthesis  of  complementary  DNA  (cDNA)  requires  the  Reverse  Transcriptase 
enzyme, initially identified as the enzyme responsible for forming DNA-RNA hybrids in 
retrovirus  replication.  Reverse  transcriptase  utilises  an  RNA  template  to  synthesise  a 
complementary DNA strand from a primer base-paired to the RNA that contains a free 
hydroxyl group at the 3’ end. Primers that can be used are either random primers, designed 
to prime at multiple sites throughout the RNA, gene specific primers (GSPs) designed to 
prime at the gene of interest, or oligo-dT primers which pair with the poly-A sequence at 
the  3¢  end  of  most  eukaryotic  mRNA  molecules.  All  instigate  the  synthesis  of  cDNA 
strands  in  the  presence  of  the  four  dNTPs.  The  RNA-DNA  hybrid  is  subsequently 
hydrolysed by raising the pH (unlike RNA, DNA is resistant to alkaline hydrolysis) or by 
using a ribonuclease.  The 3¢- end of the newly-synthesised DNA strand then forms a 
hairpin  loop  which  enables  priming  of  the  synthesis  of  the  opposite  DNA  strand.  S1 
nuclease, which recognises unpaired nucleotides, then removes the hairpin loop. 
Superscript III reverse transcriptase was used for first strand cDNA synthesis.  Superscript 
III is a version of MMLV-RT that has been engineered to reduce RNase H activity and 
provide increased thermal stability.  Briefly, total RNA samples (up to 5 µg total RNA) 
were added to 1 ul of primer (either oligo(dT), GSP or random primers) and 1µl of 10mM 
dNTPs,  and  DEPC  water  was  added  to  10µl  total  volume.    This  mixture  was  then 
denatured to remove any RNA secondary structure by heating for 5 minutes at 65
o C and 
before quenching on ice. First strand synthesis reactions were performed using the heat-
treated  RNA  in  a  reaction  mix  containing  reverse  transcription  buffer  (10x),  reverse 
transcriptase  (200  units),  DTT  (0.1  M),  RNase  inhibitor  (RNaseOUT™  40  units)  and 
MgCl2 (25 mM). The reaction was incubated at 50
o C for 50 minutes if oligo(dT) primer 
was used, or 25
o C for 10 minutes followed by 50
o C for 50 minutes if other primers were 
used, and was incubated at 85-95
o C for 5 minutes to terminate the reaction before being 
placed on ice.  Finally, RnaseH (1 µl) was added and the mixture incubated at 37
o C for 20 
minutes to remove the RNA template from the DNA-RNA hybrid. A Perkin-Elmer (PE) 64 
thermal cycler 480 was used for the reaction. cDNA was stored at 4
o C before immediate 
use or –20
o C for long term storage.  
2.2.4  Amplification of DNA by the polymerase chain reaction 
The polymerase chain reaction (PCR) is a powerful technique for amplification of specific 
DNA sequences from a complex mixture of DNA. The procedure was developed by Mullis 
and co-workers in the mid 1980’s (Mullis et al. 1986; Mullis and Faloona 1987) enabling 
large amounts of a single copy gene to be generated from genomic (Saiki et al., 1985; 
1986) or extra-genomic DNA (Kwok et al., 1987). The initial method used the Klenow 
fragment of DNA polymerase I, which had to be replenished during each cycle as it is 
readily denatured by the amplification conditions used. The substitution of the thermo-
stable Taq polymerase, isolated from Thermus aquaticus, circumvented this problem and 
allowed  the  automation  of  thermal  cycling  (Saiki  et  al.,  1988).  PCR  enables  the 
amplification of any unknown DNA sequence by the simultaneous extension of primer 
pairs flanking the unknown sequence, each complementary to opposite strands of DNA. 
The  uses  of  PCR  are  many  although  it  has  been  superseded  by  more  conventional 
molecular biological methods in many areas, including sequencing, cloning and detection 
and analysis of RNA. An extensive overview of PCR and its applications is available 
(Innis and Gelfand 1990). An overview of the procedure is given below, with more detail 
in the appropriate chapters. 
2.2.4.1 Primer design 
Primer design was aided by some basic guidelines (Innis & Gelfand 1990). An optimal 
primer  pair  should  hybridise  efficiently  to  the  sequence  of  interest  with  negligible 
hybridisation to other sequences present in the sample. The distance between primers is 
rather  flexible,  ranging  up  to  30  kbp,  however  the  PCR  reaction  is  considerably  less 
efficient in the amplification of products > 3kbp (Jeffreys et al., 1988). Smaller distances 
between primers lessen the ability to obtain much sequence information and to reamplify 
with  nested  internal  oligonucleotides,  if  required.  For  any  given  pair,  the  annealing 
temperatures and GC % were balanced. 
For many applications, primers are designed to be exactly complementary to the template. 
For others, however, such as engineering for mutagenesis or new restriction endonuclease 
sites or for efforts to clone or detect gene homologues where sequence information is 
lacking, base-pair mismatches will be intentionally or unavoidably created. It is best to 65 
have mismatches, such as in a restriction endonuclease linker, at the 5¢ end of the primer; 
the closer to the 3¢ end of the primer, the more likely a mismatch will prevent extension. 
The annealing portion of primers should generally be 18-30 nucleotides in length; it is 
unlikely  that  longer  primers  will  help  to  increase  specificity  significantly.  Additional 
sequences such as restriction enzyme sites, epitope tags or other desired motifs can be 
added to the 5¢ end of the primer, and may effect specificity of primer binding at low 
temperatures  on  complex  templates.  Accordingly,  these  primers  are  successfully  used 
when  amplifying  from  a  single  template  vector.  Primers  should  be  designed  with  an 
optimum  GC  content,  avoiding  unusual  sequence  distributions  such  as  stretches  of 
polypurines or polypyrimidines if possible. The formation of a secondary structure such as 
hairpin loops greatly effects efficiency of annealing. 
Primer-dimers are a common artifact most frequently observed when small amounts of 
template are taken through many amplification cycles. They form when the 3¢ end of one 
primer anneals to the 3¢ end of the other primer and polymerase then extends each primer 
to  the  end  of  the  other.  Therefore,  these  can  be  avoided  by  using  primers  without 
complementary sequences, especially in the 3¢ end (this can be minimised by optimising 
the MgCl2 concentration). 
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Table 2.1 Primer sets used over the course of the investigation 
Gene I.D.  Target For 
Amplification 
Primer Sequence 5’ to 3’ 
1  BPV-1 E5  GCT ACG AGA ACT GCA CCA CC 
TGG ACA TGT GCC CGC TTG C 
2  BPV-1 E6  TCC ATT CTC AGG GTT GGA TTG 
CAC AGT AGC AGC ATC TTA TGC 
3  BPV-1 E7  CGT  TGC  TGA  TTT  TAA  GTC  CAT 
GTG 
GGG ACC TCG CTT CCT AGT AGG A 
4  BPV-1 L1  CAT GTG GAC GCT GGA CTT CT 
CGT AGG CCG CCT TCA AAT AC 
5  BPV-1 L2  TCC ACG GAG ACC CTC ATT ACT C 
GAT TTA GAG GCA ATA CTG CGG G 
6  BPV-1 LCR (short)  CGG TAC ACA TCC TGT CCA GCA 
GAT GGT GTG ATT ATT GTT AAC 
7  BPV-1 LCR (full)  CAG AAG GTA AGT CAA CTG 
AAA ACC GGG GTC TG 
8  Fly 16s rRNA  TTA CGC TGT TAT CCT AA 
CAC CTG TTT AAC AAA AAC 
 
2.2.4.2 Preparation of PCR reactions 
As PCR is such a sensitive procedure it is essential to take stringent precautions to avoid 
PCR contamination from tube to tube or carry over of PCR products (Saiki, et al., 1988). 
All PCR reactions were set up in a designated separate room, at the side of the main 
laboratory where PCR products were handled. A set of micropipettes was kept for the sole 
purpose of setting up PCR reactions. Filter tip pipette tips were used to decrease the risk of 
reaction components passing from one tube to the next. A bulk reaction mix was used in 67 
order to minimise the number of pipetting steps. Reaction components (including primers) 
were aliquoted prior to use and stored at –20 
oC. 
2.2.4.3 PCR Amplification Profiles 
Table 2.2 Commonly used PCR amplification profiles 
Amplification 
profile I.D. 
Profile details 
 
1 
94˚C for 4 minutes initial denaturation; 94˚C for 30 seconds, 55˚C 
for 30 seconds, and 72˚C for 30 seconds. This cycle was repeated 
35 times after which samples were held at 4˚C until required. 
 
 
2 
94˚C for 4 minutes initial denaturation; 94˚C for 30 seconds, 55˚C 
for 50 seconds, and 72˚C for 30 seconds. This cycle was repeated 
35 times after which samples were held at 72˚C for ten minutes then 
held at 4˚C until required. 
 
 
3 
94˚C for 2 minutes initial denaturation; 94˚C for 30 seconds, 56˚C 
for 30 seconds, and 72˚C for 30 seconds. This cycle was repeated 
40 times after which samples were held at 72˚C for ten minutes then 
held at 4˚C until required. 
 
 
4 
94˚C for 2 minutes initial denaturation; 94˚C for 30 seconds, 52˚C 
for 45 seconds, and 72˚C for 45 seconds. This cycle was repeated 
45 times after which samples were held at 72˚C for five minutes 
then held at 4˚C until required. 
 
Table 2.3 Primer sets with PCR conditions and expected product size 
Gene I.D.  Aplification Profile I.D.  Expected Product Size 
1. BPV-1 E5  3  600 base pairs 
2. BPV-1 E6  2  230 base pairs 
3. BPV-1 E7  2  215 base pairs 
4. BPV-1 L1  1  86 base pairs 
5. BPV-1 L2  2  286 base pairs 
6. BPV-1 LCR 
(short) 
1  780 base pairs 
 
7. BPV-1 LCR (full)  1  800 base pairs 
8. Fly 16s rRNA  4  415 base pairs 
2.2.4.4  Purification and assessment of PCR products 
Single PCR products were purified following the QIAquickPCR purification kit protocol, 
(QIAGEN). Briefly, the DNA adhered to the filter within the column, separating it from all 
other  components  of  the  PCR  reaction  which  were  washed  away  with  various  buffer 
solutions. The PCR products were finally eluted in 30-50 ml of sterile water, 4 ml of which 
were assessed by gel electrophoresis on a 1% agarose TBE gel by comparing the bands 
created to a 100 bp molecular weight standard (Invitrogen, UK). 68 
2.2.5  Real-time relative quantitative PCR (RQ-PCR) 
Real-time Relative Quantitative PCR (RQ-PCR) was performed on 0.1  g cDNA or DNA 
samples using the specific primer probe set (Table 3) for the gene in question. Primer and 
probe sets were designed using Primer Express software where necessary. PCR reaction 
mixes contained 0.2  M forward and reverse primers, 0.1  M probe, 25  l of 2× Platinum 
Quantitative PCR SuperMix-UDG (Invitrogen, UK), 1  l ROX Reference Dye and water 
to a final volume of 50  l. Reactions were performed on a 7500 Real Time PCR System 
(Applied Biosystems) with amplification profiles specific to each primer and probe set. For 
analysis of equine fibroblast derived cDNA/DNA, a GAPDH primer and probe set was 
used as an endogenous control. For analysis of cDNA/DNA derived from fly tissue, a fly 
actin primer and probe set was used as an endogenous control. In both cases, all reactions 
were performed in triplicate. The 2-∆∆Ct method (Livak and Schmittgen, 2001) was used 
to compare the relative expression or DNA content levels.  
Table 2.4 Primer and probe sets used in RQ-PCR experiments 
Target 
Gene 
Forward Primer 
5’-3’ 
Reverse Primer 
5’-3’ 
Probe (FAM -
TAMRA) 
GAPDH  GGT GGA GCC 
AAA AGG GTC AT 
TTC ACG CCC ATC 
ACA AAC AT 
ATC TCT GCT CCT 
TCT GCT GAT GCC 
CC 
Fly Actin  AGG AAT GGA 
AGC TTG CGG TA 
AAT TTT CAT GGT 
GGA TGG TGC 
ATG CCA ACA CTG 
TCC TTT CTG GAG 
GTA 
BPV-1 L1  GGC TCA CTA 
GTC TCA ACT GAT 
AAT CAA 
ATG CAA TTC CAT 
TGT TCA TG 
AAT CGG CCC TAC 
TGG CTA TTC CGT 
GC 
BPV-1 L2  AGG AGG GCT 
AGG AAT AGG 
AAC ATG 
TGT TCG GAG TGG 
TGT GTA CCT T 
CTG GAA GGG TTG 
CTG CAG GTG GAT 
C 
BPV-1 E6  TGG CAA GGT 
GTT CCA GTA 
ACA G 
GCA TCT TAT GCA 
AAG CCT ATC AAG 
TGA GGA AGC TGA 
ATT ATT GCA TGG 
CAA AA 
BPV-1 E7  CGT TGC TGA TTT 
TAA GTC CAT 
GTG 
GGG ACC TCG CTT 
CCT AGT AGG A 
TTT CAG ACT TCC 
GTG CCA TTT CGG 
C 
 
 Amplification profiles of 2 min at 50 °C, 2 min at 95 °C and 45 cycles of 15 s at 95 °C and 
45 s at 60 °C.  69 
2.2.6  DNA sequence analysis 
2.2.6.1 Automated sequencing 
During  sample  preparation,  DNA  fragments  in  a  sample  are  chemically  labelled  with 
fluorescent dyes. The dyes allow the detection and identification of the DNA and typically 
each nucleotide is labelled with one dye molecule. More specifically, PCR reactions were 
performed using plasmid DNA samples (200-500 ng) in a total volume of 20 ml containing 
0.5mM of primers, 40mM Tris-HCl, 1mmol/L  MgCl2 and 4ml of Big  Dye Terminator 
Cycle Sequencing Ready Reaction (ABI Prism). Samples were prepared in the PE 2400 
thermal  cycler  incorporating  25  cycles  of  amplification,  each  cycle  consisting  of  a 
denaturation step 96
o C for 10 seconds followed by an annealing temperature of 50
o C for 5 
seconds, and an elongation step of 60
o C for four minutes. DNA was then purified by 
precipitation methods using a 10% volume of 3M sodium acetate (Sigma) and 2.5 volumes 
of ethanol (95%), at room temperature for 15 minutes. Pelleted DNA (14,000 rpm for 20 
minutes) was washed in ethanol (70%) and re-pelleted (14,000 rpm for 5 minutes) before 
all  ethanol  was  removed  and  the  pellets  were  dried  at  90 
oC  for  1  minute.  Template 
Suppression Reagent (25 ml) was then added and the mixture heated to 95 
oC for 5 minutes 
and chilled before transfer to genetic analyser sample tubes.  
2.2.6.1.1  Sample sequencing 
Samples  were  finally  loaded  and  run  on  the  ABI  PRISM  3010  Genetic  Analyzer  (PE 
Applied  Biosystems,  UK)  under  standard  sequencing  conditions  for  generation  of 
automated  sequence  data.  The  ABI  PRISM  3010  Genetic  Analyzer  is  a  multi-colour 
fluorescence-based  DNA  analysis  system  using  the  proven  technology  of  capillary 
electrophoresis with 16 capillaries operating in parallel. The 3010 Genetic Analyzer is 
fully automated from sample loading to data analysis.  
2.2.6.1.2  Sequence evaluation 
The length of read is 750 bases at the 98.5% base calling accuracy with less than 2% 
ambiguity. The output is in the form of a chromas file. A series of different computational 
software programs were utilised for sequence analysis including the ‘Blast’ search engine 
contained  within  the  NCBI  database,  VectorNTI  (Invitrogen),  ClustalW 
(http://www.ch.embnet.org/software/ClustalW.html), Transfac and Motif Search. 70 
2.2.7  Rolling Circle Amplification (RCA) 
RCA  was  used  to  evaluate  samples  for  the  presence  of  circular  BPV  episomes.  This 
amplification  method  preferentially  amplifies  circular  DNA  templates  with  ɸ29  DNA 
polymerase  (Rector  et  al.,  2004).  RCA  will  generate  linear  double  stranded,  high-
molecular-weight repeated copies of the complete circular BPV genomes and digestion of 
this RCA product with a restriction enzyme that has only one recognition site in the BPV 
genome,  will  result  in  multiple  double-stranded,  linear  copies  of  the  BPV  complete 
genomic DNA, which can be visualised as a single band of approximately 8kb by agarose 
gel electrophoresis.  
Reactions were carried  out using a modified procedure based on that  described in the 
TempliPhi 100 amplification kit (Amersham Biosciences). The only change to the original 
protocol was to supplement the reaction with additional dNTPs to enhance the sensitivity 
of the reaction as reported previously (Rector et al., 2004). In brief, an 11.6µl reaction 
system was composed of 5µl of sample buffer, 5µl of reaction buffer, 0.2µl (1U) ɸ29 DNA 
polymerase enzyme, 0.4µl extra dNTP mixture (25mM) and 1µl of template DNA (100ng). 
Firstly, template DNA was mixed with sample buffer and denatured at 95°C for 3 minutes, 
then cooled to room temperature. Then reaction buffer, extra dNTPs and enzyme were 
mixed with the denatured template DNA and incubated at 30°C for 16 hours. The reaction 
mixture was then heated to 65°C for 10 minutes to inactivate the ɸ29 DNA polymerase. 
3µl of the RCA product was digested with 10 U of HindIII as this is a single cutter of the 
closed BPV-1/2 complete genome. The same amount of non-amplified sample DNA that 
was used as input material for the RCA was also digested with HindIII. Restriction digests 
were separated on a 0.6% agarose gel and visualised with ethidium bromide staining. 
2.2.8  Preparation of small interfering RNA molecules (siRNAs) 
SiRNAs targeting BPV-1 E5, E6 and E7 ORFs were generated. Gene sequence information 
for E5, E6 and E7 was obtained from the National Centre for Biotechnology Information 
(NCBI) and this was then used to generate potential target sequences for siRNAs. Based on 
recommendations  from  various  online  siRNA  design  software  (www.imgenex.com, 
www.rnaidesigner.invitrogen.com, www.ambion.com), the following sense and antisense 
sequences were chosen: 71 
2.2.8.1 E6 siRNA sequence  
Target sequence (214 – 232) - 5’ GGTGAGGAAGCTGAATTAT  3’ 
siRNA sequence - 5’ GGUGAGGAAGCUGAAUUAU UU 3’ 
Scramble control sequence - 5’ GGAAGGAGUAUUGACGUAU UU 3’ 
All RNA oligonucleotides were synthesized by Dharmacon Research (Lafayette, CO). 
2.2.8.2 Introduction of siRNA into cells 
Delivery of the siRNA and scramble control sequences into the cell was achieved by using 
Lipofectamine 2000 (Invitrogen, UK) in accordance with the manufacturer’s protocol. As 
recommended  by  the  manufacturer,  cells  were  transfected  when  they  were  30-50% 
confluent. Because gene knockdown levels are generally assayed at a minimum of 24 – 72 
hours following transfection, transfecting cells at a lower density allows a longer interval 
between transfection and assay time, and minimises the loss of cell viability due to cell 
over-growth.  In  addition,  anti-biotic  free  DMEM  medium  was  used,  as  presence  of 
antibiotics during transfection results in cell death. Opti-Mem I Reduced Serum Medium 
(Invitrogen, UK) was used to dilute the Lipofectamine 2000 prior to complexing with the 
siRNA. 
2.2.8.3 Establishing efficiency of gene silencing 
RQ-PCR using E5, E6 and E7 primer probe sets were used as described previously (section  
2.2.5,  Table  2.4)  to  establish  the  level  of  knockdown  achieved  after  treatment  with 
siRNAs.  Cell  populations  were  only  used  in  subsequent  apoptosis  and  cell  survival 
analysis if the level of knockdown was determined to be at least 75%. 
2.2.9  Immunhistochemistry (IHC) 
Immunohistochemistry (IHC) is a technique that allows identification of cellular or tissue 
antigens by means of interaction between a specific antigen-antibody combination. For this 
project, staining was performed by Lynn Stevenson, Diagnostic Department, University of 
Glasgow, Department of Veterinary Medicine. Both paraffin sections of sarcoid tumours 
and cultured cell lines were analysed for presence and location of p53. Cells were grown 
on 8-well chamber slides (Lab-Tek II chamber slide system, Thermo Scientific, UK) and 
expression of p53 was evaluated using a two-step immunohistochemical technique using 
Dako EnVision kit (K4007) following the manufacturer’s instructions. Briefly, once the 8 72 
chamber frame had been removed, slides were placed in a Shandon Sequenza Staining 
System where the cells were fixed in acetone, rinsed with wash buffer and the endogenous 
biotin  activity  quenched  by  a  5  minute  application  of  Dako  Real  Peroxidase  blocking 
solution. The glass slides were incubated for 1 hour at room temperature in the presence of 
primary antibody (DO-7 p53 clone; Novocastra Laboratories, UK) diluted 1:200 in 10mM 
Tris Buffered Saline (TBS). Glass slides were then rinsed in 0.5% Tween20 in 10 mM 
TBS  and  incubated  with  polymer-HRP  anti-mouse  solution  applied  with  the  the  Dako 
EnVision kit (Dako, UK) for 30 minutes. Slides were developed with  Dako K5007 DAB 
(3,4,3’,4’-tetra aminobiphenyl hydrochloride) for 5 minutes at 37°C, washed thoroughly 
with distilled water and counterstained with Gill’s Haematoxylin (1 dip). The glass slides 
were  washed  and  a  large  glass  coverslip  mounted  over  the  cell  culture  surface.  For 
negative controls, duplicate slides were incubated with a non-related serum instead of the 
p53 primary antibody. Positive controls for p53 protein consisted of equine squamous cell 
carcinoma tissue sections. 
For sarcoid tumour sections, 3-4  m thick paraffin-embedded tissue section were cut and 
mounted on histogrip (Zymed Laboratories Inc) coated slides, then dried at 56ºC for 30 
minutes. Specimens were deparaffinized with Xylene, rehydrated in serial graded (100%, 
90%,  70%,  and  50%),  water-ethanol  solutions  and  rinsed  in  deionized  water.  Target 
retrieval was performed using the Menarini Access Retrieval Unit, Buffer Sodium Citrate 
pH6, incubated for 1 min 40 sec at 125ºC, full pressure. After antigen retrieval endogenous 
peroxidase activity was blocked by immersion of slides in peroxidase blocking solution 
(Provided in the Envision system) for 10 minutes. After washing with Tris Buffered Saline 
with  Tween  20  (TBS-T)  sections  were  incubated  with  primary  antibody  against  p53 
(mouse  monoclonal  anti-p53,  clone  DO-7,  Novocastra,  UK),  for  60  minutes  at  room 
temperature. The dilution used was 1:400 in Dako Real Antibody Diluent. The slides were 
then rinsed in TBS-T buffer and wiped to remove excess buffer, before being incubated 
with  peroxidase  labelled  polymer  complex  (provided  in  the  Envision  system)  for  35 
minutes.  All  slides  were  washed  with  1X  TBST  buffer  and  then  with  distilled  water. 
Sections  were  developed  with    Dako  K5007  DAB  (3,4,3’,4’-tetra  aminobiphenyl 
hydrochloride)  for  5  minutes  at  37°C,  washed  thoroughly  with  distilled  water  and 
counterstained with Gill’s Haematoxylin (1 dip). For negative controls, duplicate slides 
were incubated with a non-related serum instead of the p53 primary antibody. Positive 
controls for p53 protein consisted of equine squamous cell carcinoma tissue sections. 73 
2.2.9.1 Evaluation of Slides 
Slides were examined for the presence of brown nuclear and/or cytoplasmic staining within 
the tumour cells and tumour sections. The proportion of positive cells per high power field 
was calculated for each cell line and each tumour section. Assessment of each cell line or 
tumour  section  required  analysis  of  3  separate  high-powered  fileds,  and  the  resulting 
numbers were averaged to give a final score. Tumours and cell lines with p53 positive 
cytoplasm were noted. 
2.2.10 Protein Analysis 
2.2.10.1 Estimating Protein Concentration 
Protein was extracted from cultured cell lines and stored at -70°C. The amount of protein 
in cell lysates was quantified to ensure equal loading in western blot gels. Here the Bio-
Rad Laboratories (Hemel Hempstead, UK) Protein Assay was used in which known bovine 
serum albumin (BSA, Promega Corporation, Southampton, UK) concentrations, namely 
0.1 - 2 mg/ml, were used as reference values. The method is based on the Bradford assay 
(Bradford, 1976). Briefly, the 5x dye reagent concentrate was diluted 1 in 5 with deionised 
water. The standard samples were prepared as a 1:10 dilution of 10 mg/ml stock solutions 
of BSA. The stock solutions were diluted in 1x protein assay solution in sterile water 
Samples  were  prepared  by  adding  1   l  of  lysate  sample  to  1  ml  of  1x  protein  assay 
solution.  Both  samples  and  BSA  controls  were  mixed  by  inversion  and  left  at  room 
temperature for 5 minutes. Prepared standard BSA concentration samples were read at 
absorbance 595 nm and a standard curve was drawn. Protein concentrations in unknown 
samples were extrapolated from the linear part of this curve. 
2.2.10.2  Western Blotting 
Western  blotting  was  performed  using  the  Nupage  Bis-Tris  Electrophoresis  System 
(Invitrogen, UK). The Nu-Page system uses a neutral pH, discontinuous Sodium Dodecyl 
Sulphate (SDS)-PAGE pre-cast gel. The pre-cast gel is formulated with a varying gradient 
of poloyacrylamide (4% - 12%) to allow separation of a range of proteins from 1-200 kDa. 
Samples  are  treated  with  a  reducing  agent  (500  mM  dithiothreitol  -  DTT)  to  prevent 
oxidation  of  samples  and  allow  sharper  resolution  of  bands  during  electrophoresis. 
Following electrophoresis, the protein is transferred to a nylon membrane and stained with 
the primary antibody of interest, followed by detection with a secondary antibody which is 
directed  against  the  immunoglobulin  molecule  of  the  species  in  which  the  primary 74 
antibody  was  generated.  This  secondary  antibody  is  conjugated  to  a  molecule  of 
horseradish peroxidase which produces a colour change when a chromagen is added. This 
system produces amplification of the original signal sufficient to allow visualisation by 
light microscopy. 
2.2.10.2.1 Sample preparation 
Cell pellets containing approximately 2 x 10
5 cells were resuspended in 60 µl of lysis 
buffer  (0.5%  NP40,  150  mM  NaCl,  50  mM  TrisHCl  (pH  8)  with  an  added  protease 
inhibitor cocktail (Roche, UK)) and incubated on ice for 30 minutes. Samples were then 
centrifuged at 13, 000 rpm for 30 minutes at 4 
oC. Protein quantification was performed as 
previously described. 10 – 30 µg of total protein extract was added to 2 ml NuPage TM 
sample reducing agent (10x, Invitrogen) along with 5 ml NuPage TM sample buffer (4x) 
(Invitrogen). Total volume was made up to 25 ml using deionised water. The solution was 
heated to 70 °C for 10 minutes to denature the proteins.  
2.2.10.2.2 Polyacrylamide Gel Electrophresis (PAGE) 
The pre-cast gel placed in the tank (Xcell SureLock Mini-Cell (Invitrogen, UK) and an 
opposing gel or buffer dam was used to seal the system. 1 x MES (50 ml NuPage 20x MES 
Running Buffer Stock Solution (Invitrogen, UK) in 1 litre of de-ionised water) was added 
to the tank and 500 ml antioxidant agent was added to the buffer in the tank adjacent to the 
gel(s). The antioxidant is added to perform electrophoresis under reducing conditions and 
migrates  with  the  proteins  during  electrophoresis  in  order  to  prevent  reoxidation  and 
maintain the proteins in a reduced state. The antioxidant also protects sensitive amino acids 
such as methionine and tryptophan from oxidising. 25 ml protein samples and 10 ml marker 
(Seeblue Plus 2 pre-stained standard, Invitrogen, UK) were loaded onto the gel and run at 
200 V for 60 minutes. 
2.2.10.2.3 Membrane Transfer and protein staining 
Following electrophoresis, proteins were transferred to a nitrocellulose membrane. The 
membrane was then briefly stained with Ponceau S solution to confirm the protein transfer. 
Ponceau S solution was added to the surface of the membrane and rinsed off after thirty 
seconds  using  deionised  water.  Successful  transfer  was  confirmed  by  the  presence  of 
multiple red bands in each lane.  75 
2.2.10.2.4 Blocking 
Non-specific bands were blocked in 5% dried skimmed-milk powder solution (Marvel, 
UK) in Phosphate Buffered Saline (PBS) containing 0.1% Tween 20 (PBS-T) for 1 hour at 
room temperature or overnight at 4°C. 
2.2.10.2.5 Antibody staining 
Following blocking, the blocking solution was discarded and the membrane was washed in 
PBS-T for 1 hour. The primary antibody used was p53 and GAPDH antibody was used as 
a  loading  control.  Several  different  p53  antibodies  are  commercially  available.  After 
conducting a literature search, the p53 clone CM-1 (Abcm plc., UK) was selected. CM-1 
antibody recognizes both wild type and mutant forms of p53 protein under denaturing and 
non-denaturing conditions. However, the CM-1 antibody consistently failed to bind with 
the equine p53 protein, at a wide range of dilutions. A second p53 antibody was then 
chosen.  DO-7  also  recognizes  both  wild  type  and  mutant  forms  of  p53  protein  under 
denaturing and non-denaturing conditions. It had been shown to react with p53 from a 
number of different species and was recommended for use in Western blotting. It was used 
at a dilution of 1:500 in milk powder PBS-T and was incubated with the membrane for 16 
hours at 4°C.  
After staining with the primary antibody, the membrane was then washed four times in 
PBS-T for five minutes per wash. The secondary antibody, consisting of goat anti-mouse 
IgG  conjugated  to  horseradish  peroxidase  (Amersham,  UK)  was  used  at  a  dilution  of 
1:5000 and incubated for 1 hour at room temperature.  
The membrane was then washed four times in 0.1% PBS-T for five minutes per wash. 
Excess  liquid  was  drained  from  the  membrane  and  1ml  detection  reagent  (ECL-Plus 
(Amersham,  UK))  was  evenly  distributed  over  the  membrane  and  incubated  at  room 
temperature for 5 minutes. The membrane was then placed in a transparent plastic wallet 
and placed inside an autorad x-ray film cassette. In a dark room, x-ray film was placed in 
side the cassette together with the membrane and developed for 2 minutes before being 
removed  and  processed  in  an  automatic  x-ray  film  processor.  This  was  repeated  with 
exposure times of 5, 10, and 20 minutes. From these exposures, the most appropriately 
exposed film was selected for analysis. 76 
2.2.11 Flow Cytometric Analysis 
Flow cytometry (FCM) is a method for analysing and counting a heterogeneous mixture of 
biological cells one cell at a time, based upon the specific light scattering and fluorescent 
characteristics of each cell. During measurement a laser beam is passed through a fluid 
stream containing the population of interest. Excitation of the analyte within the stream 
(sample core) results in a signal dependant on the properties of the analyte in question. The 
physical properties of a given analyte can be determined by measuring scattered light of 
two types. Side scatter (SSC), detected at ~90° to the incident light is proportional to cell 
granularity  and  the  complexity  of  a  cell’s  internal  structure  (widely  used  in  the 
differentiation of cells such as granulocytes). Forward scatter (FSC), is a measurement of 
diffracted light, determined via a photodiode at a small angle to the axis of the laser beam. 
Excluding clinical haematology, all FCM analysis employs the use of flourophores. The 
determination of non-physical characteristics of a cell may be elucidated through labelling 
with an organic flourophore (e.g. fluoroscein isothiocyanate (FITC)) attached to a carefully 
chosen primary or secondary antibody. In FCM experiments data is generally presented as 
histograms or bivariate histograms either as scatter, density or contour plots. 
Recently, it has been shown that cells undergoing apoptosis break up the phospholipid 
asymmetry  of  their  plasma  membrane  and  expose  phosphatidylserine  (PS)  which  is 
translocated  to  the  outer  layer  of  the  membrane.  This  occurs  in  the  early  phases  of 
apoptotic cell death during which the cell membrane remains intact. This PS exposure may 
represent a hallmark (early and widespread) in detecting dying cells. Annexin V, belonging 
to a recently discovered family of proteins, the annexins, with anticoagulant properties has 
proven  to  be  a  useful  tool  in  detecting  apoptotic  cells  since  it  preferentially  binds  to 
negatively  charged  phospholipids  like  PS  in  the  presence  of  Ca
2+  and  shows  minimal 
binding to phosphatidylcholine and sphingomyeline. Changes in PS asymmetry, which is 
analyzed by measuring Annexin V binding to the cell membrane, were detected before 
morphological  changes  associated  with  apoptosis  have  occurred  and  before  membrane 
integrity has been lost. By conjugating FITC to Annexin V it is possible to identify and 
quantitate  apoptotic  cells  on  a  single-cell  basis  by  flow  cytometry.  Staining  cells 
simultaneously  with  FITC-Annexin  V  (green  fluorescence)  and  the  non-vital  dye 
propidium iodide (red fluorescence) allows the discrimination of intact, viable cells (FITC-
PI-), early apoptotic (FITC+ PI-) and late apoptotic (or secondary necrotic) or necrotic 
cells (FITC+ PI+). The term secondary necrosis (type 2 necrosis) refers to a process in 
which late stage apoptotic cells that failed to be engulfed by phagocytes or neighbouring 
cells undergo necrosis. Secondary necrosis is a post-apoptotic event commonly seen in 77 
cultured cells that are undergoing cell death by apoptosis in vitro, induced, for example, by 
the absence of survival factor signals or activation of death receptors by different lethal 
signals. These cells, in the absence of phagocytic cells that could engulf them, ultimately 
cease to be metabolically active, lose membrane integrity, and release their cytoplasmic 
contents into the culture medium. The Calbiochem Annexin V-FITC Apoptosis Detection 
Kit was used and the cells were processed 24 hours after UVB irradiation, or after 72 hours 
of drug exposure, according to the manufacturer’s protocol; approximately 105 to 106 cells 
were processed per sample. Adherent cells were released from their substrate using 0.05% 
Trypsin-EDTA (Invitrogen, UK). Care was taken when trypsinising to prevent excessive 
cell damage. It was necessary to remove all EDTA by washing twice in 1x PBS prior to 
labelling to avoid chelating the calcium necessary for annexin binding.  
Three control samples were used to calibrate the instrument. First, cells re-suspended in 
binding buffer only, were assessed to evaluate the level of auto-fluorescence and to adjust 
the instrument accordingly. Then, treated cells were stained separately with Annexin V-
FITC and Propidium Iodide to define the boundaries of each population. Apoptotic cells 
labelled with Annexin FITC should appear in the lower half of the dot plot, with no events 
accumulating  in  the  upper  left  or  upper  right  quadrants.  Similarly,  cells  labelled  with 
propidium iodide alone should show no events in the upper or lower right quadrants. 78 
 
 
 
Figure 2.1 A sample cytogram (from results obtained in Chapter IV) following 
Annexin V-FITC and PI staining. 
Each quadrant in the cytogram shown in Figure 2.1 represents a different sub-population of 
the cell type analysed. 
D1 represents necrotic cells or cell fragments that have only been stained with propidium 
iodide.  
D2 represents necrotic or apoptotic cells in terminal stages (secondary necrotic). These 
cells will be both Annexin V-FITC and propidium iodide positive.  
D3 represents viable cells. These cells do not bind Annexin V-FITC or propidium iodide as 
reflected in the lower left-hand quadrant of the cytogram.  
D4 represnts early apoptotic cells with exposed PS but intact cell membranes that bind 
Annexin V-FITC but exclude propidium iodide.  
A small percentage of normal cell death should be expected in routine cultures of untreated 
cells. 
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2.2.11.1 Evaluation of Flow Cytometry Results 
In the optimisation steps of the flow cytometry investigation, it became clear that some cell 
lines were more sensitive to the protocol methods than others, resulting in higher than 
expected apoptosis levels in the untreated control cells. For example, the normal equine 
fibroblast (EqPalF) and the sarcoid derived fibroblast (EqS) cell populations that were not 
treated in any way, consistently produced apoptosis levels of less than 5%. In contrast, the 
BPV-1  transformed  fibroblasts  (S6)  often  displayed  twice  this  amount.  To  ensure  that 
values obtained for the different cell lines could be reliably compared, the increase in the 
proportion of apoptotic cells was calculated using the apoptosis level observed in each 
untreated  cell  population,  as  a  control.  This  will  provide  a  standardised  value  for 
comparing apoptosis levels both within a cell line, and between different cell lines. 
2.2.12 Clonogenic Survival Assay 
Protocol used was as described by Franken et al., in Nature Protocols (2006). Cells were 
seeded at a concentration of 2000 - 4000 cells per 10cm Petri dish and maintained in 15ml 
of complete DMEM in a 37 
oC humidified atmosphere of 5% CO2 in air. From the results 
both the Plating Efficiency (PE) and Surviving Fraction (SF) of each cell line at each UVB 
dose was calculated. Different cell lines have different plating efficiencies and calculation 
of this value from the control cells is essential for establishing accurate cell survival data; 
 PE = [number of colonies formed/number of cells seeded] x 100 
This value is then used to calculate the Survival Fraction; 
SF = [number of colonies/(number of cells seeded x PE)] 
2.2.13 Statistical Analysis 
For comparison of apoptosis levels, histological grading and colony survival values, the 
Student  t-test  was  used,  with  the  level  of  significance  set  at  p<0.05.  The  t-test  is  a 
statistical test involving means of normal populations with unknown standard deviations; 
small samples are used, based on a variable t equal to the difference between the mean of 
the sample and the mean of the population divided by a result obtained by dividing the 
standard deviation of the sample by the square root of the number of individuals in the 
sample. The t-test is commonly used to show if there is a real difference between different 
treatments being tested in a controlled clinical trial. Simply put, the t-test determines a 
probability that two populations are the same with respect to the variable tested. 80 
 
 
3  CHAPTER III: 
 
Detection of BPV-1 DNA in flies. 81 
3.1  INTRODUCTION 
Although there is strong evidence that BPV types 1 and 2 are the principal causative agent 
of sarcoids, there is currently no clear evidence of a mode of transmission. As mentioned 
earlier in the epidemiology section (section 1.6.6), there may be a predilection for sarcoid 
development at wound sites and it has been proposed this may be due to flies acting as a 
vector as they move between wound sites on different horses (Chambers et al., 2003). 
Sarcoids also commonly develop in the peri-ocular region and around the lips and nostrils 
of an animal – these areas correspond to areas of frequent congregation/feeding for some 
common species of equidae associated insects (Downes, 1958; Fotedar, 2001). In 2000, 
Kemp-Symonds demonstrated that BPV DNA could be detected in face flies, and also that 
the same viral DNA sequences were detected in the horses from which the flies were 
removed. Most recent data (both anecdotal and published) suggest that sarcoid tumours are 
transmitted from equid to equid. The evidence to support this includes the observations that 
donkeys in close contact to affected donkeys are at a higher risk for sarcoid development 
(Reid et al., 1994a). The occurrence of epizootics of equine sarcoids in herds of horses and 
donkeys has been reported (Reid 1992; Ragland 1966) and more recently the reported 
outbreak of sarcoids in an isolated population of mountain zebras (Marais et al., 2007). It 
was recently shown that equine sarcoids are most often associated with a specific BPV-1 
variant which is not present in BPV-1 infections in cattle (Nasir et al., 2007), suggesting 
that there is horse to horse transmission.  There is also published data supporting equid to 
equid transmission of BPV-1 by sequence analysis of BPV-1 Long Control Region (LCR) 
(Nasir and Campo 2008).  
The  mode  of  natural  transmission  of  warts  in  cattle  caused  by  BPV  is  unknown  but 
assumed to be direct contact between infected animals or by abrasions from inanimate 
objects contaminated by virus. Crops of warts have been observed appearing at sites of 
dehorning and tattooing, around ear tags and around the nose after using contaminated bull 
leads. They were also inclined to appear along lesions produced by barbed wire (Blood et 
al., 1983). The presence of BPV DNA has subsequently been demonstrated in the blood, 
milk,  urine,  seminal  fluid,  and  spermatozoa  of  BPV-infected  animals  (Lindsey  et  al., 
2009).  The finding of BPV DNA in body fluids and tissues other than the epithelium 
demonstrates co-infection of other tissues or cell types by papillomavirus and shows the 
potential  role  of  lymphocytes,  seminal  fluid  and  spermatozoa  in  BPV  transmission 
(Lindsey  et al., 2009). In 2007, the presence and activity of BPV in  normal skin and 
peripheral blood of 4 groups of horses was evaluated: sarcoid-affected horses, horses living 82 
in contact with sarcoid-affected horses, horses living in contact with papilloma-affected 
cattle and control horses.  BPV DNA was found in the normal skin of 24 of 42 horses 
(57%). Mainly sarcoid-affected horses and horses living in contact with cattle were carriers 
(73%),  but  BPV  DNA  was  also  detected  in  50%  of  the  horses  living  in  contact  with 
sarcoid-affected horses and in 30% of the control population. BPV mRNA was detected in 
58% of the samples positive for BPV DNA, although in a much lower quantity compared 
to sarcoids (Bogaert et al., 2007). Although the results of this study could not demonstrate 
the  presence  of  BPV  DNA  in  any  of  the  blood  samples  taken,  a  more  recent  report 
demonstrates that peripheral blood mononuclear cells (PBMCs) can represent a reservoir 
of  BPV  DNA  in  sarcoid-affected  animals  (Brandt  et  al.,  2008).   Researchers  in  South 
Africa  recently  demonstrated  the  presence  of  BPV-1  and  -2  DNAs  in  zebra  sarcoid 
tumours. They then developed a real-time PCR technique to detect and distinguish between 
BPV-1 and -2 infections in zebras. With this assay it was demonstrated that BPV-1 and 
BPV -2 DNA are present in sarcoid tumour tissue, healthy, unaffected skin and the blood 
of sarcoid-affected and healthy zebras (van Dyk et al., 2009). These results support the 
hypothesis that PBMCs may serve as host cells for BPV-1/-2 DNA and both contaminated 
blood and skin of infected and uninfected animals could contribute to virus latency. In 
addition,  taken  together,  these  data  support  the  hypothesis  that  insects,  feeding  on 
contaminated skin, or from the blood of wounds/biting flies, would be exposed to BPV 
DNA which they may in turn spread to other susceptible animals, incriminating them as 
likely vectors of this disease. 
 There are many insects that are the primary or intermediate hosts or carriers of diseases. 
Pathogens  that  are  capable  of  being  transmitted  by  insects  include  protozoa,  bacteria, 
viruses, and such helminths as tapeworms, flukes, and roundworms (Spier et al., 2004; 
Forster et al., 2007).  In the simplest terms, viruses are said to be either mechanically 
transmitted or biologically transmitted by their arthropod vectors. Mechanical transmission 
refers  to  the  non-specific  transmission  of  viruses  by  single  or  multiple  vector  species, 
usually on contaminated mouthparts. The viruses are unable to replicate in the vector. 
Biological  transmission  refers  to  the  specific  association  of  a  virus  with  a  particular 
arthropod species or genus, and perhaps more importantly, it refers to the fact that the virus 
is able to propagate within the vector (Carn, C.V., 1996). Many different species of Diptera 
are implicated in the mechanical transmission of animal viruses, where the insect becomes 
contaminated  with  virus  during  normal  feeding  behaviour,  and  virus  persists  on  their 
mouthparts  or  body  until  the  next  feed.  Some  viruses  are  inactivated  rapidly  on 
mouthparts,  whereas  others  survive  for  many  days  or  weeks,  prolonging  the  potential 83 
period  of  transmission.  Some  well  studied  examples  of  common  insect  species  being 
implicated in the transmission of viral disease include; 
·  Mosquitoes  in  the  transmission  of  rabbit  papilloma  virus  (Dalmat,  H.T. 
1957). 
·  Bushflies (Musca vetustissima) in the transmission of rabbit haemorrhagic 
disease virus (RHDV) between rabbits (McColl et al., 2002). 
·  Blackflies (Simulium vittatum) in the transmission of vesicular stomatitis 
New Jersey virus (VSNJV) between cattle (Mead et al., 2009). 
·  Stable flies (Stomoxys calcitrans) in the transmission of equine infectious 
anaemia virus (Issel and Foil, 1984), sheep pox virus (Kitching and Mellor, 
1986), African swine fever virus (ASFV) (Mellor et al., 1987), bovine viral 
diarrhoea virus (BVDV) (Tarry et al., 1991). 
Common Diptera species encountered where equines are present include the house fly 
(Musca domestica), the biting stable fly (Stomoxys calcitrans), the horse fly (Tabanus spp.) 
and face flies (Musca autumnalis). Lesser house flies (LHF - Fig. 3.1a) and stable flies (SF 
- Fig. 3.1b) are commonly encountered species representing both non-biting (LHF) and 
biting (SF) types. The stable fly has a piercing-type mouthpart and both sexes feed on the 
blood of warm-blooded animals. After a blood meal, the adults fly to a vertical surface to 
digest  their  food.  House  flies  and  lesser  house  flies  do  not  bite  because  they  have  a 
sponging-type mouthpart with which they feed on semi-liquid material. Houseflies feed on 
excrement and may also feed on ocular or nasal secretions and on exudating wounds. The 
life cycles of the two species are similar, consisting of eggs, larvae (maggots), pupae, and 
the adult. During summer months the stable fly completes its life cycle in about three 
weeks and the house fly in about two weeks. Both species deposit eggs in wet, decaying 
organic matter. The house fly may breed during the winter in warm buildings if breeding 
material is present. Adult house flies are very strong fliers and can travel ¼ mile and 
sometimes much farther. Stable flies can move great distances, and have been shown to 
survive journeys of several hundred miles when carried by a weather front.  
In considering these insects as potential disease vectors it is necessary to understand their 
internal anatomies, in particular with respect to the digestive system and salivary glands, 
where viruses and bacteria ingested by the fly, have been shown to accumulate (Gray and 84 
Banerjee, 1999). These are shown in figure 3.2 a and b for the lesser house fly and the 
stable fly respectively. 
Figure 3.1 
 
Figure 3.1 External anatomies of flies of the Diptera order. 
The lesser house fly (LHF) (Fannia cannicularis; www.ento.csiro.au) (Fig. 3.1a) and the 
stable fly (SF) (Stomoxys calcitrans; www.ces.ncsu.edu) (Fig 3.1b). Figures 3.1a(i) and 
3.1b(i) show photographs taken of the LHF and stable fly after they had been removed 
from the paper fly traps. The LHF has a sponging mouthpart (Fig. 3.1a(ii)) and the SF has 
a piercing or biting mouthpart (Fig. 3.1b(iii)).  85 
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Figure 3.2 Internal anatomies of flies from the Diptera order 
The  internal  anatomy  of  a  typical  non-biting  fly  is  illustrated  in  Figure  3.2  A 
(www.earthlife.net), whereas a stylised diagram of the SF's internal anatomy is shown in 
Figure 3.2 B (www.zipcodezoo.com). 
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3.2  AIMS AND OBJECTIVES 
The aim of the study was to investigate the potential role of flies as vectors in transmission 
of equine sarcoids between infected and susceptible animals. 
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3.3  MATERIALS AND METHODS 
3.3.1  Trap Location 
The  Donkey  Sanctuary,  in  Sidmouth,  Devon,  were  collaborators  for  this  study.  The 
Donkey  Sanctuary  is  a  charitable  organisation  dedicated  to  the  rescue  and  care  of 
unwanted, neglected, and donated donkeys. The animals are maintained in dynamic groups 
and housed at pasture, with access to field shelters, for the summer months of the year. The 
fly trapping activities took place at their main premises, Slade House Farm. This farm is 
home to over 200 donkeys within 46 hectares. It houses the donkeys at various locations 
and there are usually several animals with confirmed sarcoid lesions at any time. Flies 
were trapped at several locations in the grounds of the Sanctuary – locations were selected 
on the basis of whether the stables housed sarcoid-affected (fig 3.2 a-d), or sarcoid-free 
animals. The traps were left in position for up to 2 weeks and then retrieved, individually 
bagged  and  sent  back  to  the  laboratory  for  further  analysis.  Several  separate  trapping 
periods took place over the course of the summer season (June, August and September, 
2008). At each trapping period, traps were placed and retrieved from the same 6 places; 
1. Hospital barn – sarcoid positive donkeys 
2. Main office – no sarcoid donkeys within 50 metre radius 
3. Buffalo barn – housing Poitou donkeys – one sarcoid positive 
4. Garmston – housing one sarcoid positive donkey 
5. Visitor barn – no sarcoid positive donkeys within 50 metres 
6. Shelter 3 – no sarcoid positive donkeys within 200 metres 
3.3.2  Trapping 
From  the  wide  range  of  commercially  available  fly  traps,  the  adhesive,  chemical-free 
paper-strip type traps were selected (Ref. STV 013, STV 016; dontbeapest.co.uk). These 
traps  had  been  shown  to  preserve  the  insect  in  a  relatively  intact  condition  allowing 
reasonably  easy  identification  of  the  species.  Flies  could  be  removed  from  the  strips 
without too much difficulty and any residual glue did not appear to affect the subsequent 
DNA  extraction  and  analysis.  The  traps  could  be  positioned  away  from  any  possible 
contact with the donkeys or horses, and provided an attractive vertical surface for stable 
flies  to  move  to  after  feeding.  In  addition  to  this  method  of  capture,  a  live  capture 88 
technique was employed to catch flies at location, anaesthetise them (by freezing at -20°C) 
and then perform gross dissection. This involved catching the flies in a standard butterfly 
net (Ref. 014353; alanaecology.com), on location in two of the animal accommodations 
where paper traps had been previously sited (hospital barn and shelter 3), transferring them 
to airtight containers and placing them in -20°C for 30 minutes. Some flies from the live 
capture  sessions  were  submerged  in  RNAlater  (Qiagen,  UK),  and  stored  at  4°C  for 
screening for BPV mRNA back at the Glasgow laboratory. 
Figure 3.3 
 
Figure 3.3 Sample collection at the Donkey Sanctuary. 
The Donkey Sanctuary, Sidmouth, Devon houses over 200 donkeys, several of which had 
active sarcoid infections for the duration of the fly trapping period. In a group of Poitou 
donkeys (Fig 3.3a), there was one individual with a sarcoid tumour on its sheath. A tissue 
sample was collected from the surface of the tumour using the Isohelix Buccal Swab (Fig 
3.3 b). Another donkey, housed in a different pasture, had a group of nodular sarcoids on 
the muzzle area (Fig 3.3c – house fly circled in red). A third donkey had an ulcerated 
fibroblastic sarcoid in its right axilla region (Fig 3.3d). 89 
3.3.3  Fly dissection 
Following  acquisition  of  required  anaesthesia  levels,  flies  were  removed  from  the 
container, their wings and legs were removed and discarded, and the body immersed in 
Hanks buffered saline solution (HBSS) before being bluntly dissected into head, thorax 
and abdomen parts using standard dissection pins. The heads, thoraces and abdomens of 
each different species were then stored in 100% ethanol prior to transportation back to the 
laboratory for further analysis. 
3.3.4  Swabbing 
During initial positioning of the fly traps in June 2008, Isohelix DNA Buccal Swabs from 
Cell Projects were used to collect surface samples from any sarcoid lesions evident on the 
animals housed in that location. The swabs were sealed in sterile tubes for transportation 
back to the laboratory. Sterile nitrile gloves were used when swabbing the surface of the 
sarcoid  lesion,  and  gloves  were  changed  between  each  individual  donkey  from  which 
samples were collected. 
3.3.5  DNA Extraction from Flies and Swabs 
The flies were carefully removed from the adhesive paper, photographed, provisionally 
identified  and  batched  together  in  separate  species  groups  (where  sufficient  numbers 
allowed).  Flies  parts  from  the  dissection  study  were  pooled  into  2  sets  of  6  different 
samples; (i) Stable fly heads, (ii) Stable fly thoraces, (iii) Stable fly abdomens, (iv) Lesser 
house fly heads, (v) Lesser house fly thoraces, (vi) Lesser house fly abdomens. Each ‘set’ 
contained the body parts of 5 individual flies. DNA was extracted from the fly samples and 
swabs using a Qiagen DNeasy Blood and Tissue Kit in accordance with the manufacturer’s 
instructions (Chapter II; section 2.2.2.1.2). The DNA extracts were then subject to PCR 
using the LCR and E5 primers as described previously in Chapter II; section 2.2.4 and 
Table 2.1. 
3.3.6  Polymerase chain reaction (PCR) 
The extracted DNA was first screened for the presence of BPV-1 DNA using a standard 
PCR protocol with LCR primers LCRfullF and LCRfullR (Table 2.1) used to amplify a 
target sequence of approximately 800 bp. Products were analysed on a 1% agarose gel 
containing  2  µg  ethidium  bromide,  and  those  samples  which  were  deemed  to  contain 
sufficient amounts of amplified DNA for sequencing were stored at 4 
oC and the other 
samples subjected to a further round of PCR amplification using a nested PCR protocol 
with a different set of LCR primers that amplify a slightly smaller fragment of the LCR 90 
gene  sequence.  The  sequences  of  the  primer  sets  used  are  listed  in  Chapter  II;  Table 
2.1.
 
Figure 3.4 Diagrammatic representation of the nested PCR procedure (image sourced 
from the Institute for Viral Pathogenesis). 
The target DNA sequence of one set of primers (termed ‘inner’ or ‘nested’ primers) is 
located within the target sequence of the second set of primers (termed ‘outer’ primers). 
Firstly, a standard PCR reaction is run using the ’outer primers’. Then a second PCR 
reaction  is  run  with  the  ‘inner  primers’  using  the  product  of  the  first  reaction  as  the 
amplification target. This procedure increases the sensitivity of the assay by reamplifying 
the  product  of  the  first  reaction  in  a  second  reaction.  The  specificity  of  the  assay  is 
increased because the inner primers will only  bind if the first PCR reaction  yielded a 
specific product. 
Briefly, 2 microlitres of the PCR product were added into a second master mix containing 
LCR primers LCRF and LCRRev and designed to amplify a 780bp product. The PCR 
cycling  conditions were the same as those described previously in Chapter  II; Section 
2.2.4.3, Table 2.3.  91 
After analysing these products on a gel (Fig 4) (Chapter II; section 2.2.4.4), amplified 
products  that  were  positive  for  LCR  were  further  processed  in  preparation  for  DNA 
sequencing (Chapter II; section 2.2.6).    
To assess the quality of the DNA that was extracted from the fly samples, internal fly 
primers  designed  by  Simon  et  al.  (1994)  which  targert  the  16s  rRNA  gene  (415  bp 
product), were used (Chapter II; Table 2.1). This analysis confirmed that the BPV-1 DNA 
was present only in samples in which fly DNA was also present. There were also samples 
which contained good quality fly DNA in the absence of BPV-1 LCR DNA. 
3.3.7  DNA sequencing and sequencing analysis 
Viral genomic DNA PCR products were purified using a Qiagen mini-prep clean-up kit 
and  subjected  to  sequence  analysis.  Sequencing  reactions  were  performed  using  the 
Applied Biosystems Big Dye terminal sequencing kit and sequencing performed on an ABI 
3100  automated  sequencer.  Prior  to  comparative  analysis  with  the  ClustalW  program 
provided by EMBNet, the data from all sequences were evaluated using Chromas (Version 
1.44) analysis software. All PCR reactions used for sequencing were performed twice in 
duplicate to eliminate PCR-induced errors or sequencing errors. Full details of the method 
can be found in Chapter II, section 2.2.6. 
3.3.8  Real-time Absolute Quantitative PCR (AQ-PCR) to determine viral load 
A real-time Absolute Quantative RT-PCR was used to assess the viral load per genome 
equivalent (g.e.) of fly DNA. Serial dilutions of BPV plasmid were used to generate a 
standard curve and insect actin primer and probe set was used as an internal control for 
normalisation of input DNA amount. A primer and probe set that amplifies BPV-1/2 E7 
gene was used to assess the amount of viral DNA present, and AQ-PCR was performed on 
0.1 µg DNA samples on a 7500 Real Time PCR system (Applied Biosystems, Warrington, 
UK) with an amplification profile of 2 min at 50 °C, 2 min at 95 °C and 45 cycles of 15 s 
at 95 °C and 45 s at 60 °C. Reactions were performed in duplicate. The primer and probe 
sequences used are detailed in Chapter II; Table 2. Total weight of input fly DNA was 
determined using a nanodrop spectrophotometer and genome equivalents of Diptera cells 
were calculated based on the fact that an average haploid Diptera cell nucleus contains a 
total DNA mass of 0.89 pg (as recorded by Gregory, T.R. (2005), in the Animal Genome 
Size Database, www.genomesize.com).  92 
3.3.9  RQ-PCR to compare viral load in different anatomical locations 
Real-time Relative Quantitative PCR (RQ-PCR) was performed on 1  l of each DNA 
sample using E7 specific primer probe set. An insect specific actin primer and probe set 
was used as an endogenous control. Details of the primer and probe sequences and a full 
description of the method used can be found in Chapter II; Table 2.4. PCR reaction mixes 
contained  0.2   M  forward  and  reverse  primers,  0.1   M  probe,  25   l  of  2×  Platinum 
Quantitative PCR SuperMix-UDG (Invitrogen, UK), 1  l ROX Reference Dye and water 
to a final volume of 50  l. Reactions were performed on a 7500 Real Time PCR System 
(Applied Biosystems) with an amplification profiles specific of 2 min at 50 °C, 2 min at 95 
°C and 45 cycles of 15 s at 95 °C and 45 s at 60 °C. The dissected fly parts (2 sets of 6 
distinct anatomical parts) were each analysed in triplicate and the 7500 Real Time PCR 
System software was used to express the results relative to the viral DNA amounts in the 
stable fly heads. 
3.3.10 RQ-PCR to screen fly samples for presence of viral mRNA   
RNA  was  extracted  from  fly  samples  stored  in  RNAlater  and  cDNA  synthesised  as 
described in Chapter II; section 2.2.3.1.4. RQ-PCR was performed using BPV-1 E6 and E7 
primer and probe sets (Table 2.4) on cDNA samples generated using the RT enzyme and 
on cDNA samples synthesised with no RT enzyme, as a negative control. 93 
3.4  RESULTS 
3.4.1  Both biting and non-biting flies are positive for BPV-1 DNA 
The number of flies on each trap ranged from 2 or 3 to over a dozen. Traps from the June 
trapping period yielded the least number of flies, and those from August yielded the most. 
The predominant species of fly in each batch, was the lesser house fly (Fannia carnicularis) 
or regular house flies (Musca domestica). Both these species are non-biting flies, described 
as having ‘sponging’ mouthparts. A small number of traps had trapped sufficient numbers 
of stable flies (Stomoxys calcitrans) and these biting flies were processed as a separate 
batch from the non-biting house fly types. These samples are marked with an asterisk (*) 
on the results table (Table 3.1). At the first collection flies were collected from 3 locations 
which each housed one sarcoid affected donkey (sites 1, 3 and 4) and one location where 
there was no evidence of sarcoid affected animals (site 2).  
After extraction, the fly DNA was checked for quality by screening the extracts with insect 
specific primers (16s RNA). Figure 3.5 shows the agarose gels obtained from running 
these PCR products. 94 
Figure 3.5. 
A                1        2         3          4           5                -ve 
 
 
415 bp 
 
 
    
 
B               1           2           3           4            5          -ve 
 
415 bp 
 
 
Figure 3.5 PCR amplification of DNA extracted from fly samples (1 – 5) using the 
internal control primers for the fly (16s RNA gene) and a re-PCR protocol (where the 
'inner' and 'outer' primer sets are the same).  
A – after the first thermo-cycling profile, only a very faint band is evident in sample one at 
the correct size (415 bp) 
B – 2 µl aliquots from the amplicons shown in figure A were subjected to a further round 
of amplification. A positive result was obtained from all the fly DNA samples. 
In panel B, the sample in the no-template control column was an aliquot of PCR product 
from  the  no-template  control  sample  in  panel  A  –  this  methodology  ensures  that  any 
product seen in the re-PCRed samples is NOT due to the contamination of the samples in 
panel A. These fly DNA extracts were from capture session 1 in June 2008. Although all 
the samples are positive for the fly internal primer target, only two of the 5 samples (shown 
here in lane 1 and 2) were positive for BPV-1 DNA when examined using the BPV-1 LCR 
primer set. 95 
3.4.2  BPV-1 DNA recovered from fly samples contains equine specific LCR 
variants 
Figure  3.6  lists  the  sarcoid  specific  LCR  sequences  variants  that  were  detected  in  the 
comprehensive study undertaken by Nasir et al., in 2007 (sequences I, II, III, IV and V) 
and compares them to a reference BPV-1 LCR sequence obtained from a papilloma that 
was removed from a Highland cow in Scotland, and the  standard (STD) BPV-1 LCR 
sequence. Sequence data from analaysis of the fly-derived BPV DNA was compared to the 
LCR sequence variants (I – V) and the reference BPV-1 LCR sequence.  
As shown in Table 3.1, sarcoid swabs from the three donkeys at sites 1, 3 and 4 were all 
positive for BPV-1 LCR and sequence analysis revealed that all contained BPV-1 LCR 
variant IV (Accession No. DQ855068) (Nasir et al., 2007).  Analysis of the fly DNA 
samples showed that BPV-1 DNA could be detected in flies from sites 1 and 2 and that 
these flies harboured BPV-1 LCR variant IV. No BPV-1 DNA was detected in flies from 
site 3. At the second collection flies were trapped at 3 of the original locations (sites 1, 3 
and 4) and one additional site (site 5). Flies from all 4 sites were positive for BPV-1 DNA 
and contained BPV-1 LCR variant II (Accession No. DQ855066). At the final collection in 
September, flies were trapped at all 5 locations; BPV-1 DNA was detected in flies from 4 
sites (sites 1, 2, 4 and 5) and all contained BPV-1 LCR variant II. In summary, all fly 
samples that were positive for BPV-1 LCR DNA contained an equine specific LCR variant 
– none of the BPV-1 DNA isolated matched the reference or STD BPV-1 LCR sequence.  
Figure 3.7 shows the typical results from a BPV-1 LCR screening experiment using a 
nested PCR protocol that utilised 2 different LCR primer sets. 
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Figure 3.7. 
 
     
 A                            S         1          2         3          4           5          6                     -ve 
               
    
800 bp  
 
                                     
 
 
 
 
     
 B                          1           2          3           4          5           6                      -ve 
 
780 bp 
 
 
Figure 3.7 Products from PCR amplification of DNA extracted from flies using the 
BPV-1 LCR primer sets in a re-PCR protocol. 
A – first round of PCR amplification using 6 fly DNA samples (1 – 6) and DNA extracted 
from a sarcoid tumour as a positive control (S). None of the fly samples show any evidence 
of the presence of BPV-1 DNA, but a positive result from the sarcoid DNA of the correct 
size (800 bp) shows the profile and primers are working correctly. 
B – a second round of PCR was performed on samples 1 – 6 using the nested PCR protocol 
and the 'inner' LCR primer set. All samples are positive for the presence of BPV-1 DNA 
demonstrating the presence of a 780 bp product. 
-ve  =  column  representing  no-template  control  sample.  Sterile,  de-ionised  water  was 
substituted for DNA. The –ve column in panel B contains 2 µl of the no-template control 
amplification product shown in panel A. In this way, if environmental contamination had 
given rise to the bands seen in panel B, these bands would also be seen in the no-template 
control sample. 
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3.4.3  Viral load is low in captured flies 
Table  3.2  shows  the  weight  of  input  fly  DNA  as  determined  by  using  a  nanodrop 
spectrophotometer and the standard curve generated from the BPV-1 serial dilutions was 
used to calculate the number of viral genomes present. 
Table 3.2 Analysis of fly DNA samples. 
Fly 
Sample 
Sample ID  Avg fly DNA amount 
ng/ul 
Avg Viral 
Genomes/sample 
Standard 
Deviation in viral 
genome number 
1A  June Site 1  64.15  110  74.3 
1B  June Site 2  249.6  334  131.3 
2A  Aug Site 1  78.15  210.5  13.2 
2B  Aug Site 3  91.25  156.5  15 
2C  Aug Site 4  92.6  532  304.5 
2D  Aug Site 5  138.05  129.5  28 
3A  Sept Site 1  75.45  247.5  23 
3B  Sept Site 2  468.55  100.5  51.8 
3C  Sept Site 4  52.95  38.5  4.4 
3D  Sept Site 5  72.4  83  7.85 
 
This table is shows the average amount of fly DNA in each sample that had shown to be 
positive for BPV DNA, along with the average number of viral genomes present in that 
sample as deduced from the AQ-PCR results.  
BPV-1/2 viral load in Diptera cells was then determined as number of BPV-1/2 copies per 
genome equivalent (g.e.) of cell. For this, the C-value for Diptera species was considered. 
The term C-value refers to the amount of DNA contained within a haploid nucleus of a 
eukaryotic organism. Often, among diploid organisms, the terms C-value and genome size 
are used interchangeably. Genome equivalents of Diptera cells were calculated based on 
the fact that an average Diptera cell contains total DNA of the mass 0.89 pg (as recorded in 
the Animal Genome Size Database, www.genomesize.com). If one fly genome contains 
0.89 pg of DNA then 1.1236 fly genomes contain 1 pg and so 1123.6 fly genomes are 
equivalent to 1 ng of DNA. Using the data in Table 3.2, the viral load was calculated and 
shown in Table 3.3. 101 
 
Table 3.3 Calculation of viral load. 
Sample 
I.D.  No.  of fly 
genomes  
Avg No. 
Viral 
Genomes 
Viral load 
per fly cell 
viral load per 
1000 fly cells 
SD (viral 
genome)  SD  
1A  72078  110  0.00152  1.526  74.3  1.0 
1B  280449  334  0.00119  1.190  131.3  0.5 
2A  87809  210.5  0.00239  2.397  13.2  0.2 
2B  102528  156.5  0.00152  1.526  15  0.1 
2C  104044  532  0.00511  5.113  304.5  2.9 
2D  155112  129.5  0.00083  0.834  28  0.2 
3A  84775  247.5  0.00291  2.919  23  0.3 
3B  526460  100.5  0.00019  0.190  51.8  0.1 
3C  59494  38.5  0.00067  0.647  4.4  0.1 
3D  81348  83  0.00102  1.020  7.85  0.1 
 
Viral load was subsequently calculated and estimates of viral genome equivalent (g.e.) per 
1000  diploid  fly  cells  demonstrate  that  flies  harbour  low  viral  loads.  SD  –  standard 
deviation. 
3.4.4  The whole BPV-1 genome could not be detected as a circular genome in 
the DNA extracted from the captured flies 
Attempts to amplify the entire BPV-1 genome using RCA techniques failed to demonstrate 
the  presence  of  circular  BPV-1  DNA  in  any  of  the  fly  samples  (Fig  3.8).  Using  the 
standard  protocol  it  was  possible  to  obtain  a  positive  result  from  the  positive  control 
supplied with the kit, and also using DNA extracted from EqS04b cells (a sarcoid derived 
cell line) using a protocol optimised previously in the lab by Yuan et al. 2007.  
                                           1        2          3         4        5         6 
          
Figure 3.8 Results from rolling circle amplification (RCA) performed on fly DNA 
samples.                
1 – positive control, 2 – water (negative control), 3 – EqS04b DNA (an additional positive 
control), 4, 5 and 6 – fly DNA samples. 
8.0 kbp 102 
Additional attempts were made to further optimise the RCA protocol in the hope that the 
right balance of input material from the fly samples could be determined and included 
consulting the TempliPhi manufacturer’s online Troubleshooting resource. Due to the fact 
that the kit and protocol had been shown to be in working order and additional RCA 
screenings failed to demonstrate the presence of circular DNA in any of the fly samples, 
other options for establishing the presence of an entire BPV-1 genome were evaluated. 
Full length BPV-1 primers and ‘back to back’ BPV-1 primers, which have previously been 
shown to amplify the whole BPV-1 genome (Hatama et al., 2008; Brandt et al., 2008) were 
used with Platinum Taq (Invitrogen, UK) without success. These back to back primers 
were also used with the Expand High Fidelity Plus system (Invitrogen, UK) with a variety 
of amplification profiles and MgCl2 concentrations. This included the implimentation of a 
touchdown  thermal  profile.  Touchdown  polymerase  chain  reaction  or  touchdown  style 
polymerase chain reaction is a method of polymerase chain reaction by which primers will 
avoid amplifying nonspecific sequences. The annealing temperature during a polymerase 
chain reaction determines the specificity of primer annealing. The melting point of the 
primer sets the upper limit on annealing temperature. At temperatures just below this point, 
only very specific base pairing between the primer and the template will occur. At lower 
temperatures,  the  primers  bind  less  specifically.  The  earliest  steps  of  a  touchdown 
polymerase  chain  reaction  cycle  have  high  annealing  temperatures.  The  annealing 
temperature is decreased in increments for every subsequent set of cycles (the number of 
individual cycles and increments of temperature decrease is chosen by the experimenter). 
The primer will anneal at the highest temperature which is least-permissive of nonspecific 
binding that it is able to tolerate. Thus, the first sequence amplified is the one between the 
regions of greatest primer specificity; it is most likely that this is the sequence of interest. 
These fragments will be further amplified during subsequent rounds at lower temperatures, 
and will out-compete the nonspecific sequences to which the primers may bind at those 
lower temperatures. If the primer initially (during the higher-temperature phases) binds to 
the sequence of interest, subsequent rounds of polymerase chain reaction can be performed 
upon the product to further amplify those fragments. Unfortunately, none of the methods 
outlined above produced evidence of the presence of an entire, intact, BPV-1 genome. 
Figure 3.9 shows the results of screening the fly DNA samples with the BPV-1 E5 primer 
set (Chapter II; Table 2.1) 103 
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Figure 3.9 Re-PCR technique using BPV-1 E5 primers on DNA samples extracted 
from flies. 
Despite an inability to  detect the  BPV-1  genome as an  entire structure, standard PCR 
screening techniques revealed BPV-1 E5 was present in some of the fly samples. 
3.4.5  All dissected fly body parts (heads, thoraces and abdomens) were 
positive for presence of BPV-1 DNA 
The two sets of data obtained from the RQ-PCR results were combined (Table 3.4). All 
anatomical section samples were positive for BPV E7 and the relative amounts in each 
body section (head vs. thorax vs. abdomen), are shown in Figure 3.10.  
Table 3.4 Results from BPV-1 screening of the grossly dissected fly body parts. 
Anatomical Section  RQ value A  RQ value B  Avg RQ value  SD 
SFH  1  1  1  0 
SFT  2.11  3.9  3.005  1.265721 
SFA  0.712  7.3  4.006  4.658419 
LHFH  5.9  11  8.45  3.606245 
LHFT  2  1.56  1.78  0.311127 
LHFA  3.3  2.17  2.735  0.799031 
 
All anatomical section samples were positive for BPV E7 DNA and the relative amounts 
present were expressed in relation to the amount present in the stable fly head samples.  
·  SFH – stable fly heads;  
·  SFT – stable fly thoraces;  
·  SFA – stable fly abdomens;  
·  LHFH – lesser house fly heads;  
·  LHFT – lesser house fly thoraces;  
·  LHFA – lesser house fly abdomens;  
·  SD – standard deviation. 104 
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Figure  3.10  RQ-PCR  analysis  of  the  different  anatomical  sections  for  quantity  of 
BPV-1 DNA present. 
The amount of BPV-1 DNA present in each fly body section is shown relative to the 
amount detected in the stable fly head (SFH) sections. Values were calculated from RQ-
PCR experiments using the BPV-1 E7 primer and probe set and the fly actin gene as an 
internal control. SFT – stable fly thoraces; SFA – stable fly abdomens; LHFH – lesser 
house fly heads; LHFT – lesser house fly thoraces; LHFA – lesser house fly abdomens. 
Lesser house flies, with their sponging mouthparts, had over an 8 fold increase in the 
amount of viral DNA present. In the biting stable flies, a relatively higher proportion of 
viral DNA was detected in the thoraces and abdomens, whereas in the lesser house flies, 
there was comparatively less in these body sections. 
3.4.6  BPV-1 mRNA could not be detected in any fly samples 
In the flies that had been stored in RNA later, viral mRNA could not be detected after 
screening using standard PCR, nested PCR, or the more sensitive RQ-PCR methods. After 
the initial extraction of RNA and generation of cDNA, PCR performed on the samples 
containing reverse transcription enzyme (RT) demonstrated bands of equal intensity to 
those seen from the samples to which no RT was added. This result suggested there was 
DNA contamination of the cDNA. All samples were subjected to another DNase I digest 
and the PCR was repeated. The results obtained were the same – both the RT positive and 105 
the RT negative samples showed evidence of PCR amplification (LCR primers were used). 
A new DNase I kit was ordered and the methodology repeated, again with the same results.  
At this stage, it was decided to analyse the cDNA samples in an RQ-PCR experiment. 
Because it seemed that there was a low level of DNA contamination that could not be 
removed with sequential DNase I treatments, using an RQ-PCR technique would enable a 
comparison of the relative amounts of BPV-1 DNA present in each sample. The theory 
being  that  samples  with  RT  enzyme  added  would  have  both  the  cDNA  and  the 
contaminating DNA, whereas the RT negative samples would only have the contaminating 
DNA present. And so, there should be a detectable difference in the amounts of BPV-1 E7 
present as assessed by RQ-PCR. The results of the RQ-PCR assessment showed there was 
no difference between the RT positive and RT negative samples, making it very unlikely 
that there was any viable RNA in the fly samples. This is perhaps not an entirely surprising 
result, as RNA is notoriously vulnerable to rapid degradation. Future work will require 
samples  to  be  processed  immediately,  or  for  micro  dissection  to  be  performed  on  the 
specimens, prior to storage in a solution such as RNA later. 106 
3.5  DISCUSSION 
Although a causal relationship between BPV-1 and equine sarcoids is well established, 
how equidae become infected with BPV-1 remains unknown. The transmission between 
animals  has  been  proposed  to  be  by  direct  or  indirect  contact,  however  both 
epidemiological data and development of sarcoids in animals in the absence of contact 
with horses (or cattle) has led to the proposition that flies may acts as vectors of disease 
transmission  (Torreontegui  and  Reid  1994,  Reid  et  al.,  1994,  Knottenbelt  1995, 
Knottenbelt and Pascoe 1994). The potential role of insects in the spread of some viral 
diseases to and between humans and domestic animals has been confirmed in many studies 
(Dalmat, H.T. 1957; Issel and Foil, 1984; Mellor et al., 1987; Tarry et al., 1991; McColl et 
al., 2002; Mead et al., 2009). The house fly, Musca domestica, and the stable fly Stomoxys 
calcitrans  have  long  been  considered  as  potential  agents  for  disease  transmission,  and 
pathogens have been isolated from faeces, vomitus, external surfaces, and internal organs 
of these species.  
We have shown that all body parts of the fly tested positive for the presence of BPV-1 
DNA. From the blunt dissection work in stable flies, there was found to be more viral 
DNA present in the thorax and abdomen sections compared to the amount detected in the 
head when analysed by RT-QPCR. According to the anatomy of this species, this may 
correlates to the salivary glands which extend through the thorax and in to the abdomen. 
Conversely,  the  lesser  house  fly  was  found  to  have  comparatively  more  BPV-1  DNA 
present in the head sections. Because this species has large sponging mouth parts, and well 
developed salivary glands in both the head and thorax, this correlates with the hypothesis 
that the virus may accumulate in the salivary glands of both species. However, it could also 
be argued that due to the fact BPV-1 DNA could be detected throughout the entire body of 
the fly, our results demonstrate nothing more than ingestion of the viral DNA by the fly 
during  feeding,  and  potentially,  subsequent  degradation.  More  precise  dissection 
techniques would be required to confirm this hypothesis absolutely.  
In this study the most commonly detected BPV-1 LCR variant in the fly samples, variant 
II, is the most commonly detected variant in equine sarcoids, at least in the UK accounting 
for approx. 66% of all sarcoid infections. Variant II is rare in cattle BPV-1 infections 
(Nasir  et  al.,  2007)  suggesting  that  flies  may  act  as  vectors  for  BPV-1  transmission 
amongst equids. At the first trapping (Table 3.1), LCR variant  IV was detected in fly 
samples. Whilst LCR variant IV is common in cattle BPV-1 infections (Nasir et al., 2007),  107 
the sarcoid tumour at the site of fly trapping also contained variant IV (Nasir et al., 2007) 
which could account for the presence of variant IV in the flies.  
While we were unable to detect BPV mRNA in the flies caught in the live capture session, 
it would be difficult to dismiss the possibility that BPV replication occurs in at least one of 
the species of flies where BPV DNA has been shown to be present. As demonstrated by 
the fact that BPV DNA can be detected in all body parts of dissected flies, it seems likely 
that some virus is internalised in the fly, and may be present in cell types permissive to 
virus replication. Any viral mRNA is likely to be degraded rapidly once the fly has been 
killed, and due to the likelihood of an internalised location, would not be preserved by 
immersing the fly sections in RNAlater after dissection.  
Attempts to amplify the entire BPV-1 genome using RCA techniques failed. It is likely that 
because the viral DNA was present in such small quantities, and in such a comparatively 
large  amount  of  bulky  genomic  DNA  molecule,  conditions  were  unsuitable  for 
amplification of the entire circular genome. Because we managed to identify LCR DNA 
(Fig. 3.7.) and E5 DNA (Fig. 3.9.) via nested PCR techniques, and we were also able to 
detect BPV E6 and BPV E7 using RQ-PCR and AQ-PCR, we are confident that the entire 
viral genome was present, and, for a large part, undegraded. 
The data presented in this chapter supports the hypothesis that fly species which commonly 
feed from the tissues around sarcoid lesions (including M. domestica and S. calcitrans) 
may transmit viable BPV material between infected and uninfected animals. However, the 
data by no means provides irrefutable evidence that flies are indeed viral vectors in equine 
sarcoid transmission. This study indicates that flies can harbour BPV-1 DNA, and our 
variant analysis implies that the common variants detected in sarcoids are the same as 
those we detect in flies. This, together with the distribution of lesions and the epidemiology 
of sarcoids, strongly suggest that flies are significant. But he ability of the fly to carry 
viable viral material from a sarcoid-affected animal to vulnerable areas of skin on healthy 
equidae has yet to be demonstrated, and how the fly and the virus are linked is another 
matter yet to be established.  
 
It is worth bearing in mind that the viral load in equine sarcoid lesions has been shown to 
be incredibly low (Yuan et al., 2007; Boegart et al., 2007), often just a few viral copies per 
cell. The viral load analysis we carried out showed an even lower viral load in the insect 
cells. Before the role of these insects as vectors of disease can be confirmed, work needs to 
be done to establish what the infectious dose is for the development of a sarcoid lesion on a 108 
susceptible  animal.  Perhaps  the  virus  accumulates  in  or  on  the  fly.  Or  perhaps  it 
concentrates at certain anatomical sites within the fly allowing transference of sufficient 
quantities  of  viral  material  on  to  or  in  to  the  skin  of  uninfected,  susceptible  animals. 
Alternatively, the accumulation of viral material could occur on the skin of the animals on 
which the fly lands to feed. 
 
Further  studies  are  also  required  to  establish  whether  these  flies  excrete  the  virus  in 
vomitus or faeces, and if so, is the virus present in larger quantities/higher concentrations 
in  these  substances?  It  should  also  be  possible  to  establish  whether  flies  are  purely 
mechanical vectors or whether the virus is active in particular insect cells. This would 
require  micro  dissection  experiments  to  establish  the  existence,  or  otherwise,  of  BPV 
mRNA.  
 
Additional evidence to determine the link between virus and fly and sarcoid transmission 
could  be  supplied  by  designing  and  implementing  controlled  transmission  experiments 
where pathogen free insects were allowed to feed on sarcoid tissue for a certain amount of 
time before being incubated with a susceptible, uninfected animal. Such experiments are 
probably  the  only  way  to  prove  conclusively,  that  flies  such  as  M.  domestica  and  S. 
calcitrans can indeed transmit the disease from an infected animal, to an uninfected one.  109 
4  CHAPTER IV: 
 
Evaluation of apoptosis and cell survival 
in BPV-1 transformed equine fibroblasts 110 
4.1  INTRODUCTION 
Apoptosis,  or  programmed  cell  death  (PCD),  is  a  genetically  programmed  process  of 
cellular  destruction  that  is  essential  for  normal  development  and  homeostasis  of 
multicellular organisms.  
 
Figure 4.1 Overview of the 2 main apoptosis pathways – the INTRINSIC, and the 
EXTRINSIC (modified from source: www.imgenex.com). 
Apoptosis can be initiated by internal events which lead to activation of the ‘Intrinsic 
Pathway’. This involves the disruption of mitochondria and the release of the enzyme 
cytochrome C, in turn leading to the downstream activation of caspases. Alternatively, cell 
surface receptors can be activated by specific ligands that bind to ‘death receptors’ and 
thus leading to activation of the ‘Extrinsic Pathway’. Death receptors are members of the 
tumour necrosis factor (TNF)/nerve growth factor (NGF) receptor superfamily. They make 111 
up  a  subfamily  characterized  by  the  intracellular  death  domain  (DD).  The  extrinsic 
pathway is typically mediated by immune cells, to initiate intracellular signaling and the 
downstream  activation  of  relevant  caspases.  As  illustrated  in  Figure  4.1,  the  apoptosis 
pathways are highly complex and there are molecules common to both the intrinsic and 
extrinsic pathways. In addition to pro-apoptotic proteins such as Bcl-2 and APAF-1, there 
are a family of proteins known as the Inhibitor of Apoptosis Proteins or IAP (lower central 
box, Fig. 4.1) that can inhibit both the intrinsic and extrinsic pathways once they have been 
activated.  
Apoptosis is a term that only describes the morphological changes a cell undergoes during 
this mode of cell death (Kerr et al., 1972). Specifically, the cell draws inward shrinking 
dramatically, the plasma membrane ‘blebs’, the endoplasmic reticulum forms vacuoles, 
and the chromatin is digested and condenses along the nuclear membrane, often forming 
spheres and/or crescent shapes (Strasser et al., 2000). In contrast, necrosis, another form of 
programmed cell death, has distinct morphological features. During necrosis, cells first 
swell,  then  the  plasma  membrane  collapses  and  cells  are  rapidly  lysed.  Biochemical 
hallmarks  of  apoptosis  such  as  caspase  activation  and  DNA  fragmentation  are  usually 
absent in necrotic cells (Proskuryakov et al., 2003).  
The  terms  ‘immediate’,  ‘intermediate’,  and  ‘delayed’  apoptosis  separate  the  different 
apoptotic mechanisms into three kinetic categories, whereas the terms pre-programmed 
cell  death  (pre-PCD)  and  programmed  cell  death  (PCD)  describe  the  underlying 
mechanisms. Immediate apoptosis (T < 0.5 h post-exposure) is triggered by singlet-oxygen 
damage  that  opens  the  mitochondrial  megachannel  (Ball  et  al.,  1998),  which  can  be 
mediated by photo-dynamic therapy (PDT) or ultra violet A1 (UVA1) radiation. It is a pre-
PCD mechanism of apoptosis, i.e., protein synthesis is not required post-insult, because all 
the necessary components are constitutively synthesized and only need to be activated. 
Intermediate apoptosis (0.5 h > T < 4 h) is initiated by receptor cross-linking on the plasma 
membrane (Wang et al., 1997), which can be achieved using high doses of UVB or ultra 
violet C (UVC) radiation. It is also a pre-PCD mechanism. Delayed apoptosis (T > 4 h) is 
induced by DNA damage that can be caused by X-rays, UVC, UVB, UVA, and PDT. It is 
a PCD mechanism of apoptosis, i.e., protein synthesis is required post-insult (Godar 1996). 
These three apoptotic mechanisms have shared and overlapping signalling pathways and 
cells dying by different forms may display varying degree and combination of features 
(Jaattela 2004).  112 
 
Figure 4.2 Regulation of the Cell Cycle (modified from Fred Hutchinson Cancer 
Research Centre website www.fhcrc.org) 
Green = Positive Regulators 
 
Pink = Negative Regulators 
 
Dark Borders = Protiens with dark grey borders have been shown to be defective in some 
cancer cell lines. 
 
Disruption of cell cycle control mechanisms is a common biological feature in human 
cancers,  however  its  occurrence  in  sarcoid  pathology  remains  poorly  investigated. 
Progression through the cell cycle is mediated by protein complexes composed of cyclins, 
cyclin dependent kinases (CDKs) and cyclin dependent kinase inhibitors (CDKIs). The 
CDKIs act as inhibitors of the cell cycle and hence function as tumour suppressors, where 
loss  of  function  can  lead  to  cellular  transformation  (Hartwell  and  Kastan,  1994  and 
Swanton 2004). The low levels of expression of cell cycle regulatory proteins in equine 
sarcoids  (cyclin  A,  CDK-2,  p27
kip1  and  p53;  Nixon  et  al.,  2003)  suggest  that  sarcoid 
molecular  pathology  is  generally  not  associated  with  abnormal  cell  cycle  control 
mechanisms. This implies that sarcoid lesions may in fact be associated with abnormalities 
in apoptotic pathways, where the balance of cell growth and cell death is perturbed. Many 
viruses  have  evolved  specific  gene  products  to  modulate  the  apoptotic  process.  For 
example, in adenoviruses several viral proteins act to regulate apoptosis in infected cells. 113 
The adenovirus E1A protein increases cellular levels of p53 and induces p53-dependent 
apoptosis.  This  apoptosis  is  counteracted  by  the  adenovirus  E1B  19  kDa  (inhibts  the 
downstream pro-apoptotic actions of p53) and E1B 55 kDa proteins (interacts directly with 
p53  and  mediates  its  inactivation,  translocation  to  the  cytoplasm,  ubiquitination,  and 
degradation) (McNees and Gooding, 2002). 
4.1.1  BPV-1 gene products and apoptosis 
Like all death-domain-containing members of the Tumour Necrosis Factor receptor (TNF-
R) superfamily, TNF-R1 is involved in death signalling. Tumour Necrosis Factor (TNF) is 
a  17-kDa  inflammatory  cytokine  that  mediates  a  variety  of  immune  and  inflammatory 
reactions (Tracey and Cerami, 1993). Some tumour cell lines are sensitive to TNF, but 
most  are  resistant  (Carswell  et  al.,  1975;  Sugarman  et  al.,  1985).  In  1999,  it  was 
demonstrated that BPV-1 E6 and E7 genes independently sensitise cells to TNF-induced 
apoptosis. BPV-1 E6 induced apoptosis independently of p53 and E7 induced apoptosis 
independently  of  the  retinoblastoma  protein  (pRb),  a  tumor  suppressor  protein  that  is 
dysfunctional in many types of cancer (Rapp et al., 1999; Liu et al., 2000). 
In  Fas-mediated  apoptosis,  in  contrast  to  TNF-mediated  apoptosis,  E6  and  E7 
demonstrated opposite effects: while E7 potentiated apoptosis triggered by an agonistic Fas 
antibody, E6 attenuated the effect. The Fas (CD95/APO-1) receptor is a member of the 
Tumour Necrosis Factor receptor (TNF-R)/ nerve growth factor receptor superfamily. Fas 
is expressed on the cell surface and transduces apoptotic signals upon cross-linking with 
the Fas ligand (FasL). Since BPV-1 exerts contrasting effects on TNF- and Fas- mediated 
apoptosis, E6 may target distinct components of these pathways, the most upstream of 
which are the death receptors Fas and TNF-R. Liu et al., in 2005 used flow cytometry to 
show  that  surface  Fas  expression  was  greatly  reduced  in  E6  expressing  mouse  cells, 
compared to E7 expressing mouse cells. The reduced Fas protein level on the cell surface 
is  not  accompanied  by  a  decrease  in  total  Fas  levels  in  E6-expressing  cells.  Instead, 
considerably more Fas protein is found in the cytoplasm of cells expressing E6 (Liu et al., 
2005). 
The papillomavirus E2 protein plays a central role in the viral life cycle as it regulates both 
transcription and replication of the viral genome.  In 1997, a research  group in  France 
showed that transient expression of BPV-1 E2 in HeLa induced apoptosis and that the 
effects of E2 on cell cycle progression and cell death follow distinct pathways involving 
two different functions of p53 (Desaintes et al., 1997). 114 
4.1.2  Ultra Violet-B (UVB) irradiation and DNA damage 
UVB-mediated  apoptosis  is  a  highly  complex  process  in  which  a  variety  of  signaling 
pathways  are  involved.  Following  UVB  irradiation,  apoptosis  can  be  initiated  through 
DNA  damage  response  pathways,  generation  of  reactive  oxygen  species,  CD95/Fas 
receptor signalling, TNF-R1 signalling and TRAIL receptor signalling (Chow and Tron, 
2006). Upon absorption, UVB primarily induces two types of DNA lesions, cyclobutane 
pyrimidine dimers and 6–4 photoproducts (Patrick, 1977). Under normal conditions these 
photolesions are removed by the nucleotide excision repair (NER). UVB can also affect 
molecular targets located in the cytoplasm or at the cell membrane; a direct and ligand-
independent activation of membrane-bound cell death receptors has been demonstrated 
(Kulms and Schwarz, 2002). Death receptors are members of the tumor necrosis factor 
(TNF) receptor superfamily (Ashkenazi and Dixit, 1998). Besides the TNF receptor-1, the 
TNFα-related apoptosis inducing ligand (TRAIL) receptors and death receptor-3 (DR-3), 
CD95 (Fas, APO-1) represents one of the most potent mediators of programmed cell death. 
Activation of these pathways results in triggering of a cascade of cystein proteases, called 
caspases, the executioners of apoptosis (Peter and Krammer, 1998). The range of exposure 
levels of UVB for inducing apoptosis (0, 250 and 500 mJ/cm) used in this chapter, are 
considered ‘high’ levels of exposure, consistently resulting in apoptosis in treated cells. 
This is in contrast to the exposure level used to assess p53 function (30 mJ/cm) which is 
considered  low,  and  therefore  more  likely  to  result  in  activation  of  the  DNA  repair 
response, than in cell apoptosis (Cotton and Spandau, 1997). 
4.1.3  Chemotherapeutic agents and DNA damage 
Cisplatin and its analogs are heavy metal complexes containing a central atom of platinum 
surrounded by two chloride atoms and two ammonia molecules in the ‘cis’ position. The 
current accepted theory about cisplatin mechanism of action is that the drug induces its 
cytotoxic properties through binding to nuclear DNA and subsequent interference with 
normal  transcription,  and/or  DNA  replication  mechanisms.    Cisplatin  has  biochemical 
properties  similar  to  that  of  bifunctional  alkylating  agents,  producing  interstrand, 
intrastrand and monofunctional adduct cross-linking in DNA. However, there is now much 
evidence suggesting that the cytotoxic effects induced by binding of cisplatin to non-DNA 
targets  (especially  proteins)  may  contribute  to  its  biochemical  mechanism  of  action 
(Fuertesa  et  al.,  2007).  Several  studies  have  shown  cisplatin  to  be  a  useful 
chemotherapeutic  option  in  the  treatment  of  equine  sarcoids  with  one  particular  study 115 
observing complete regression in 78% of the tumours. It was also stated that no systemic 
side-effects were encountered (Spoormakers et al., 2002). 
As  a  pyrimidine  analogue,  5-fluorouracil  (5-FU)  is  transformed  inside  the  cell  into 
different cytotoxic metabolites which are then incorporated into DNA and RNA. 5-FU also 
inhibits the nucleotide synthetic enzyme thymidylate synthase (TS), and finally induces 
cell cycle arrest and apoptosis by inhibiting the cell's ability to synthesize DNA. It is an S-
phase  specific  drug  and  only  active  during  certain  cell  cycles.  In  addition  to  being 
incorporated in DNA and RNA, the drug has been shown to inhibit the activity of the 
exosome complex, an exoribonuclease complex of which the activity is essential for cell 
survival.  It  has  been  shown  that  the  use  of  intratumoural  5-fluorouracil  compares 
favourably  with  other  treatment  modalities  for  sarcoids,  with  a  long  term  successful 
resolution rate of 61.5%. However the study recommended that owners should be warned 
that  resistant  sarcoids  and  sarcoids  larger  than  13.5  cm3  have  a  poorer  prognosis  for 
resolution and more aggressive therapeutic options should be considered (Stewart et al., 
2006). 
4.1.4  Small Interfering RNA (siRNA) technology 
Small interfering RNA (siRNA), also known as short interfering RNA or silencing RNA, is 
a class of 20-25 nucleotide-long, double-stranded RNA molecules that play a variety of 
roles in biology. Most conspicuously, siRNA is involved in the RNA interference (RNAi) 
pathway,  where  it  interferes  with  the  expression  of  a  specific  gene.  RNAi  can  trigger 
degredation or translation repression of homologous RNA targets in a sequence-specific 
manner. At least three distinct roles of RNAi have been identified; 
i) antiviral response (Mourrain et al., 2000),  
ii) protection of the genome (Grishok et al., 2000),  
iii) and regulation of development (Bohmert et al., 1998) 
The complexity of these pathways is only now being elucidated.  
Figure 4.3. illustrates the mechanism of action of RNAi. Since the only RNA found in a 
cell  should  be  single  stranded,  the  presence  of  double  stranded  RNA  signals  is  an 
abnormality. The cell has a specific enzyme (Dicer) that recognizes the double stranded 
RNA and chops it up into small fragments between 21-25 base pairs in length. These short 
RNA  fragments  (called  small  interfering  RNA,  or  siRNA)  bind  to  the  RNA-induced 116 
silencing  complex  (RISC).  The  RISC  is  activated  when  the  siRNA  unwinds  and  the 
activated complex binds to the corresponding mRNA using the antisense RNA. The RISC 
contains  an  enzyme  to  cleave  the  bound  mRNA  (Slicer)  and  therefore  cause  gene 
suppression.  Once  the  mRNA  has  been  cleaved,  it  can  no  longer  be  translated  into 
functional protein. 
 
Figure 4.3 Mechanism of action of RNAi. Image sourced from The Science Creative 
Quaterly, Issue 4, 2009. 
To  date,  RNAi  has  been  extensively  used  as  a  novel and effective tool for  functional 
genomic studies, and has exhibited great potential in treating human diseases, including 
human genetic and acquired disorders such as cancer and viral infections. Numerous in 
vitro and animal studies have provided proof-of-concept; major viral pathogens including 
HIV-1,  respiratory  viruses  such  as  influenza  A,  respiratory  syncitial  virus  (RSV),  and 
hepatitis viruses, have been shown to be susceptible to siRNA treatment (van Rij and 
Andino, 2006). Indeed, several RNAi-based antiviral drugs are currently being tested in 
clinical trials (Hasnoot et al., 2007). 
In principle, RNA interference (RNAi) is a straightforward method for inducing sequence-
specific silencing of one or more genes of interest with the simple introduction of small 
interfering RNAs. In practice, there are fundamental challenges to be considered in order 117 
to achieve successful gene silencing. Major hurdles to therapeutic applications of RNAi 
include the delivery of the siRNA into the target cell and across cellular membranes into 
the relevant cell types, the bioavailability and stability of siRNAs, and the prevention of 
off-target effects and toxicity. The introduction of excessive concentrations of siRNA can 
result in nonspecific events due to activation of innate immune responses. Evidence to date 
suggests that this immune system response is most likely due to activation of the dsRNA 
sensor PKR, although retinoic acid inducible gene I (RIG-I) may also be involved (Sledz et 
al.,  2003;  Sledz  and  Williams  2004).  Off-targeting  arises  as  a  result  of  genes  with 
incomplete complimentarity being inadvertently downregulated by the siRNA. This can 
lead to problems with data interpretation and toxicity.  Consequently, siRNA design and 
production is of fundamental importance, as not all siRNAs directed against a given target 
silence  with  equivalent  efficiencies.  A  scrambled  siRNA  control  (the  same  nucleotide 
composition as the gene-specific siRNA, but lacking significant sequence homology to the 
genome) is used to discount any changes to the gene expression profile that may result 
from the siRNA delivery  method. For the purposes of this study,  Lipofectamine 2000 
(Invitrogen,  UK)  was  considered  to  be  the  most  suitable  delivery  method  available. 
Nucleic acids carry a net negative charge under normal physiological conditions, and must 
come  into  contact  with  a  cell  membrane  that  also  carries  a  net  negative  charge. 
Lipofectamine 2000 is a cationic liposome formulation that functions by complexing with 
nucleic acid molecules, allowing them to overcome the electrostatic repulsion of the cell 
membrane and to be taken up by the cell. 
The  efficiency,  safety  and  long-term  duration  of  siRNA  delivery  remain  the  major 
challenges to its clinical application. siRNA delivery to specific cell types is also a key 
challenge. A number of cell specific ligands including polysaccharide, antibody, antibody 
fragment, and peptide have been employed to achieve targeted delivery of siRNA. Recent 
studies using multilayered polyelectrolyte films (MPFs – consisting of alternate layer by 
layer deposition of polycations and polyanions), have shown this technique to represent a 
successful approach for the efficient delivery of siRNAs to target cells to combat viral 
infection (Dimitrova et al., 2008). There is currently a  great deal of work being done 
investigating innovative solutions for delivery of RNAi therapeutics, however it should 
also be kept in mind that virus-specific challenges exist such as virus-encoded suppressors 
of RNAi and virus escape.  
To  counter  the  antiviral  RNAi  response,  plant  and  invertebrate  viruses  have  evolved 
proteins that actively interfere with distinct steps of the RNAi machinery (Li and Ding, 118 
2005).  Some  mammalian  viruses  also  encode  factors  that  exhibit  RNAi  suppression 
activity and it is currently unclear to what extent these suppressors can interfere with the 
activity of RNAi-based therapeutics (Andersson et al., 2005; Haasnoot et al., 2007). 
Another hurdle is the fact that viruses readily escape from RNAi suppression by single 
mutations  or  deletions  of  the  target  sites  and  mutations  outside  the  target  sites.  Two 
strategies may delay or even prevent viral escape; use siRNA designed to target a highly 
conserved sequence of the viral genome, and employ the simultaneous use of multiple 
siRNAs (Schubert et al., 2005).  119 
4.2  AIMS AND OBJECTIVES 
In this chapter, the aim was to investigate the hypothesis that equine sarcoid tumours arise 
primarily as a result of cellular resistance to apoptosis rather than as a result of increased 
cellular proliferation. More specifically, to;   
i) Investigate the effects of a variety of DNA damaging agents (UVB, 5-fluoruracil and 
cisplatin) on apoptosis levels in BPV-1 transformed equine fibroblast cell lines. 
ii)  Evaluate  long-term  cell  survival  following  DNA  damage  in  normal,  and  BPV-1 
transformed equine fibroblast cell lines.  
iii) Identify the viral gene(s) responsible for altering the apoptotic response and long term 
survival of BPV-1 transformed equine fibroblast cells. 120 
4.3  MATERIALS AND METHODS 
4.3.1  Cell Culture 
Normal  equine  fibroblasts  (EqPalF  cells),  sarcoid  derived  BPV-1  transformed  equine 
fibroblasts (EqS cells) and experimentally transformed equine fibroblasts (S6 cells) were 
cultured and maintained as described in Chapter II; section 2.2.1. 
4.3.2  Apoptosis detection using FCM analysis 
Cell culture, UVB and drug treatments were performed as previously described in Chapter 
II;  section  2.2.  FCM  analysis  was  implemented  after  24  hours  (in  the  case  of  UVB 
exposure) or 72 hours (cisplatin and 5-fluoruracil) post-treatment to assess the levels of 
apoptosis present (Chapter II; section 2.211). FCM optimisation was carried out with each 
DNA  damaging  treatment  to  obtain  optimal  apoptosis  levels  of  50  –  60%  per  cell 
population and treatment. This optimisation resulted in the selection of UVB irradiation 
levels of 250 and 500 mJ/cm2, cisplatin concentrations of 10 and 25 µg/ml and 5-FU 
concentrations of 10 and 15 mg/ml.  
4.3.3  Clonogenic Survival Assay 
Since BPV-1 positive cell lines tended to show increased apoptosis in the presence of DNA 
damaging agents compared to BPV-1 negative EqPalF cells, we then studied the long term 
survival of these cells. Once cells had been treated and harvested for FCM analysis either 
24 (UVB treated cells) or 72 (cisplatin and 5-FU treated cells) hours after initial exposure 
to  the  DNA  damaging  agent,  a  small  proportion  of  the  harvested  cells  (5,000)  were 
retained and used in a clonogenic survival assay. The methodology for these assays is 
outlined in Chapter II; section 2.2.12. After about 10 days, colonies were fixed, stained and 
counted and the plating efficiencies and survival fractions for each cell line and treatment 
level were calculated.   
4.3.4  siRNA design and transfection 
EqS04b cells have previously been shown to express higher levels of BPV-1 genes than the 
other sarcoid derived cell lines (Yuan et al., 2007), so this cell line was chosen for use in 
the siRNA experiments. Initially, 3 BPV genes of interest were selected for evaluation; E5, 
E6  and  E7.  siRNA  design  software  was  used  to  generate  suitable  siRNA  sequences 
targeted to each gene. These siRNA sequences are detailed in Chapter II; section 2.2.8. The 
E6 targeted siRNA molecule was shown to be the most effective when knock-down was 121 
assessed  by  RQ-PCR  (section  2.2.5).  EqS04b  cells  were  transfected  with  E6  targeted 
siRNA as described in Chapter II; section 2.2.8.4.  
4.3.5  RQ-PCR to establish efficiency of siRNA knockdowns 
RNA extraction from cultured cells was carried out as described in Chapter II; section 
2.2.3.1. From the RNA, cDNA was synthesised (section 2.2.3.1.4) and analysed by RQ-
PCR (section 2.2.5) using either an E5, E6 or E7 primer and probe set (Table 2.4). EqS04b 
cells that had either been left untreated or had been transformed by the siRNA scramble 
control sequence were used as control cells, and served as standards for the amount of BPV 
gene product detected in the gene specific siRNA transfected cells. By analysing both the 
untreated ES04b cells and the scramble sequence siRNA treated cells, any suppression of 
viral  gene  expression  by  merely  the  presence  of  the  short  RNA  sequences,  or  the 
transfection reagent used, could be detected. 
4.3.6  Statistical Analysis 
RQ-PCR  error  bars  were  calculated  as  described  in  section  2.2.5.  The  differences  in 
apoptosis and cell survival levels between the different cell lines were then analysed for 
statistical significance (p < 0.05) by using the t-test method (section 2.2.13).  
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4.4  RESULTS 
4.4.1  Flow cytometric analysis (FCM) reveals that both normal, and BPV-1 
transformed equine fibroblast cell lines undergo apoptosis following 
DNA damage. 
Figure 4.4 shows results obtained from FCM analysis of BPV-1 negative fibroblasts (Fig. 
4.4 A (i) and B (i)) and sarcoid tumour derived, BPV-1 transformed fibroblasts (Fig. 4.4 A 
(ii) and B (ii)) both before and after exposure to UVB irradiation. Both cell lines show a 
small amount of apoptosis in the untreated cell populations which is to be expected as a 
result of normal cell turnover, and a response to the trypsinisation and Annexin V staining 
protocol. This is why it was important to keep the reactions on ice for the majority of the 
protocol (section 2.2.11). At the highest UVB exposure level (500 mJ/cm2), the normal 
equine fibroblasts show a lower percentage of apoptotic cells (27.5%) compared to the 
BPV-1  transformed  cell  lines  (34.1%)  24  hours-post  insult.  For  each  DNA  damaging 
method, all the cell lines were assessed after three independent treatment sessions and the 
results averaged. The differences in apoptosis levels between the different cell lines were 
then  analysed  for  statistical  significance  (p  <  0.05)  by  using  the  t-test  method.  These 
results are shown in Figures 4.5, 4.6 and 4.7. 
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Figure 4.4 
 
A (i)  EqPalF  no UVB exposure      (ii) EqS04b  no UVB exposure 
 
B (i) EqPalF post-UVB exposure      (ii) EqS04b post-UVB exposure 
 
Figure 4.4 Plots from FCM analysis of normal equine fibroblast (EqPalF) cells and 
sarcoid derived BPV-1 transformed equine fibroblast (EqS04b) cells. 
x axis: log Annexin V- FITC; y axis: log propidium iodide 
D1 – necrotic cells (propidium iodide only) 
D2 – secondary necrotic (propidium iodide AND Annexin V) 
D3 – viable cells (no uptake of Annexin V or Propidium iodide) 
D4 - early apoptotic (Annexin V only) 
A (i) – EqPalF cells with no UVB exposure 
A (ii) – EqS04b cells with no UVB exposure 
B (i) – EqPalF cells 24hrs after exposure to 500 mJ/cm
2 UVB 
B (ii) – EqS04b cells 24hrs after exposure to 500 mJ/cm
2 UVB 124 
4.4.2  Sarcoid derived fibroblast cell lines consistently show significantly 
higher levels of apoptosis following UVB irradiation compared to 
normal equine fibroblast cells. 
To investigate the hypothesis that equine sarcoids may be associated with abnormalities in 
apoptotic  pathways,  rather  than  with  an  increase  in  cell  proliferation,  we  exposed  the 
different  cell  lines  to  UVB  irradiation  as  described  in  Chapter  II;  section  2.2.1  and 
measured the resulting levels of apoptosis by FCM analysis (section 2.2.11), 24 hours later.  
As shown in Figure 4.5, both the BPV-1 transformed cell lines and sarcoid derived cell 
lines show increased levels of apoptosis following UVB exposure compared to uninfected 
equine fibroblast control cells. This increase was shown to be statistically significant in 
two of the experimentally transformed cell lines (S6-2 at 500 mJ/cm2, and S6-3 at 250 
mJ/cm2), and in all the sarcoid derived cell lines (EqS cells, Fig. 4.5), either at just one 
(EqS03 and EqS04b; 500 mJ/cm2), or both exposure levels (EqS03 and EqS04b). 
The literature cautions that levels of apoptosis observed within 24 hours of the initial DNA 
damaging insult may not reflect the true extent of eventual cell death as some cells may not 
succumb to apoptosis for days after the DNA damage occurs (Brown and Wouters, 1999). 
And so perhaps the results obtained here are more a reflection of the rate of apoptosis, 
rather  than  the  overall  level  of  cell  death.  This  is  one  of  the  reasons  why  we  felt  it 
important to conduct colony survival assays in combination with the short-term apoptosis 
experiments. However, it is worth pointing out at this stage that the literature is almost 
exclusively  referring  to  data  which  suggested  some  cancer  cell  lines  were  resistant  to 
certain treatments based on initial levels of apoptosis observed, whereas if the treated cells 
were cultured in a colony survival assay, the overall cell death would be much higher than 
the initial levels of apoptosis suggested. As illustrated in Figure 4.5, my results are the 
opposite of those most commonly encountered in apoptosis evaluation in cancer cell lines, 
with  higher  levels  of  apoptosis  following  UVB  exposure  clearly  demonstrated  in  the 
transformed cell lines. 
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4.4.3  Sarcoid derived cell lines and control cells show similar levels of 
apoptosis induced by 72hrs incubation with Cisplatin.  
The same panel of cell lines were then exposed to two different concentrations of cisplatin 
(10, 25 µg/ml) for 72 hours and apoptosis measured by FCM analysis. As shown in Figure 
4.6, the increase in apoptosis levels were generally more marked in the in-vitro BPV-1 
transformed cell lines (S6-1, S6-2, S6-3), compared to the response seen in the sarcoid 
derived cell lines. At the lower cisplatin concentration (10 µg/ml) there was no significant 
increase  in  apoptosis  levels  in  any  of  the  sarcoid  derived  cells  lines  (EqS01,  EqS02, 
EqS03, EqS04b) compared to the BPV-neagtive control cells. However, all of the BPV-1 
transformed cell lines (S6-1, S6-2, S6-3) showed a significant increase in apoptosis levels. 
The  increased  apoptosis  at  the  higher  concentration  of  cisplatin  (25  µg/ml)  was  not 
statistically significant in the sarcoid derived cell lines (EqS01, EqS02, EqS03) bar one 
(EqS04b) and was only marginally significant (p = 0.049 and 0.035 respectively) for the 
experimentally transformed cell lines (S6-1 and S6-2). 
4.4.4  Sarcoid derived cells are less sensitive to apoptosis induced by high 
doses of 5-Fluorouracil 
To determine resistance or susceptibility to apoptosis induced by 5-FU, cells were cultured 
in the presence of two concentrations of 5-FU (10 and 15 mg/ml) and apoptosis rates 
measured by FCM analysis after 72 hours. The results have shown that in contrast to UVB 
and  Cisplatin,  sarcoid  derived  fibroblasts  (EqS01,  EqS02,  EqS03,  EqS04b)  are  more 
resistant  to  apoptosis  induced  by  incubation  with  15  mg/ml  5-FU,  compared  to  BPV-
negative control cells (Fig. 4.7). Figure 4.7 also shows that the in vitro BPV-1 transformed 
cell lines (S6-1, S6-2 and S6-3) demonstrate a similar level of apoptosis as that shown by 
the BPV-negative fibroblasts (bar the S6-2 cell line at the higher 5-FU concentration which 
shows a significantly lower apoptotic response). At the lower concentration of 5-FU (10 
mg/ml), there is no statistical significance between the levels of apoptosis shown by any of 
the cell lines. 
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4.4.5    Sarcoid derived cell lines show enhanced cell survival rates following 
exposure to DNA damaging agents  
 The results in Figure 4.8 and Figure 4.9 show that despite having a higher percentage of 
apoptotic cells in the original populations, as assessed by FCM analysis, sarcoid derived 
and in vitro BPV-1 transformed cell lines exposed to either UVB or cisplatin both showed 
enhanced cell survival levels compared to the BPV-negative control fibroblasts. 
In contrast to the results obtained with UVB and Cisplatin, when cells treated with 5 FU 
were subjected to clonogenic assays, all cell lines show very limited cell survival levels 
after  exposure  to  the  higher  5-FU  concentration  (15  mg/ml).  At  the  lower  5-FU 
concentration, all the BPV-1 transformed cell lines bar S6-1, showed a significantly higher 
level of cell survival compared to the control EqPalF cells (Fig. 4.10). It is also worth 
noting that although the survival fractions following 5-FU treatment appear to be at least as 
large as the results obtained following UVB and cisplatin treatment, the scale on the y-axis 
reveals that the highest survival fraction achieved after 5-FU treatment is barely as high as 
the lowest survival fraction in the other two treatment groups. This is demonstrated to 
greater affect in Fig. 4.11. 
As discussed in Chapter II; section 2.2.12, plating effeciencies (PE) were calculated for 
each  cell  line  and  from  these  PEs,  the  survival  fraction  (SF)  for  the  cell  line  can  be 
generated. This allows for the fact that different cell lines will have differing efficiencies in 
forming colonies and produces a standardised value (the SF) for comparison.  
PE = [number of colonies formed/number of cells seeded]x100 
This value is then used to calculate the Survival Fraction; 
SF = [number of colonies/(number of cells seeded x PE)]x1000 
The average plating efficiency for each cell line is shown below in Table 4.1 
Table 4.1 Average plating efficiencies for all cell lines. 
Cell Line  Average Plating Efficiency 
EqPalF  30 
S6-1  35 
S6-2  50 
S6-3  40 
EqS01  40 
EqS02  25 
EqS03  50 
EqS04b  85 
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Figure 4.11 Comparison of the different DNA damaging agents and the respective 
survival fractions for each cell line.  
This  figure  shows  the  relatively  small  degree  of  cell  survival  across  all  the  cell  lines 
following treatment of the cells with 5-FU, compared to the survival fractions for UVB and 
cisplatin.  This  figure  also  shows  the  relative  inability  of  the  BPV-negative  fibroblasts 
(EqPalF) to survive any sort of DNA damage in the long term, even though the initial 
levels of apoptosis as assessed by FCM analysis in these cell lines, was generally lower 
than the apoptosis levels seen in the BPV-1 transformed cell lines (S6 and EqS). 
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4.4.6  Introduction of siRNA targeted to BPV E6 results in reduced expression 
of E2, E5, E6 and E7 genes.  
When the E6 siRNA was introduced in to EqS04b cells it consistently resulted in reduced 
expression (> 80%) of the BPV-1 genes E2, E5, E6 and E7. This initial analysis work is 
reproduced with the kind permission of Dr Zhenguaig Yuan who carried out the initial 
evaluation of the E6 siRNA efficacy using the RQ-PCR protocol described in section 2.2.5. 
For all the remaining siRNA work included in this thesis, RQ-PCR analysis of the EqS04b 
cells  to  determine  the  success  of  E6  knockdown  prior  to  proceeding  with  the 
apoptosis/colony survival experiments, was performed as described in Chapter II, section 
2.2.12, by the author. Only if the E6 knockdown was shown to be at least, 70%, did further 
experiments progress. 
Figure 4.12 shows the RQ-PCR results obtained by Dr. Yuan after transfection of the 
EqS04b cells with the E6 targeted siRNA; 
 
Figure 4.12 RQ-PCR analysis of expression of BPV-1 genes E2, E5, E6 and E7 in 
EqS04b cells 48 hours after cell transfection with E6 siRNA molecules. 
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4.4.7  Treatment of sarcoid derived cells with E6 siRNA prior to treatment 
with DNA damaging agent, does not result in altered apoptosis levels. 
Figures 4.13, 4.14 and 4.15 show that there is no significant difference in the apoptotic 
response (as measured by FCM analysis) following insult with the DNA damaging agents 
UVB, cisplatin and 5-FU between untreated EqS04b cells and those treated with either the 
E6  siRNA  sequence,  or  the  scramble  control  sequence.  These  results  show  that  the 
transfection protocol itself and the presence of the siRNA within the cell and cell nucleus 
does not significantly impact on the cellular response to DNA damage. 
 
 
Figure 4.13 Treatment with E6 targeted siRNA prior to UVB-irradiation, does not 
significantly alter apoptotic response.  
Apoptosis levels were measured 24 hours after exposure to UVB using Annexin V/PI FCM 
analysis. 
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Figure 4.14 Treatment with E6 targeted siRNA prior to incubation with cisplatin, 
does not significantly alter apoptotic response.  
Apoptosis levels were measured after 72 hours incubation with cisplatin containing media, 
using Annexin V/PI FCM analysis. 
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Figure 4.15 Treatment with E6 targeted siRNA prior to incubation with 5-
Fluorouracil, does not significantly alter apoptotic response. 
Apoptosis levels were measured after 72 hours incubation with 5 – Fluorouracil in the 
media, UVB using Annexin V/PI FCM analysis. 
4.4.8  Treatment of sarcoid derived cells with E6 siRNA prior to treatment 
with a DNA damaging agent results in reduced cell survival. 
Following harvesting of the different EqS04b cell populations for analysis in the FCM 
analysis  experiments  described  above,  a  proportion  of  each  population  (EqS04b  cells, 
EqS04b  cells  with  Lipofectamine  reagent  added  to  the  growth  media,  EqS04b  cells 
incubated  with  the  E6  siRNA  and  fourthly,  EqS04b  cells  incubated  with  an  siRNA 
scramble  control  sequence),  were  retained  for  use  in  colony  survival  assays.  The 
clonogenic assays were performed as described in Chapter II; section 2.2.12. Briefly, 3000 
cells from each EqS04b treatment population were seeded into new 10cm Petri dishes and 
incubated in normal growth media for 10 to 14 days until the colonies had reached a 
suitable  size  for  counting.  Colonies  were  fixed,  stained  and  counted  and  the  plating 
efficiencies and survival fractions for each cell line and treatment level were calculated.   138 
In  contrast  to  the  results  seen  in  assessment  of  apoptosis  levels  in  E6  siRNA  treated 
EqS04b  cells,  analysis  of  the  clonogenic  survival  assay  data  revealed  a  significant 
reduction in the degree of cell survival in the E6 siRNA treated cells compared to both 
unmodified EqS04b cells and cells incubated with the sacramble control siRNA sequence. 
The use of the scramble control siRNA and the inclusion of unmodified EqS04b cells in 
the  experiment  demonstrates  that  the  reduced  cell  survival  levels  cannot  be  attributed 
merely to the presence of the E6 siRNA molecules in the cell, but must be a consequence 
of the targeted reduction in the expression of the BPV-1 genes. 
Figure 4.16 and 4.17 show the results obtained in the clonogenic assay of the various 
EqS04b cell lines after UVB exposure. These images clearly show that those EqS04b cell 
populations  that  were  treated  with  the  E6  targeted  siRNA  molecules  had  significantly 
reduced cell survival. 
Figure 4.18 contains images from the UVB clonogenic survival assay after the plates have 
been  fixed and stained. The  reduction in the number of colonies present in the plates 
containing the E6 siRNA cells can clearly be seen (Figure 4.18 E and F). 
Figure 4.19 and 4.20 show the results obtained in the clonogenic assay of the various 
EqS04b cell lines after incubation with cisplatin. 
 
Figure 4.16 Survival Fractions calculated from colony survival data of EqS04b cells 
after UVB irradiation.     
* = statistically significant result p < 0.05 139 
 
 
 
Figure 4.17 Survival Fraction of EqS04b cells treated with E6 targeted siRNA. 
Shows that cells treated with E6 siRNA prior to UVB irradiation demonstrate significantly 
less potential for long term cell survival when compared to cells treated with a scramble 
siRNA sequence control. 
* = statistically significant result p < 0.05 140 
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Figure 4.18 Treatment with BPV-1 E6 targeted siRNA prior to UVB exposure results 
in significantly reduced long term cell survival. 
A – EqS04b cells after exposure to 250 mJ/cm
2 UVB 
B – EqS04b cells after exposure to 500 mJ/cm
2 UVB 
 
C – EqS04b cells treated with Scramble siRNA sequence then exposed to 250 mJ/cm
2 
UVB 
D - EqS04b cells treated with Scramble siRNA sequence then exposed to 500 mJ/cm
2 UVB 
 
E - EqS04b cells treated with E6 siRNA sequence then exposed to 250 mJ/cm
2 UVB 
F - EqS04b cells treated with E6 siRNA sequence then exposed to 500 mJ/cm
2 UVB 
E6 siRNA 
Scramble siRNA 
No siRNA 141 
 
Figure 4.19 Survival Fractions calculated from colony survival data of EqS04b cells 
after incubation with cisplatin.  
* = statistically significant result p < 0.05 
                     
 
Figure 4.20 Treatment with E6 target siRNA results in reduced cell survival. 
Cells treated with E6 siRNA prior to 72 hours incubation with media containing cisplatin 
demonstrate significantly less potential for long term cell survival when compared to cells 
treated with a scramble siRNA sequence control. * = statistically significant result p < 0.05 142 
4.5  DISCUSSION 143 
4.6  DISCUSSION 
Throughout  Chapter  4  it  is  assumed  that  the  overwhelming  cell  response  to  the  DNA 
damaging treatments used was apoptosis. It might be argued that sub-populations of the 
cell  lines  used  may  in  fact  have  merely  entered  cell-cycle  arrest  rather  than  the 
programmed cell death pathway, and these populations of cells, in turn, may affect the cell 
survival data subsequently obtained. The exact mechanism(s) that determine the fate of a 
cell during the stress response are not yet fully understood. Intrinsic differences in a cell’s 
response to a particular type of stress may be determined by which effectors are activated 
under  particular  conditions  (in  the  case  of  BPV  positive  cells  –  the  presence  of  viral 
proteins). BPV negative control cells may be more likely to enter cell cycle arrest after 
DNA  damage,  and  while  these  cells  would  not  register  as  apoptotic  during  FCM 
assessment, neither would they go on to form colonies in the cell survival experiments. 
However,  during  the  experiment  design  process,  the  different  cell  populations  were 
assessed by light microscopy for several days following DNA damage by UVB irradiation, 
and within 3 days of treatment, the majority of cells from all the different cell lines were 
found to be dead. The levels of exposure to UVB and DNA damaging pharmaceutical 
drugs, when compared to those previously described in the literature, were considered high 
enough to anticipate that the levels of DNA damage caused would overwhelm potential 
arrest and repair pathway options, resulting in the activation of apoptosis pathways in the 
majority  of  cases.    Therefore,  in  light  of  previous  work  already  done  which  suggests 
sarcoid molecular pathology is generally not associated with abnormal cell cycle control 
mechanisms  (Nixon  et  al.,  2003),  it  seems  reasonable  to  interpret  the  results  obtained 
working under the assumption that apoptosis is the standard cell response. 
Apoptosis is induced in all cell lines following treatment with the DNA damaging agents 
UVB,  Cisplatin  and  5-FU  as  shown  by  FCM  analysis.  Clonogenic  survival  assays 
demonstrate that even  with increased apoptosis levels immediately after insult, sarcoid 
derived cell lines and BPV-1 transformed cell lines are more able to continue to grow and 
divide even with DNA damage levels that prevent the majority of normal fibroblasts from 
surviving.  
During  experiment  optimisation,  levels  of  UVB  and  drug  exposure  were  selected  that 
resulted in a maximum of 40 - 60% cells becoming apoptotic as detected by FCM analysis. 
In this way, it is expected that comparisons between the clonogenic survival assays can be 
accurately  made.  It  is  possible  that  the  surviving  colonies  contain  clones  that  are 
particularly  resistant  to  treatment  therapies  and  the  presence  of  such  resistant  cells  in 144 
naturally occurring sarcoid tumours may help explain why certain tumours on individual 
animals remain refractory to treatment. We have observed that although the pattern of 
behaviour is the same for all sarcoid derived cell lines, there is an element of variation 
within this group. In previous studies, the viral load between cells isolated from naturally 
occurring sarcoid tumours has been shown to vary by as much as a four-fold difference 
(Bogaert et al., 2007; Yuan et al., 2008a). This fact may explain the variation in response 
seen within the sarcoid derived cell lines, and also the more uniform response observed in 
the experimentally transformed S6 cells where the viral load varies very little between the 
cell  lines.  Both  naturally  and  experimentally  BPV-1  transformed  fibroblasts  showed 
increased susceptibility to apoptosis induced by UVB and cisplatin, however the sarcoid 
derived  cell  lines  were  more  resistant  to  apoptosis  induced  by  5-FU  compared  to  the 
experimentally transformed cells. Previous studies looking at the expression of the viral 
genes E6 and E7 in various cell lines have shown that both proteins can sensitise cells to 
apoptosis (Liu et al., 2000; Liu et al., 2005). We have shown that infection of BPV-1 in 
equine fibroblasts sensitises these cells to apoptosis induced by UVB and cisplatin and in 
BPV-1 transformed fibroblasts treated with 5-FU. Experimentally transformed fibroblasts 
will almost certainly have a different cellular physiology in comparison to sarcoid derived 
fibroblasts.  The  cellular  physiology  of  sarcoid  derived  fibroblasts  will  have  been 
influenced  and  altered  by  viral  gene  products  for  a  considerably  longer  duration  than 
transformed cells. Microarray assessment of sarcoid derived fibroblasts have shown altered 
expression of over 80 genes in these cells compared to normal equine skin fibroblasts 
(Yuan  et  al.,  2008).  In  order  to  explain  the  variation  between  the  levels  of  apoptosis 
observed with the different DNA damaging agents, it is necessary to consider the different 
apoptotic pathways that are activated by each individual agent. It is beyond the scope of 
this investigation to describe each pathway in absolute molecular detail but it is possible to 
examine these results in the context of one particular gene product which has been shown 
to  be  dysfunctional  in  sarcoid  tumours,  namely  p53  (Nixon  et  al.,  2005).  p53  will  be 
discussed  in  more  detail  in  Chapter  V  where  the  location  and  functionality  of  p53  is 
investigated in tumour tissue and tumour derived cell lines. For now, it is sufficient to say 
that  both  UVB  and  cisplatin  can  induce  apoptosis  by  both  p53  dependent  and  p53 
independent pathways (Zamble et al., 1998, Wang et al., 1999). 5-FU however, induces 
apoptosis in a p53 dependent manner (Pritchard et al., 1998). This basic variation between 
the mechanisms of apoptosis induction may explain why apoptosis levels are lowest with 
5-FU which relies on p53 to induce apoptosis but p53 function is compromised in sarcoid 
derived cells. In addition to the potential dysregulation of p53 specifically, HMGA-1 was 
shown in the Yuan (2008b) microarray paper to be up-regulated by nearly 30 fold and 145 
work by Pierantoni et al. in 2007 demonstrated that over-expression of HMGA-1 inhibited 
p53 apoptotic function by promoting homeodomain-interacting protein kinase 2 (HIPK2) 
cytoplasmic relocalisation. It seems clear from our data that the extent of apoptosis is not a 
reliable indicator of cellular sensitivity to these chemotherapeutic agents and so perhaps 
apoptosis and the genes controlling it, such as p53, appears to play little or no role in the 
sensitivity of sarcoid derived cells to killing by cisplatin, fluorouracil or UVB-irradiation. 
What was particularly intriguing from these results, was that despite having higher initial 
levels  of  apoptosis  after  DNA  damage  as  detected  by  flow  cytometry,  the  BPV-1 
transformed fibroblasts then went on to show significantly higher levels of cell survival in 
the  clonogenic  assays,  compared  to  the  BPV-negative  control  fibroblasts.  The  control 
fibroblasts  generally  showed  lower  levels  of  apoptosis  initially,  but  then  went  on  to 
demonstrate a much reduced cell survival potential in the clonogenic studies. Apoptosis 
(programmed cell death) has for a long time been considered as a one-way process – once 
begun, there is no turning back. In a recent paper in the British Journal of Cancer, Tang et 
al. (2008) show that apoptosis may be reversible. They had taken a panel of several cancer 
cell lines and treated them with an inducer of apoptosis for a few hours, and then washed it 
off.  When  they  monitored  the  cells  over  the  next  hours,  they  found  that  many  cells 
transiently exhibit morphological signs of apoptosis: they shrunk, the nuclei condensed, 
and mitochondria were degraded, but a few hours later the cells returned to their normal 
shape.  The  limiting  event  from  which  the  cells  had  no  chance  of  return  was  when 
degradation of the nucleus had begun.  
The hallmarks of apoptosis that were investigated in the above study reflect degradation in 
three  steps:  First,  the  cytoskeleton,  leading  to  cell  shrinkage.  Then,  the  mitochondria, 
shutting off the cell’s aerobic metabolism. And finally, the nucleus, with the entire gene 
regulatory system. But the cytoskeleton is made to be remodelled, so it’s not that surprising 
that  the  cells  can  cope.  With  the  mitochondria,  the  situation  is  much  more  complex. 
Mitochondria are what remain of symbiotic bacteria that in the last couple of thousands of 
millions of years have became integral parts of the cells of many living beings. In contrast 
to  normal  differentiated  cells,  which  rely  primarily  on  mitochondrial  oxidative 
phosphorylation to generate the energy needed for cellular processes, most cancer cells 
instead rely on aerobic glycolysis, a phenomenon termed ‘the Warburg effect’ (Kim and 
Dang, 2006). Aerobic glycolysis is an inefficient way to generate adenosine 5'-triphosphate 
(ATP), however, and the advantage it confers to cancer cells has been unclear. Theories 
include  the  speculations  that,  compared  to  healthy  cells,  glycolytic  cells  do  not  need 146 
oxygen for their metabolism and although this is very inefficient it has advantages such as 
the capability of surviving in environments that do not have vasculature in the vicinity, and 
the  ability  to  acidify  the  surrounding  environment  which  may  make  other  cells  enter 
programmed cell death thus providing space in which the glycolytic cells can grow. What 
is most interesting about the function of mitochondria, in the context of the information 
determined  by  our  investigations,  is  that  it  is  involved  in  one  of  the  principal  death-
signalling pathways. The mitochondrion acts as an integrating sensor of multiple insult 
inputs by releasing cytochrome c into the cytosol where it triggers caspase activation. It 
would be interesting to speculate that when the mitochondrial function is lost or impaired 
in cancer cells, pro-apoptotic pathways may be shut down too, so that these cells exhibit 
enhanced survival after an insult that would result in a complete apoptotic result in healthy 
cells. This theory is reinforced by the results observed in the healthy fibroblast cell line (a 
control group of cells that was not included in the Hong Kong study!). Low initial levels of 
apoptosis still translate  into a much  reduced  cell survival outcome suggesting that the 
majority of cells that enter apoptosis after the initial insult, do not escape from, or reverse 
this  process.  Due  to  the  fact  the  cell  membrane  disruption  and  thus  exposure  of 
phosphatidylserine has been shown to be an early event in the apoptosis pathway, it seems 
quite possible that the BPV-1 transformed cells have developed the ability to halt and 
subsequently  reverse  the  programmed  cell  death  pathway,  after  the  disruption  of  the 
membrane  occurs  (as  determined  by  the  FCM  analysis).  The  higher  initial  levels  of 
apoptosis may be linked to the fact that cells expressing BPV-1 E6 and E7 have been 
shown to be more susceptible to certain types of induced apoptosis (Rapp et al., 1999; Liu 
et al., 2000; Liu et al., 2005). 
Researchers at the University of Harvard Medical School have created a method based on 
RNAi in order to restore mitochondrial function, not with the purpose of normalising the 
metabolism of tumour cells, but for the role they play in programmed cell death. The result 
of applying this therapy resulted in a surge of tumour cells undergoing apoptosis (Fantin et 
al., 2006). 
Chemotherapy is one of the major cancer treatments and the overall mechanism of action is 
to induce cancer cells into apoptosis. However, cancer (and sarcoids are notable for this 
particular trait) may recur even during repeated courses of treatment, and that has been 
mainly  attributed  into  the  deficiency  of  apoptotic  pathways  in  these  affected  cells, 
anticancer drugs resistance of tumorigenic stem cells, and inefficiency of drug penetration 
into  solid  tumours  (Coley,  2009).  These  new  findings,  involving  the  possibility  of 147 
mitochondrial-mediated  resistance  to  apoptosis,  uncover  another  mechanism  that  may 
contribute to sarcoid cell survival during therapy  and, therefore, suggest potential new 
avenues for research and targets for therapy. 
From the cell survival data, our results suggest that cisplatin is perhaps less suitable as a 
chemotherapeutic equine sarcoid treatment option in vivo. In fact, it could be postulated 
that using cisplatin may select for particularly resistant cells, resulting in a tumour that is 
refractory  to  continued  chemotherapeutic  treatment.  It  is  interesting  to  consider  the 
possible synergistic  effects of combined cisplatin and 5-FU treatment  and future work 
could assess these effects on the apoptosis levels and, more importantly from a clinical 
point of view, clonogenic survival levels. 
Due to the fact the viral component of the aetiology of sarcoids is now widely accepted, it 
makes sense to focus future treatment direction towards specific anti-viral agents and/or 
other  specific  anti-viral  immune  response  modifiers,  instead  of  toxic  chemotherapeutic 
agents and expensive surgical intervention. Our investigation to identify the viral protein 
responsible  for  conferring  the  enhanced  survival  ability,  and  then  assessing  this  as  a 
potential therapeutic target using siRNA technology, identified the BPV E6 as a gene of 
interest.  
The  siRNA  sequence  that  was  designed  to  target  BPV-1  E6  showed  consistent  E6 
knockdown levels of over 75%. The sequence used to target E6 (shown in Chapter 2; 
section 2.2.8.2) was also shown to consistently knock down the BPV-1 genes E2, E5 and 
E7 (Figure 4.12). Cells that were treated with E6 siRNA 24 hours prior to DNA damage 
showed  very  little  difference  in  the  apoptosis  levels  detected  using  flow  cytometry, 
compared to the untreated sarcoid control cells and E6 Scramble sequence siRNA treated 
cells.  However,  once  those  cells  were  cultured  in  dishes  for  the  clonogenic  assay,  it 
became evident that the E6 siRNA treated cells were unable to survive the initial DNA 
damage and there was significantly less colony formation with these cells, compared to 
untreated, and E6 Scramble sequence siRNA treated sarcoid cells. 
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5  CHAPTER V: 
 
The p53 protein in equine sarcoids 149 
5.1  INTRODUCTION 
In the 1980’s, the p53 tumour suppressor protein was identified as having a key role in the 
early stages of neoplastic disease development and progression, and today it continues to 
be an ever expanding area of research (with only three studies listed by Med Line in 1989 
but  1027  listed  in  1997).  Since  1989,  over  570  different  mutations  of  p53  have  been 
identified, in more than 8000 human cancers (Hainaut et al., 1998) with the listing data 
base being updated twice a year. 
The p53 protein has become the subject of such intense investigation for several reasons; 
p53 is the most commonly altered gene yet discovered in human cancer (Vogelstein and 
Kinzler, 1992; Hollstein et al., 1991); it suppresses the growth of tumour cells containing 
multiple genetic changes (Baker et al., 1990); germ line mutation of p53 has been linked to 
an  inherited  predisposition  to  cancer  (Li-Fraumeni  syndrome)  (Malkin  et  al.,  1990; 
Srivastava et al., 1990); increased amounts of cellular p53 protein after DNA damage have 
been associated with cell-cycle arrest (Kastan et al., 1991) and programmed cell death 
(apoptosis) (Shaw, et al., 1992); and mutations or losses of p53 have been associated with 
gene amplification (Livingstone et al., 1992; Yin et al., 1992) and polyploidy. Given its 
ability to monitor DNA damage and to promote damaged cell’s responses (by repair and 
continued survival, or death), p53 has been called ‘the guardian of the genome’ (Lane, 
1992). Discoveries about the biological properties of p53, and the molecular mechanisms 
of its functions, have given p53 much attention among tumour suppressor genes. P53 was 
chosen as ‘molecule of the year’ in 1993 by Science (Koshland, 1993).  
p53 was first identified in 1979 by virtue of its association with simian virus 40 (SV4O) 
large T-antigen and by its apparently high expression in chemically induced tumours or 
spontaneously transformed cells (Lane and Crawford, 1979; Linzer and Levine 1979). For 
the next decade, p53 was thought to be a transforming oncogene whose expression resulted 
in increased DNA synthesis, a necessary feature of cellular proliferation. As early as 1984 
Maltzman and Czyzyk observed that exposure of non-transformed cells to UV radiation 
stimulated p53 production, on the basis of a post translational stabilization (Maltzmaand 
Czyzyk 1984) and by  1987 p53 association with cellular heat shock protein had been 
observed in transformed cells (Hinds et al., 1989). By 1989 several lines of evidence were 
beginning to suggest that the wild-type p53 gene was actually a tumour suppressor gene 
instead of an oncogene. Over the past several years, studies have begun to clarify the 
molecular basis for tumour suppression by p53, as well as provide insight into the role of 150 
p53 in normal growth control. An ever increasing number of p53-associated proteins as 
well  as  p53-regulated  genes  have  been  identified.  Scores  of  studies  have  catalogued 
mutations of p53 in human tumours. The value of early detection of p53 gene and gene 
product alterations, and their utility in assessing prognosis, are currently being explored.  
5.1.1  Molecular Structure of the p53 Gene  
The term ‘p53’ was originally given to the phosophoprotein of molecular weight 53 kDa 
(Lane and Crawford 1979). The protein was discovered before the gene, but both gene and 
its protein are called p53. The p53 gene is comprised of 11 exons within a chromosomal 
domain  of  20  kilobases  (Reisman  et  al.,  1988).  Reisman  et  al.  (1988)  indentified  2 
promotors; the first is located 100 to 250 bp upstream of the non-coding first exon and is 
responsible for transcription of the major p53 mRNA species. The second (p53p2), is a 
stronger  promoter  than  the  first  and  is  located  within  the  10,738-bp  first  intron, 
approximately 1,000 bp downstream of exon 1.  
5.1.2  Role of p53 in Normal Cells 
In  normal  cells,  an  equilibrium  is  established  between  growth,  as  determined  by  cell 
progression through the cell cycle, cellular differentiation, and restriction of cell growth 
(Evan and Vousden, 2001). Apoptosis is a mechanism commonly employed in normal cells 
to control cellular numbers (Elmore, 2007).  Although it is often a common feature of 
tumour  development,  escape  from  apoptosis  is  not  essential  for  tumour  growth  and 
progression.  Tumour  cell  accumulation  will  occur  if  an  increase  in  cell  proliferation 
exceeds cell loss produced by apoptosis (Darnton, 1998). The central influence of p53 on 
cell proliferation is via control of cell cycle with wild-type p53 primarily involved with this 
control, and in the control of apoptosis. Studies of p53 have shown that it is not essential 
for normal growth, differentiation, and function because transgenic mice, with both copies 
of p53 deleted, develop normally but multiple tumours appear after a few months of life 
(Donehower  et  al.,  1992).  After  DNA  damage,  there  is  a  possibility  that  cells  with 
oncogenic mutations will survive and continue dividing if no measures were in place to 
prevent their cell cycle progression. However, in normal cells following DNA damage 
such as that caused by UV light, ionising radiation, or chemotherapeutic agents, levels of 
p53 protein rise rapidly (Maltzman and Czyzyk, 1984; Kastan et al., 1991; Linke et al., 
1996). The wild-type p53 protein binds to p53 binding sites on DNA and activates the 
expression of downstream genes that negatively control growth and/or invasion. Cell entry 
in to the S-phase (DNA replication) is blocked by expression of these downstream targets, 
most notably p21, resulting in arrest of the cell cycle in the G1 phase. This is achieved 151 
primarily through inhibition of cyclin dependent kinases (CDKs) and proliferating cell 
nuclear antigen (PCNA) (Harper et al., 1993; El-Deiry et al., 1993; Xiong et al., 1993). 
The resulting growth arrest allows time for DNA repair or, if repair is unsuccessful, then 
wild-type p53 can trigger apoptosis (Vogelstein and Kinzler 1992).  
Details of the wild-type p53 response to DNA damage are still not fully known. What is 
known, is that recently discovered p53 pathways and interactions are making the picture 
ever more complex. p53 is known to act as a cell cycle checkpoint and to induce apoptosis 
by  downstream  trans-activation  of  a  multiplicity  of  genes  (Ruley,  1996).  A  simplified 
summary of these cellular interactions is given in Figure 5.1.  
 
Figure 5.1 Cellular interactions of p53 [Source: Adapted from www.web-books.com]. 
 
(a)  The  cell  cycle  progression  into  the  S  phase  requires  the  cyclin-dependent  kinase 
enzyme Cdk2, which can be inhibited by p21. The progression into the M phase can also 
be inhibited by p21, GADD45 (a DNA damage responsive gene) or 14-3-3 (a protein that 
binds to other regulatory proteins to regulate cell cycle progression). P53 regulates the 
expression of these inhibitory proteins to induce growth arrest.    152 
(b) Apoptosis can be induced by the binding of Caspase 9 (an initiator caspase in the 
mitochondrial death pathway) to cytochrome c (an essential part of the electron transfer 
chain) and Apaf1 (Apoptotic protease activating factor 1). P53 may activate the expression 
of Apaf1 and Bax (pro-apoptotic member of the Bcl-2 family). The latter can then initiate 
the release of cytochrome c from mitochondria. 
5.1.3  P53 Dependent Apoptosis  
In  solution,  the  p53  protein  aggregates  as  a  tetramer  and  has  a  short  half-life  of 
approximately  20  minutes  in  non-stressed  cells.  This  is  due  to  its  association  with  a 
protein, Mdm2, which targets it for degradation by virtue of its E3-ubiquitin ligase activity. 
Triggers  for  p53  dependent  apoptosis  include  DNA  damage,  inappropriate  oncogene 
activation, certain cytokines (Eizenberg et al., 1995) or cytokine deprivation (Canman et 
al.,  1995),  hypoxia  (Canman  et  al.,  1995)  and  heat  shock  (Graeber  et  al.,  1994).  In 
response to stress, p53 becomes post-translationally modified, initially by phosphorylation 
and  later  by  acetylation.  These  modifications  cause  an  increase  in  p53  half-  life,  and 
activate p53 as a transcription factor. Mutated p53 also has an increased half-life resulting 
in the positive immunostaining of p53 in cells containing mutated copies and in S-phase 
cells (Momand et al., 2000). While much remains to be learnt about the mechanisms by 
which  p53  senses  damage  there  is  evidence  that  the  cell  cycle  checkpoint  kinase, 
Chk2/hCds1, when in contact with damaged DNA becomes activated and phosphorylates 
p53 on serine 20. This results in dissociation of preformed complexes of p53 with MDM2. 
The activated form of Chk2/hCds1, but not inactive mutants, causes G1 arrest in cells 
containing wild type but not mutant p53 (Chehab et al., 2000). These results are consistent 
with other reports that the inactivation of Chk2/hCds1 in knockout mice renders them 
unable to mount a p53 response after irradiation (Hirao et al., 2000), and that merely 
increasing the amount of 53 within the cell (which may be considered to be comparable to 
stabilization  of  the  protein)  was  insufficient  to  increase  transcription  of  p53  activated 
genes. Transcriptional activation only occurs after post-translational modification induced 
by DNA damage (Xiao et al., 2000). At present it is not clear if the checkpoint kinase itself 
senses DNA damage or responds to unknown additional signals. Activation of p53 as a 
transcription factor results in increased transcription of several genes involved in DNA 
repair, G1 arrest and apoptosis. Events concerned with DNA repair and G1 arrest are the 
best understood. Transcription of GADD45 by activated p53 produces a protein which can 
recognise an altered chromatin state and cause destabilisation of histone DNA interactions 
by  interacting  directly  with  the  four  core  histones.  The  expected  result  is  increased 
accessibility of damaged DNA to proteins involved in repair processes (Carrier  et al., 153 
1999). The role of GADD45 in DNA repair is further suggested from studies in mice in 
which this gene was deleted; these mice have increased genome instability and increased 
incidence of carcinogenesis (Hollander et al,. 1999). Cells from these knockout animals 
were also deficient in ultraviolet repair (Smith et al., 2000). GADD45 also appears to have 
a second function in causing G2 arrest, probably by its known association with the Cdc2-
cyclin B1 protein complex, causing its dissociation as a result of direct interaction between 
the GADD45 AND CDC2 proteins (Jin et al., 2000). P53 also transcriptionally activates 
expression of p21, which as discussed above, binds to a number of cyclin/Cdk kinases so 
as to inhibit their phosphorylation of retinoblastoma protein (RBp) and thus inhibit G1/S-
phase transit (el Deiry et al., 1993; el Deiry et al., 1994). Thus activation of p53 induces 
genes  which  cause  cell  cycle  arrest,  thereby  allowing  time  for  DNA  repair,  and  also 
modifies  the  state  of  chromatin  so  as  to  allow  access  of  repair  proteins  to  DNA. 
Mechanisms by which p53 stimulate apoptosis are poorly understood as are the conditions 
that determine whether p53 should signal cell cycle arrest, a reversible phenomena, or 
apoptosis which is historically understood to be irreversible (although this understanding 
has been challenged recently, as discussed in Chapter IV). One of the problems appears to 
be that different cells respond differently to stressful stimuli making creation of an overall 
model  difficult.  There  is  also  evidence  that  p53  can  trigger  apoptosis  by  mechanisms 
requiring  transcription  and  also  by  transcription-independent  mechanisms.  Apoptosis is 
triggered  by  changes  in  mitochondrial  membrane  potential  leading  to  release  of 
cytochrome c, calcium and other factors. Recent studies have shown that p53 localises to 
the mitochondria at the onset of p53-dependent apoptosis but not during p53-independent 
apoptosis or p53-mediated cell cycle arrest. Moreover, targeting of p53 to mitochondria 
using  peptide  leader  sequences  is  sufficient  to  induce  apoptosis,  strongly  suggesting  a 
central role for this translocation (Marchenko et al., 2000). In summary, p53 induces cell 
death  by  a  multitude  of  molecular  pathways  involving  activation  of  target  genes  and 
transcriptionally  independent  direct  signalling,  and  it  is  clear  that  much  remains  to  be 
learnt about the mechanisms of p53 induced apoptosis.   
5.1.4  Papillomaviruses and the p53 protein 
In Human Papillomavirus (HPV) infections, E6 is expressed early after viral infection and 
facilitates viral production by implementing several cellular changes. It can prolong the 
cellular lifespan via inhibition of apoptosis and by increasing telomerase activity. HPV E6 
interacts  with  an  ubiquitin-3  ligase  and  the  E6  associated  protein  (E6-AP)  to  form 
complexes with p53. The p53 is then degraded by way of a ubiquitin-dependent proteolytic 
mechanism (Huibregtse et al., 1993; Scheffner 1998). E6 can also block translocation of 154 
p53 into the nucleus (Mantovani and Banks 1999) and thereby inhibit the gene regulatory 
functions of p53. The consequence of p53 degradation and blocking of p53 transport into 
the nucleus is disruption of p53 mediated cell cycle control and the cell can continue to 
divide in spite of DNA damage.  In contrast, BPV E6 does not appear to bind to p53 
(Scheffner et al., 1990; Rapp et al., 1999). However, BPV-1 E6 has been shown to interact 
with CBP/p300 in the same way as described for the E6 proteins of oncogenic human 
papillomaviruses. This interaction results in an inhibition of the transcriptional co-activator 
function  of  CBP/p300  required  by  p53  and  probably  by  other  transcription  factors 
(Zimmermann et al., 2000). 
The loss of the normal tumour suppressive properties of the p53 protein has been reported 
in  a  wide  variety  of  human  cancers  (Hollstein  et  al.,  1994)  and  in  some  tumours  of 
domestic animals (Teifke and Lohr, 1996). Several investigators have examined the role of 
the tumour suppressor gene p53 in equine sarcoids. Bucher et al. (1996) failed to detect 
p53  gene  mutations  in  equine  sarcoid  tumours,  suggesting  that  p53  does  not  play  a 
significant  role  in  the  pathogenesis  of  sarcoids.  However,  more  recently,  aberrant 
perinuclear localization of p53 has been demonstrated in 44 % of equine sarcoid lesions 
(Martens et al., 2000), suggesting that mutational independent inactivation of p53 occurs 
commonly in sarcoids. p53, a key protein in tumourogenesis, has previously been shown to 
be dysfunctional and abnormally located in a subset of sarcoids, and the transactivation 
function of p53 was shown to be compromised in cells with cytoplasmic p53 (Nixon et al. 
2005).  155 
5.2  AIMS AND OBJECTIVES 
 The aims of this chapter were to; 
i) To evaluate p53 protein expression in equine sarcoid tumour tissue, cultured 
tumour derived equine fibroblasts and BPV-1 transformed equine fibroblast cell 
lines. 
ii) Determine what, if any, correlation exists between p53 protein expression and 
the clinical presentation of tumours. 
iii) To examine the functionality of p53 protein in equine sarcoid derived equine 
fibroblasts and BPV-1 transformed equine fibroblast cell lines 156 
5.3  MATERIALS AND METHODS 
5.3.1  Cell Culture 
Normal  equine  fibroblasts  (EqPalF  cells),  sarcoid  derived  BPV-1  transformed  equine 
fibroblasts (EqS cells) and experimentally transformed equine fibroblasts (S6 cells) were 
cultured and maintained as described in Chapter II; section 2.2.1. 
5.3.2  RQ-PCR to determine p53 transcription levels 
RNA extraction from cultured cells was carried out as described in section 2.2.3.1. From 
the RNA, cDNA was synthesised (section 2.2.3.1.4) and analysed by RQ-PCR (section 
2.2.5) using the p53 primer and probe set (Table 2.4).  
5.3.3  Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) protocols for the staining of p53 in cultured cells and sarcoid 
tumour sections have been described in section 2.2.9. The sarcoid tumours were sent to our 
research lab from the University of Liverpool, Department of Veterinary Medicine. The 
tumours had been histopathologically confirmed as sarcoid tumours. An equine squamous 
cell carcinoma tumour was also sent from the University of Liverpool to be used as a 
positive  control.  There  were  52  tumour  pieces  altogether;  51  sarcoid  tumours  and  1 
squamous cell carcinoma. 
5.3.4  Western Blot (WB) 
A  standard  Western  blot  (WB)  protocol  is  also  described  in  section  2.2.10.2.  For 
assessment of p53 response to UVB, cells were irradiated with 250 mJ/cm2 UVB (process 
described in section 2.2.1) and then left for 4 hours before being harvested for WB. For 
assessment of p53 transactivation activity, cells were irradiated with a much lower dose of 
UVB (30 mJ/cm2), incubated overnight (~ 10 hours) and then harvested to look for the 
presence of p21 protein. The p21 protein was initially identified as a cell cycle regulatory 
protein  that  can  cause  cell  cycle  arrest.  Expression  of  p21  has  been  shown  to  be  up-
regulated by p53 in response to DNA-damaging agents (Vouden and Lu, 2002; Liu et al., 
2003). Due to the difference in molecular weight of the two target proteins, p53 and p21, it 
was possible to probe for both proteins on the same single membrane without having to 
resort to stripping the membrane between looking at each protein. After protein transfer 
from the gel to the membrane (section 2.2.10.2.3), the membrane was cut midway between 
the positions of the expected bands, and after blocking, the two halfs of the membrane 
were separated and incubated with their respective specific antibodies as described in the 157 
WB methodology (section 2.2.10.2.5) GAPDH was used as a loading control in all WB 
analysis. GAPDH has a molecular weight of ~ 40 kDa and splitting of the membrane when 
simultaneously  probing  for  p53  (band  of  ~  50  kDa)  and  GAPDH  needs  to  be  done 
carefully. 
5.3.5  Half life determination 
Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms, produced by 
the bacterium Streptomyces griseus. Cycloheximide exerts its effect by interfering with the 
translocation step in protein synthesis (movement of two tRNA molecules and mRNA in 
relation to the ribosome) thus blocking translational elongation. Cycloheximide is widely 
used in biomedical research to inhibit protein synthesis in eukaryotic cells studied in vitro 
(en.wikipedia.org).  
Due  to  significant  toxic  side  effects,  including  DNA  damage,  teratogenesis,  and  other 
reproductive effects, including birth defects and toxicity to sperm (Department of Health 
Services, Hazard Evaluation System and Information ervices, California), cycloheximide is 
generally used only in in vitro research applications, and is not suitable for human use as a 
therapeutic antibiotic compound. Although it has been used as a fungicide in agricultural 
applications, this application is now decreasing as the health risks have become better 
understood. 
Cycloheximide can be used as an experimental tool in molecular biology to determine the 
half-life  of  a  protein.  Treating  cells  with  cycloheximide  in  a  time-course  experiment 
followed  by  Western  blotting  of  the  cell  lysates  for  the  protein  of  interest  can  show 
differences in protein half-life. Cycloheximide treatment provides the ability to observe the 
half-life of a protein without confounding contributions from transcription or translation. 
For  p53  half-life  experiments,  fibroblasts  cell  monolayers  in  10cm  Petri  dishes  were 
treated with 40  g cycloheximide per ml of medium approximately 48 hours after the 
fibroblasts were seeded. Zero time points were harvested immediately  using Trypsin  - 
EDTA, and subsequent time points were incubated in medium containing cycloheximide at 
37 °C for  30, 60, 120 or 300 min as indicated. Cells were then processed as described in 
section  2.2.10.2.  Images  were  digitally  acquired  using  an  HP  ScanJet  5200C  Scanner 
(Hewlett-Packard) and quantified using NIH ImageJ Software analysis (NIH). The levels 
of p53 were normalized against the corresponding GAPDH level. 158 
5.4  RESULTS 
5.4.1  Equine sarcoid tumours show abnormal nuclear/cytoplasmic staining 
To evaluate p53 expression in equine sarcoids, 51 tumour samples (Chapter V; section 
5.5.3) were stained for p53 as described in Chapter II; section 2.2.9. Figure 5.2 A and B 
shows  a  tumour  section  of  an  equine  squamous  cell  carcinoma  to  demonstrate  the 
usefulness of this tumour type as a positive control in p53 IHC. Figure 5.2C illustrates the 
importance of having a corresponding negative control slide for each sarcoid section that 
was stained. Figure 5.2C is a normal equine skin section with evidence of extensive brown 
staining throughout. This is not p53 however, but the natural pigment melatonin which 
may be misinterpreted as a positive result, if there was no negative control slide to compare 
it to. The melanin would appear as the brown staining in a positive slide section, and the 
negative control slide, but p53 would only be present in the positive slide. 
Having  established  from  the  positive  control  slides  (equine  squamous  cell  carcinoma; 
Figure 5.2 A and B) that the D0-7 p53 antibody is reliable in detecting equine p53 in 
equine tumour tissue sections, all 51 tumour samples from the University of Liverpool 
were submitted to the University of Glasgow Pathology Department for IHC processing 
and staining with D0-7. Figure 5.3 shows the range of p53 staining observed in analysis of 
the sarcoid tumour sections. Some sections showed no positive staining at all (Fig. 5.3A), 
others showed a low percentage (1 – 10%) of p53 positive nuclei (Fig. 5.3B), a medium 
percentage  (10  –  20%;  Fig.  5.3C),  or  a  high  percentage  (  >  20%;  Fig.  5.3D).  The 
percentage of p53 positive cells were calculated from 3 high-power fields of each tumour 
and the results are tabulated in Table 5.1. A more detailed description of the IHC slide 
analyses is given in section 2.2.9.1. Table 5.1 shows that different tumours removed from 
the same animal, can demonstrate different degrees of p53 positivity. For example, animal 
D had tumours which were mostly p53 negative, but it was also the source of one sarcoid 
tumour  with  a  low  percentage  of  p53  staining,  and  another  tumour  with  a  medium 
percentage of p53 staining. 
The majority of tumour sections stained revealed exclusively nuclear localisation of the 
p53 protein. However one tumour, ID 51, demonstrated abnormal peri-nuclear staining as 
shown in Figure 5.4. 159 
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Figure 5.2 Tissue sections following immunohistochemical staining with the D0-7 p53 
antibody. 
A – equine squamous cell carcinoma (x 40). 
B – equine squamous cell carcinoma (x 100). Note the nuclear accumulation of p53. 
C – cross section through normal equine skin (x 200). The brown staining on this slide is 
due to the presence of the naturally occurring skin pigment, melanin. To avoid confusing 
melanin staining with p53 positive staining in the tumour sections, each tumour section 
was stained with a p53 negative control solution and any p53 positive tumour slides were 
compared to the corresponding negative control section to prevent false positives being 
recorded. 
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Figure 5.3 Sarcoid tumour tissue sections stained with D0-7 p53 antibody. 
Some  tumours  showed  no  staining  at  all  (A).  Others  were  found  to  show  a  range  of 
percentages of p53 positive nuclei. P53 positive nuclei are indicated in the images above 
by the red arrows. Figure B demonstrates a tumour with a 'low' percentage of positive 
nuclei (1 – 10%), figure C is a tumour with a 'medium' percentage of positive nuceli (10 – 
20%) and tumours such as that shown in figure D were categorised as having a 'high' 
percentage of positive nuclei (> 20%). The numbers of tumours determined to be in each 
category are shown in Table 5.1. 161 
 
Table 5.1 p53 positivity and clinical classification of the tumour samples. 
Tumour 
ID 
Classification  Animal 
ID 
Clinical Type 
1  0  A  Pendulous fibroblastic (Fig 1.1f(ii)) 
2  0  A  Pendulous fibroblastic 
3  0  B  Exterior of tumour A; 
A = nodular/fibroblastic (mixed) 
4  0  B  Margin of tumour A (mixed) 
5  0  B  Base of tumour A (mixed) 
6  LOW  B  Exterior of tumour B; 
B = nodular/fibroblastic (mixed) 
7  LOW  B  Margin of tumour B (mixed) 
8  0  B  Base of tumour B (mixed) 
9  MED  C  Isolated nodular lesion  
10  LOW  C  Fibroblastic lesion  
11  MED  C  Fibroblastic lesion  
12  SCC  D  SCC 
13  LOW  D  Nodular  
14  0  D  Nodular  
15  MED  D  Nodular  
16  0  D  Nodular  
17  0  D  Verrucose  
18  0  D  Mixed 
19  MED  D  Fibroblastic  
20  0  D  Occult  
21  MED  E  Data unavailable 
22  MED  E  Data unavailable 
23  MED  E  Data unavailable 
24  HIGH  E  Data unavailable 
25  HIGH  F  Fibroblastic  
26  MED  F  Fibroblastic  
27  0  F  Fibroblastic 
28  HIGH  F  Fibroblastic 162 
29  0  F  Nodular 
30  0  F  Nodular 
31  0  G  Nodular  
32  0  G  Nodular  
33  0  G  Nodular  
34  0  G  Nodular  
35  0  H  Verrucose 
36  HIGH  H  Fibroblastic 
37  0  I  Verrucose  
38  0  I  Nodular 
39  MED  I  Nodular 
40  0  J  Data unavailable 
41  LOW  J  Data unavailable 
42  LOW  J  Data unavailable 
43  0  J  Data unavailable 
44  0  J  Data unavailable 
45  HIGH  K  Fibroblastic 
46  0  K  Mixed 
47  HIGH  K  Fibroblastic  
48  MED  K  Nodular 
49  HIGH  K  Nodular  
50  HIGH  K  Fibroblastic 
51  0  K  Nodular 
52  HIGH*  L  Malevolent sarcoid 
 
Table 5.1 shows p53 positive rating and clinical presentation for all of the 51 individual 
sarcoid tumour samples sent from Liverpool University (tumour ID 12 was a SCC and so 
is not included in analysis of the p53 staining data).  
* = peri-nuclear staining evident (see Fig. 5.4) 
SCC = squamous cell carcinoma (confirmed by histopathology) 
LOW = 0 – 10% of cells have p53 positive nuclei 
MED = 10 – 20% positive 
HIGH = > 20% positive 163 
Figure 5.4 below shows the peri-nuclear nature of the p53 staining observed in tumour 51.  
 
Figure 5.4 p53 staining of sarcoid tumour ID 52. Granular, peri-nuclear/cytoplasmic p53 
has been circled in red. 
5.4.2  High Levels of p53 positivity is associated with clinically aggressive 
tumours 
Over half the tumours (51 %) were negative for p53 and represented all clinical types of 
tumour (with the exception of the malevolent type; Table 5.2). Table 5.2 illustrates that the 
majority of tumours that exhibit high levels of p53 positive staining appear to be associated 
with primarily fibroblastic and mixed lesions. These lesions are generally thought of as 
more aggressive in their clinical behaviour than other types. 
Table 5.2 Association of p53 positivity with clinical type (n = 42). 
p53 
score 
(A) 
No. of  
tumours 
(B) (%) 
No. of (A) 
that are 
occult (%) 
No. of (A)  
verrucose 
(%) 
No. of (A) 
nodular 
(%) 
No. of (A) 
fibroblastic 
(%) 
No. of (A) 
mixed 
(%) 
0  23 (54)  1 (5)  2 (9)  10 (44)  5 (21)  5 (21) 
LOW  4 (9.5)  0 (0)  0 (0)  1 (25)  1 (25)  2 (50) 
MED  8 (20)  0 (0)  0 (0)  2 (25)  6 (75)  0 (0) 
HIGH  7 (16.5)  0 (0)  0 (0)  1 (15)  6 (85)  0 (0) 
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5.4.3  Sarcoid derived cell lines also exhibit abnormal nuclear/cytoplasmic 
protein expression. 
To compare and contrast in vivo p53 staining results with in vitro p53 staining of BPV-1 
transformed fibroblasts, normal and BPV-1 transformed equine fibroblast cells were grown 
and maintained in monolayer cell culture as described in section 2.2.1. To evaluate p53 
expression in these cell lines, IHC staining for p53 was carried out as described in section 
2.2.9. Having consulted the literature regarding the use of p53 antibodies in investigating 
p53 in equine cells, the D0-7 clone is a monoclonal antibody raised in mice that binds to 
human  p53  wild  type  and  mutant  forms  under  both  denaturing  and  non-denaturing 
conditions.  The  D0-7  clone  has  been  successfully  implemented  in  several  equine  p53 
studies (Martens et al., 2000; Bogaert et al., 2007). As shown in Figure 5.5 and subsequent 
immunohistochemistry and Western blot images, this antibody works well in both IHC and 
Western blot applications. 
Figures 5.5 to 5.8 show the staining patterns observed in all of the cell lines studied. As 
expected, no p53 staining was detected in the control equine fibroblasts (EqPalF cells; 
Fig.5.5). As seen in figures 5.6 and 5.7, the experimentally transformed fibroblasts and the 
sarcoid derived fibroblasts (EqS01 – 03) all show p53 positive nuclei to varying degrees. 
The percentage of p53 positive cells present in each individual cell line was calculated 
from the average seen in 3 different high powered fields. The results of this analysis are 
shown in Figure 5.9. The EqS04b cells show a different pattern of staining to the other 
BPV transformed fibroblasts (Fig. 5.8) exhibiting an entirely peri-nuclear expression of the 
p53 protein. Due to this peri-nuclear expression, the EqS04b cells were excluded from the 
quantative analysis summarised in Figure 5.9. 165 
Figure 5.5. 
 
Figure 5.5 Staining of control fibroblasts (EqPalF) with D0-7 p53 antibody.          
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Figure 5.6. 
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Figure 5.6 p53 staining of experimentally transformed equine fibroblasts (S6 cells). 
A – S6-1 cells, untreated;  
B - S6-2 cells, untreated;  
C - S6-3 cells, untreated;  
There is a relatively higher percentage of p53 positive nuclei in these cells. The differences 
in p53 positivity between the different cell lines is quantified in Figure 5.9 167 
Figure 5.7. 
 
A                 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
C                 
 
Figure 5.7 p53 staining of sarcoid tumour derived fibroblast cell cultures (EqS cells). 
A – EqS01 cells, untreated;  
B – EqS02 cells, untreated; 
C – EqS03 cells, untreated;  
As observed in the experimentally transformed fibroblasts (S6 cells), there is also a higher 
percentage of p53 positive nuclei present in the EqS cell lines (summarised in Figure 5.9). 168 
 
Figure 5.8. 
 
 
Figure 5.8 p53 staining in sarcoid derived fibroblast cell line EqS04b. 
In the equine sarcoid derived fibroblast cell line EqS04b, p53 staining reveals that all the 
cells present exhibit peri-nuclear expression of the p53 protein. 169 
5.4.4  BPV-1 transformed fibroblasts exhibit a significantly higher percentage 
of p53 positive nuclei compared to the control fibroblasts as determined 
by IHC 
Analysis of the p53 stained fibroblast culture involved counting the number of p53 positive 
nuclei  present  per  high  powered  field,  and  expressing  this  as  percentage  of  the  total 
number of cells present in that field. A total of 3 different images for each cell population 
were analysed. Figure 5.9 shows the results obtained from this analysis. 
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Figure  5.9  The  average  percentage  of  p53  positive  nuclei  present  in  the  different 
untreated cell populations. 
The  normal  equine  fibroblast  cell  line  (EqPalF)  demonstrated  a  significantly  lower 
percentage of p53 positive nuclei compared to both the BPV-1 transformed cells (S6-1, S6-
2, S6-3) and the sarcoid derived cell lines (EqS01, EqS02, EqS03) (p < 0.05). The BPV-1 
transformed cell lines (S6 cells) were found to have a significantly higher proportion of 
p53 positive cells compared to the naturally transformed, sarcoid derived fibroblasts (EqS 
cells).  All  four  cell  lines  that  have  been  successfully  cultured  from  sarcoid  tumours 
samples (the EqS cell lines), showed abnormal p53 expression. Three of them (EqS01, 02 
and 03) showed a nuclear accumulation of p53 compared to BPV-negative control cells 
(Fig. 5.9) and the fourth, EqS04b, showed peri-nuclear accumulation of p53. 170 
5.4.5  In vitro p53 staining results correspond to results obtained in vivo 
Following analysis of the 51 tumour samples, p53 staining of equine fibroblast cell lines 
cultured at the University of Glasgow was carried out by IHC. The tumours from which the 
cell lines established by Yuan in 2007 were cultured, EqS01, EqS02, EqS03 and EqS04b, 
were not available for IHC staining and so a direct comparison between the parent tumour 
and it’s derived cell line could not be performed. Therefore, in order to compare in vitro 
(tissue culture) results and in vivo (tumour section) results, a case study was performed on 
a horse presented to the Weipers Centre for Equine Welfare, University of Glasgow, for 
treatment of a chronic sarcoid problem. Images of the tumour prior to surgery are shown in 
Figure 5.10A. Following removal of the tumours, histopathology sections were obtained 
and stained with the results shown in Figure 5.10B. Figure 5.10C shows the results of p53 
staining on tissue culture established from the same tumour (tissue samples were removed 
from the tumour prior to its histology processing). It can quite clearly be seen that the 
extensive  peri-nuclear  staining  of  p53  in  the  tumour  tissue  section  (Fig.  5.10B)  is 
replicated in the p53 staining of the tissue culture obtained from that same tumour. This 
result confirms that the cell lines cultured from sarcoid tissue samples represent a valuable 
resource in the study of sarcoid pathogenesis. 171 
Figure 5.10. 
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Figure 5.10 Equine sarcoid in situ (A), p53 staining of sarcoid tumour section (B) 
removed from horse in A. Primary cell culture established from a sarcoid removed 
from horse A and stained for p53 (C). Note the abnormal peri-nuclear/cytoplasmic 
p53 staining evident in both the tumour section and the cell culture slide. 172 
5.4.6  p53 is not transcriptionally upregulated in BPV-1 transformed cell lines 
It has previously been shown that equine sarcoids harbour the wild-type p53 (Bucher et al., 
1996). Therefore, in order to begin examining the functionality of p53 in equine sarcoids, 
we first examined the baseline expression of p53 by determining levels of p53 mRNA 
using RQ-PCR (section 2.2.5, p53 primer and probe set Table 2.4). The amount present in 
the BPV-1 transformed equine fibroblasts was compared to the mRNA levels in normal 
equine fibroblasts (EqPalFs). Figure 5.11 shows that there was no significant up-regulation 
of p53 mRNA in any of the BPV-1 transformed fibroblast cell lines. 
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Figure  5.11  Analysis  of  p53  mRNA  levels  by  RQ-PCR  in  the  different  cell  types 
revealed  no  significant  difference  in  p53  transcription  levels  between  the  control 
fibroblasts (EqPalF) and the BPV-1 transformed fibroblasts (S6 and EqS cell lines). 173 
 
5.4.7  BPV-1 transformed equine fibroblast cells, p53 expression increases 
following UVB irradiation indicating a normal p53 response 
p53 accumulation in response to DNA damage, amongst other cell stressors, is a well 
documented event (Albrechsten et al., 1999; Vogelstein et al., 2000). Irradiation by UVB 
is known to cause DNA damage and induce p53 (Yarosh et al., 2002) and so, to examine 
whether  the  p53  protein  in  BPV  transformed  fibroblasts  was  functional,  monolayer 
fibroblast cultures were stained for p53 before, and 4 hours after, UVB irradiation. The 
experiment was carried out on all cell lines (S6-1, S6-2, S6-3, EqS01, EqS02, EqS03, 
EqS04b), which were then stained for p53 in accordance to the IHC method outlined in 
section 2.2.9. In all cell lines, an increase in p53 following exposure of the cells to UVB 
was observed. Evidence of an increase in the amount of p53 present was determined by 
counting the number of p53 positive nuclei observed before, and after irradiation. This is 
shown in Figures 5.12 and 5.13. The fact that elevated levels of p53 are detected in all cell 
lines following UVB irradiation, indicates a normal function of this protein in these cell 
lines. 
The cell lines shown in Figure 5.12 are representative of the 3 different cell types used 
throughout this investigation; normal (EqPalF), experimentally transformed by BPV-1 (S6) 
and sarcoid tumour derived fibroblasts (EqS). As can clearly be seen here, all three cell 
lines  demonstrate  an  increase  in  p53  following  UVB  irradiation.  This  response  was 
quantified in terms of actual percentages of p53 positive nuclei before and after irradiation 
and is shown in Figure 5.14. 
As alluded to previously, the EqS04b cell line represents somewhat of an anomaly in terms 
of  p53  expression  as  the  p53  present  in  the  untreated  EqS04b  cells  appears  to  be 
exclusively located in a peri-nuclear arrangement in the cytoplasm of the cell. Figure 5.13 
shows the results obtained when the EqS04b cells were irradiated and then stained for p53 
4 hours later.  
After UVB irradiation, there was no significant difference between the BPV-1 transformed 
S6 and EqS cell lines (compare this to the result seen in the untreated cells (Fig. 5.9), 
where a significant difference between these two cell lines was observed). The control cell 
line (EqPalF) did, on average, show a lower proportion of p53 positive nuclei after UVB 
irradiation compared to both the S6 and EqS cells, but the results were only found to be 
statistically significant in comparing the EqPalF and S6 cells lines. 174 
Figure 5.12 
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Figure 5.12 p53 staining of cell lines before, and 4 hours post-UVB irradiation. 
 
A and B – normal equine fibroblasts (EqPalF) 
C and D – experimentally transformed fibroblasts (S6-2) 
E and F – sarcoid derived fibroblasts (EqS03) 175 
Figure 5.13. 
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Figure 5.13 p53 staining in sarcoid derived fibroblast cell line EqS04b. 
    A – EqS04b cells, untreated 
    B – EqS04b cells, 3 hours after exposure to 250 mJ/cm
2 UVB radiation 
Note  that  although  the  majority  of  the  p53  detected  in  the  untreated  EqS04b  cells  is 
cytoplasmic (Fig 5.14 A), after UVB irradiation, there is evidence of nuclear p53 (arrows), 
suggesting an intact, at least partially, p53 response pathway. 176 
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Figure 5.14 
Figure 5.14 Analysis of p53 positivity before and after UVB irradiation across all the 
cell lines. 
This chart clearly shows a marked difference in all cell lines between the proportion of p53 
positive  cells  seen  before  UVB  irradiation,  and  the  proportion  observed  after  UVB 
irradiation. The difference of the before and after values was determined to be significant 
(p < 0.05) across all the cell lines using the statistical analysis method outlined in Chapter 
II; section 2.2.13. 
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5.4.8  Western blot analysis demonstrates that p53 protein levels increases in 
all cell lines in response to DNA damage by UVB irradiation 
To  confirm,  particularly  in  regard  to  the  BPV  transformed  cells,  that  the  increase  in 
positivity detected by  IHC was specifically due to an increase in the  presence of p53 
protein, Wester blot analysis was performed on these cell lines. Cells were UVB irradiated 
and subsequently harvested and prepared for Western blot analysis as described in section 
2.2.10.2.  
Figure 5.15 shows the results of western blot analysis of BPV-1 negative (EqPalF) equine 
fibroblasts and BPV-1 transformed equine fibroblasts (S6 and EqS cell lines) both before 
(Fig. 5.15 A) and after UVB irradiation (Fig 5.15 B). Following transfer of the protein 
bands from the WB gel to the membrane, the membrane was cut horizontally at the 45 kDa 
level and the top half of the membrane probed for p53, while the bottom half was probed 
for GAPDH, which was used as a loading control. All cell lines show an increase in p53 
amount 3 hours after exposure to 150 mJ/cm
2 UVB irradiation. The BPV-1 transformed 
cell lines (A2, A3, A4 and A5) show the presence of higher levels of p53 prior to UVB 
exposure compared to the BPV-negative fibroblasts (A1). This was confirmed by scanning 
the image and using NIH ImageJ Software analysis (NIH – data not shown). The levels of 
p53 were normalized against the corresponding GAPDH level and the amount of p53 in 
normal fibroblasts was found to be 3 – 4 times lower than in the BPV-1 transformed cells. 
This result correlates with the results from immunhistochemical staining where there was a 
significantly  higher  percentage  of  p53  positive  nuclei  in  the  BPV-1  transformed  cells, 
compared to the BPV-negative fibroblasts (Figure 5.9). 178 
Figure 5.15. 
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Figure 5.15 Western Blot analysis of control fibroblasts and BPV-1 transformed 
fibroblasts, pre- and post- UVB irradiation. 
1 – normal equine fibroblast cells (EqPalF) 
2 – BPV-1 transfected fibroblast cells (S6-2) 
3 – BPV-1 transfected fibroblast cells (S6-3) 
4 -  sarcoid derived fibroblast cells (EqS02) 
5 -  sarcoid derived fibroblast cells (EqS04b) 
A – prior to UVB irradiation 
B – post-UVB irradiation (6 hours) 
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5.4.9  p53 protein in BPV-1 transformed fibroblasts transactivates p21 
expression indicating p53 protein is transcriptionally active in these 
cells. 
For assessment of p53 transactivation activity, cells were irradiated with a low dose of 
UVB (30 mJ/cm
2), incubated overnight (~ 10 hours) and then harvested to look for the 
presence of p21 protein. As mentioned earlier, p21 expression is up-regulated by p53 as 
part of the DNA damage response pathway (Vousden and Lu, 2002; Liu et al., 2003). 
Figure 5.16 shows that p21 levels in all the cell lines studied increase after exposure to 
UVB irradiation. This suggests that the transactivation function of p53 is intact in BPV-1 
transformed equine fibroblasts.  180 
 
Figure 5.16 
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Figure 5.16 Western Blot analysis of p53 function in BPV-1 transformed cells by 
evaluation of p21 transactivation. 
1 – Normal equine fibroblasts (EqPalF) prior to UVB exposure 
2 – Normal equine fibroblasts 9 hours post-exposure to a low dose of UVB 
3 – BPV-1 transfected fibroblasts (S6-2) prior to UVB exposure 
4 – BPV-1 transfected fibroblasts 9 hours post-exposure to a low dose of UVB 
5 – sarcoid derived fibroblasts (EqS04b) prior to UVB exposure 
6 – sarcoid derived fibroblasts 9 hours post-exposure to a low dose of UVB 
This Western Blot figure clearly shows both the increase of p53 in each cell line, plus the 
activation of p21 in each cell lines, following exposure of the cells to a low dose (30 
mJ/cm
2) of UVB irradiation. These results suggest that p53 is functionally active in BPV-1 
transformed equine fibroblasts. 
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5.4.10 The half life of p53 is increased in sarcoid derived and BPV-1 
transformed cells  
To investigate the hypothesis that the p53 accumulation observed in BPV-1 transformed 
cells is as a result of an increased half life of the protein in these cells, cycloheximide was 
added to the media as described in Chapter V; section 5.3.5. Figure 5.18. shows the results 
of  treating  BPV-negative  and  BPV-1  transformed  fibroblast  cell  cultures  with 
cycloheximide and the harvesting the cells at different time points (0, 0.5, 1, 2.5 and 5 
hours) post-addition of the drug to the media.  
 
 
Figure 5.17. 
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Figure 5.17 Half-life study of p53 in control equine fibroblasts (EqPalF - A) and 
sarcoid derived equine fibroblasts (EqS04b – B). 
Cycloheximide  was  added  to  the  media  of  the  different  cell  lines,  and  the  cells  were 
harvested at the time intervals indicated. The p53 in the BPV-1 transformed cell lines is 
clearly  evident  up  to  at  least  5  hours  after  cycloheximide  was  added.  In  contrast,  the 
amount  of  p53  in  the  BPV-negative  fibroblasts  decreases  markedly  from  1  hour  post-
incubation with cycloheximide. 
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5.5  DISCUSSION 
These  results  reveal  some  important  information  regarding  the  cellular  location  and 
functionality of p53 in equine sarcoids. Before this information is interpreted it is probably 
worthwhile  stating  that  in  the  interpretation  of  these  data,  we  are  operating  under  the 
assumption that the p53 present in equine sarcoids is wild-type p53. This assumption is 
based on evidence from a number of studies (Bucher et al., 1996; Nasir et al., 1999; Mayr 
et al., 2000) that looked for mutations in the equine p53 gene sequenced from equine 
sarcoid affected animals. In all these studies, there was no evidence of p53 mutations, 
which makes it likely, although does not exclude entirely the possibility of the presence of 
mutations, that the p53 present in equine sarcoid tumours is wild-type p53. 
5.5.1  p53 Accumulation in the Nucleus 
Our data demonstrates that BPV-1 transformed cells, in vitro and in vivo, show abnormal 
nuclear  accumulation  of  p53.  In  the  ordinary  cellular  response  to  DNA  damage,  p53 
accumulates in the nucleus due to its phosphorylation by ATM/Chk2 or ATR/Chk1, and 
subsequent stabilisation. There, it then activates transcription of proteins involved in either; 
cell cycle arrest and DNA repair, or proteins involved in activating apoptosis. Whether or 
not a cell enters cell cycle arrest or undergoes apoptosis after activation of p53 depends on 
myriad factors:  
i)  The type of cellular stress that caused the p53 activation in the first place. 
For  example,  in  some  types  of  cell,  hypoxic  conditions  result  in  p53 
activation  and  transcription  of  a  hypoxia-specific  target  (Bnip3L)  which 
encodes a protein that promotes apoptosis (Fei et al., 2004). 
ii)  The cell type can control the multiple functions of p53 by preferentially 
activating p53 pathways associated with cell arrest and DNA repair, OR 
those pathways that lead to apoptosis. For example, cells of haematological 
origin  will  tend  to  enter  cell  cycle  arrest  and  DNA  repair  after  DNA 
damage,  whereas  mature  B-cells,  have  evolved  to  evade  both  p53-
dependent DNA repair AND apoptosis (Phan and Dalla-Favera, 2004; Wu 
et al., 2005). 
iii)  The presence of co-factors that can also lead to the preferential activation of 
either  pathway.  For  example  BRCA1  suppresses  the  transcription  of 183 
apoptosis-related genes whilst promoting the transcription of those genes 
involved in DNA repair (MacLachlan et al., 2002). 
iv)  Recently, different isoforms of p53 have been discovered and have been 
shown to affect the activity of wild-type p53 (Qu et al., 2004; Harms and 
Chen, 2005). 
Accumulation of p53 in the nucleus without an initiating DNA damage event is most 
commonly associated with mutated p53, and is seen in some types of cancer (Esrig et al., 
1994; Ranzani et al., 1995; Quinn et al., 2000). Research in the area has also shown that 
the nature of the p53 mutation can determine whether or not p53 accumulation in the 
nucleus will occur (Tsuda and Hirohashi, 1994). It is generally accepted that the reason for 
mutant p53 accumulation is that has an increased half life compared to wild-type p53, as 
the mutation seems to confer stability and/or a resistance to degradation. Accumulation of 
wild-type p53 in the nucleus is a less common occurrence, but has been observed in some 
examples of neoplastic disease (Rubio et al., 1993; Ellison et al., 1995). The reasons for 
this accumulation are not well understood (Jaquet et al., 1999).  
It is reasonable to theorise that an increase in levels of p53 in the BPV-1 transformed cells 
is due to an increase in p53 transcription. However, as shown in Figure 5.3, we have 
demonstrated here that this is not the case. 
Another possibility is that the p53 protein has been stabilised in the nucleus, leading to an 
increased  half-life.  This  hypothesis  is  supported  by  the  results  of  the  cycloheximide 
experiments (Fig. 5.13) which show that p53 is detectable for significantly longer in BPV-
1 transformed fibroblasts after protein transcription has been halted by  the addition of 
cycloheximide (CHX) to the cell growth media, compared to the untransformed control 
fibroblasts. The explanation for this increase in p53 half-life is less simple to elucidate and 
there are several possibilities to consider. It could be as a result of lower proteasomal 
degradation activity as also shown in adenovirus E1A-infected cells, in which inhibition of 
proteasomal activities by targeting the proteasomal regulatory subunit S2, extended p53 
half-life and increased the level of p53 without inhibiting the p53 ubiquitination process 
(Turnell et al., 2000; Zhang et al., 2004). 
It  may  also  be  caused  by  a  dysregulated  p53  ubiquitination  process,  specifically;  the 
regulation  of  p53  by  the  murine  double  minute  protein  (mdm2)  is  compromised.  The 
mdm2 protein regulates the activity of the p53 protein with more than one mechanism. It 
can block the transcriptional activity of the p53 protein, export p53 from the nucleus to the 184 
cytoplasm and promote the degradation of p53. To promote degradation of p53, the mdm2 
protein functions as a ubiquitin ligase and can ubiquitinate p53 (Honda et al., 1997, Fuchs 
et al., 1998). Ubiquitination targets the p53 protein for degradation by the proteasome. 
Additionally,  through  binding  to  p53,  mdm2  shuttles  p53  out  of  the  nucleus  to  the 
cytoplasm  for  degradation  (Freedman  and  Levine  1998).  DNA  damage  induces 
phosphorylation of the p53 protein at multiple sites, including those overlapping with the 
mdm2-binding sites, thus preventing the association between mdm2 and p53 (Shieh et al., 
1997), resulting in an increase in the amount of p53 present in the cell (Buschmann et al., 
2000, Buschmann et al., 2001). Mdm2 is p53 responsive so that when p53 is stabilised, and 
p53  levels  increase,  so  too  do  mdm2  levels.  Thus  there  is  a  negative  feedback  loop 
relationship  between  p53  and  mdm2.  Limited  details  regarding  the  status  of  mdm2  in 
equine  sarcoid  makes  it  difficult  to  speculate  on  the  theory  of  mdm2/p53  imbalance 
without further work in that area.  
A  final  possibility  is  that  the  shuttling  of  p53  from  the  nucleus  to  the  cytoplasm  is 
impaired, resulting in  an accumulation of p53  in the nucleus,  even in the presence of 
normally functioning mdm2. As a shuttling protein, p53 is constantly transported through 
the nuclear pore complex. p53 nucleocytoplasmic transport is carried out by a bipartite 
nuclear localisation signal (NLS) located at its C-terminal domain and two nuclear export 
signals (NESs), located in its N- and C-terminal regions. Mutations disrupting the NLS 
block p53 export and prevent mdm2-mediated cytoplasmic degradation (O’Keefe et al., 
2003). So, theoretically, BPV-1 proteins may interfere with the shuttling ability of the p53 
molecule. 
5.5.2  p53 in BPV-1 transformed cell lines is transcriptionally functional 
This is evident from the Western blot analysis of the cell lines after they were analysed 9 
hours post-exposure to low levels of UVB irradiation and then probed with p21 antibody 
(Fig 5.15). The p21 protein functions as a cyclin-dependent kinase inhibitor (CKI). It binds 
to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a 
regulator of cell cycle progression at G1 (He et al., 2005). The expression of the p21 gene 
is controlled by p53, through which p21 mediates the p53-dependent cell cycle G1 phase 
arrest in response to a variety of stress stimuli.  
The  Western  blot  evidence  from  probing  with  the  p53  antibody  also  supports  the 
hypothesis of an intact p53 response to DNA damage (Fig. 5.15 and 5.16) as levels of p53 
protein  in  all  cell  lines  significantly  increase  after  a  DNA  damaging  insult.  The 
immunohistochemical staining of the cultured fibroblast cell lines also supports this theory, 185 
as there is clearly an increase in p53 positive nuclei in all cell lines after the cells have been 
exposed to a DNA damaging stimuli (Figs. 5.12, 5.13 and 5.14). Even the sarcoid-derived 
cell line that exhibited cytoplasmic p53 staining (EqS04b) showed evidence of nuclear p53 
accumulation after DNA damage (Fig. 5.13). 
5.5.3  Cytoplasmic sequestration of p53 
Cytoplasmic sequestration of p53 has been commonly observed in certain tumours, such as 
neuroblastomas, and breast and colon cancer (Bosari et al., 1995; Lilling et al., 2002). In at 
least a subset of these tumours, MDM2 is responsible for the cytoplasmic accumulation of 
p53 (Lu et al., 2000), and other proteins have also been implicated in cytoplasmic retention 
(Truant et al., 1995; Takada et al., 1997; Zhan et al., 1998; Weber et al., 1999). Several 
viral proteins also influence p53 localisation, such as human papilloma virus (HPV) E6 
protein (Thomas et al., 1999), adenoviral E1B 55 kDa protein and the HBV HBx protein 
(Querido et al., 1997; Ahn et al., 2001; Ahn et al., 2002). In addition, defects in p53 
import/export have also been reported in different tumour types (Fabbro and Henderson, 
2003). 
In the IHC staining of cell culture and tumour tissue sections, the cytoplasmic localization 
of  p53  did  not  appear  to  form  a  punctate  pattern  or  be  localised  in  a  distinct  p53 
cytoplasmic body as frequently identified in cells infected with adenovirus Type-12 E1B-
oncoprotein (Zhao and Liao, 2003). Neither did it resemble finely dispersed constitutive 
cytoplasmic  p53  as  observed  in  cells  productively  infected  by  human  herpesvirus-6 
(Takemoto  et  al.,  2004).  Both  hyperactive  nuclear  export  and  existence  of  tethering 
mechanisms should also be considered as contributing to the cytoplasmic sequestration of 
p53 in some BPV-1 transformed fibroblasts, but these mechanisms were not investigated in 
this study. 
What was interesting from our results, is that although p53 was present at abnormally high 
levels in all the BPV-1 transformed cell lines as determined by the percentage of p53 
positive nuclei detected in these cells (Fig. 5.14.), in the EqS04b and EqS013 (EqS013 is 
the cell line established from a sarcoid removed from the equid in Figure 5.10) cell lines, 
which demonstrated cytoplasmic localisation of p53, ALL the cells in the images captured 
showed the presence of p53 (Fig. 5.13, fig. 5.10 C). I.e. these sarcoid derived cell lines 
demonstrated 100% positivity for p53. It is also interesting to note that even though the 
p53 in untreated EqS04b cells appears to be located exclusively in the cytoplasm (Fig. 
5.13), after UVB irradiation, p53 appears to be present in the cytoplasm AND the nuclei of 
these  cells  (Fig  5.13).  Together  with  the  data  that  demonstrates  the  transactivation 186 
functionality of p53 in this cell line is intact (Fig. 5. 15 – detection of p21) this could be 
interpreted as evidence supporting the theory that p53 is not, in fact, inactivated in BPV-1 
transformed fibroblast cells. 
5.5.4  What conclusions can be drawn? 
5.5.4.1 In vitro 
·  All BPV-1 transformed fibroblasts exhibit abnormal p53 expression, most 
commonly manifested as an increase in the amount of p53 positive cells 
present, but also seen as cytoplasmic accumulation in a number of sarcoid 
derived cell lines. 
·  The sarcoid derived cell lines where cytoplasmic accumulation of p53 was 
evident originated from sarcoid tumours that have previously been shown to 
harbour  a  higher  than  average  viral  load/level  of  viral  gene  expression 
(EqS04b cells: Yuan et al., 2007) or to come from clinically aggressive and 
persistent  tumours  (EqS013  cells:  From  clinical  case  featured  in  figure 
5.16). 
·  EqS013 cells in vitro, matched the pattern of p53 expression seen in the 
same sarcoid tumour in vivo (Fig. 5.10) 
5.5.4.2 In vivo 
·  Just over 50% of the tumours stained for p53 did not show any abnormal 
p53 expression. Of the tumours that did show abnormal p53 expression, 
there was a greater degree of abnormality detected in those tumour types 
considered to be more clinically aggressive (Table 5.2). 
It has been reported in the study of squamous cell carcinomas (SCC), that p53 expression 
increased as the degree of dysplasia and the grade of SCC advanced. In 1994, Sauter et al., 
reported an increasing number of positive cases from 28% in mild dysplasia, to 45% in 
moderate dysplasia, to 54% in severe dysplasia and 50% in carcinoma in-situ. Our results 
demonstrate a lower overall level of p53 positivity – even in those sarcoid tumours that had 
over 20% of nuclei being p53 positive and were graded as ‘HIGH’, the highest percentage 
in  this  group  was  under  30%.  Back  to  the  work  done  in  SCC,  one  study  found  a 
statistically significant increase in p53 expression in cases presenting with nodal metastasis 
and linked a higher p53 expression to a poorer prognosis (Jain et al., 2008). 187 
It seems reasonable, given the nature of our own findings, to speculate that higher levels of 
p53 expression in sarcoid tumours indicates a tendency to aggressive clinical behaviour, 
and the presence of cytoplasmic p53 suggests a malevolent tumour type that is very likely 
to  recur  after  treatment.  How  useful  these  findings  are  in  clinical  context  is  unclear, 
although knowledge of p53 status in some instances may influence treatment approach, 
stable management practices and potential breeding risks. 
Although  we  have  shown  that  the  half-life  of  p53  is  considerably  longer  in  BPV-1 
transformed cells it is not possible, from our results, to determine how and why this has 
occurred. Unlike p53 anomalies that develop in cells infected by the adenovirus or the 
human cytomegalovirus (HCMV), there appears to be no consistency in the pattern of p53 
alterations in BPV-1 infected cells. Research into adenoviruses and HCMV has determined 
the exact viral proteins responsible for  interfering with, and inactivating, p53, and in the 
case of HCMV, the exact stage of infection at which the changes to p53 occur. So with 
those viruses, it is possible to confidently state that infection of a cell with either of those 
viruses,  will  result  in  inactivation  of  p53  by  means  of  a  reasonably  well  understood 
mechanism(s).  With  our  in  vitro  results,  it  is  possible  to  state  with  confidence,  that 
transformation of an equine fibroblast by BPV-1 results in an increase in p53 expression. 
However,  the  in  vivo  analysis  of  the  tumour  sections  (confirmed  histologically  to  be 
sarcoid tumours) revealed that in some cases, there was no evidence at all of an increase in 
p53 expression. Additionally, a minority of the sarcoid derived cell lines (EqS04b and 
EqS013) showed total cytoplasmic localisation of p53 – if this was indeed caused by the 
presence of BPV-1, why wasn’t it evident in all BPV-1 transformed cell lines? Further 
work is required to elucidate the mechanisms responsible for nuclear p53 accumulation 
and, in some cases, export to, and accumulation in, the cytoplasm. 
5.5.4.3 In summary 
i)  p53 expression is higher in BPV-1 transformed cells 
ii)  p53 transcription is not upregulated in BPV-1 transformed fibroblasts 
iii)  half-life of p53 in BPV-1 transformed fibroblasts is increased 
iv)  p53 in BPV-1 transformed cells is transcriptionally active 
v)  increased  levels  of  p53  abnormality  (high  nuclear  p53  positivity  and 
cytoplasmic  p53)  correlate  with  clinical  appearance/behaviour  of  sarcoid 
tumour 188 
6  General Discussion 
6.1.1  Transmission 
i)  Flies harbour BPV-1 DNA 
ii)  BPV-1 DNA has been found to be equine-specific variant most commonly 
isolated from sarcoid tumours 
Further work is needed to confirm absolutely that flies can act as mechanical vectors of 
BPV-1/sarcoid  tumours  between  affected  and  susceptible  animals.  This  would  involve 
designing experiments where a sarcoid affected animal was kept isolate in a room with 
pathogen-free  flies.  The  BPV  DNA  from  the  sarcoid  of  the  affected  horse  would  be 
isolated and sequenced. After a certain period of time, the animal would be exchanged for 
another, sarcoid-free animal, which would also be kept isolated with the flies. If and when 
that animal developed a sarcoid or sarcoids, these could be removed and analysed and the 
DNA sequence compared to that isolated from the original animal. Care would need to be 
taken to remove any BPV contamination of the environment before the second animal was 
introduced, and thus minimise the likelihood that this could be a source of infection for the 
second animal. Once the second animal had successfully be infected, capture and analysis 
of the flies should be done to confirm that they harbour the same sequence/sequences of 
BPV DNA as the original animal. In the interests of efficiency, it might be necessary to 
introduce several animals into the fly room after the first animal has been removed. This 
would address the problem of the fact that some animals are genetically more resistant to 
developing sarcoids than are others. 
6.1.2  Apoptosis, Cell Survival and p53 
This chapter provides evidence that BPV-1 transformed fibroblasts are NOT more resistant 
to apoptosis compared to BPV-negative equine fibroblasts following UVB irradiation, and 
to a lesser extent, cisplatin treatment. The reasons for an increased sensitivity to apoptosis 
could be the presence of BPV proteins E6 and E7, which have previously been shown to 
sensitise infected cells to certain types of apoptosis. Additionally, the results from analysis 
of p53 in the final chapter could be applied here to help explain the significantly higher 
levels of apoptosis seen in BPV-1 transformed  cells, soon after certain types of DNA 
damage. It has been shown that over-expression of wild-type p53 results in cells that are 
more sensitive to apoptosis induced by DNA damage (Tak et al., 2000; Gu et al., 2004), 
and so it seems reasonable to suggest that the accumulation of functioning p53 in BPV 189 
transformed  cells,  would  contribute  to  the  higher  apoptotic  index  seen  in  these  cells 
following  DNA  damage.  This  also  fits  with  the  observation  that  the  experimentally 
transformed fibroblasts (the S6 cells) showed a considerably higher apoptotic index in the 
untreated control populations when assessed by FCM analysis, compared to the sarcoid 
derived  (EqS)  cells,  and  the  BPV-negative  control  fibroblasts.  Chapter  5,  Figure  5.14 
illustrates this perfectly. The S6 cells demonstrate by far the highest proportion of p53 
positive nuclei, the sarcoid derived cells are more p53 positive than the control fibroblasts 
(by 4 – 6 fold), but to a lesser degree than the S6 cell lines, which demonstrate a 10 – 12 
fold increase compared to the control BPV-negative fibroblast cell line. That is why the 
FCM analysis data was presented as relative levels of apoptosis, to compensate for this 
factor. 
Cell survival was enhanced in BPV-1 transformed cells, despite higher initial levels of 
apoptosis  after  DNA  damage.  A  review  of  the  p53  literature  in  1999  by  Brown  and 
Wouters, states that “We find that because wild-type p53 predisposes cells to a more rapid 
rate of cell death after DNA damage, particularly with normal or minimally transformed 
cells,  that  short-term  assays  have  led  to  the  conclusion  that  mutations  in  p53  confer 
resistance to genotoxic agents. On the other hand, if clonogenic survival is used to assess 
killing in cells derived from actual solid human tumours, then apoptosis and the genes 
controlling it, such as p53 and bcl-2, appear to play little or no role in the sensitivity of 
these cells to killing by anticancer drugs and radiation.”  (Brown and Wouters, 1999). This 
information, coupled with the very recent observations that some cancer cells are able to 
‘reverse’ the apoptotic process, even after morphological cellular changes (associated with 
apoptosis) have taken place, provides a convincing argument to explain the data collected 
in this thesis. 
Despite  the  fact  that  the  exact  mechanisms  and  pathways  that  underpin  the  events 
described  above  are  not  fully  understood  in  BPV  transformed  cells,  what  is  useful  to 
consider, is the results that were obtained following E6 siRNA treatment of the equine 
sarcoid derived cell line EqS04b. Very little change in apoptosis levels was detected by 
FCM analysis, and yet, very significant change was observed in the clonogenic survival 
assay. By ‘silencing’ BPV E6 in these cells, the cell survival potential following DNA 
damage  was  greatly  reduced.  This  has  exciting  implications  for  the  development  of  a 
universally successful sarcoid treatment. Already topical siRNA therapies are in clinical 
trials in the treatment of a range of virally-induced human diseases. Given the encouraging 
results  detailed  in  this  thesis,  it  seems  that  a  sensible  area  of  future  research  into  the 190 
treatment of equine sarcoids, resides in the development of a technique that will introduce 
BPV  targeted  siRNA  molecules  into  tumour  cells  and  either,  allow  the  animals  own 
immune system to then recognise and remove the virally infected cells, or, enhance the 
efficacy  of  more  traditional  sarcoid  treatments,  such  as  excision,  by  being  used  in 
conjunction with them. The electropulsation technique currently being used for delivering 
cisplatin  or  5-fluorouracil  deep  into  tumour  tissue,  would  be  a  useful  approach  to 
delivering the siRNA molecules to the optimal depth.  
Further research in to the suitability of siRNA therapy as a treatment option should focus 
on several issues; 
i)  Additional  tests  are  required  to  confirm  the  in  vitro  silencing  is  viral 
specific. 
ii)  In  vitro  effects  of  siRNA  on  normal  equine  fibroblasts  should  be 
determined. 
iii)  The safety and tolerability of topical/intradermal siRNA delivery needs to 
be assessed in vivo. 
iv)  The efficacy of intratumoral siRNA treatment needs to be established. 191 
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